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At sites of vascular injury, the critical blood clotting enzyme thrombin is generated 
from prothrombin via Prothrombinase, a macromolecular, Ca2+-dependent enzymatic 
complex consisting of the serine protease factor Xa and the non-enzymatic cofactor factor 
Va, assembled on the membranes of activated platelets. Platelets regulate thrombin 
formation by providing specific binding sites for the components of Prothrombinase and 
by releasing a platelet-derived factor V/Va molecule that is more procoagulant than its 
plasma counterpart and partially resistant to proteolytic inactivation. This dissertation 
identifies and characterizes the subpopulation of platelet-derived factor V/Va that is 
responsible for the observed protease resistance, and the mechanism by which 
Prothrombinase bound to platelets differs from a model system using vesicles composed 
of 75% phosphatidylcholine (PC) and 25% phosphatidylserine (PS), PCPS vesicles.  
Previous studies have demonstrated that activated platelets release a dissociable 
pool of factor V/Va and a non-dissociable, membrane-bound pool, which is covalently 
attached to the platelet membrane through a glycosylphosphatidyl inositol (GPI) anchor. 
Data described herein demonstrate unequivocally that the pool of platelet-derived factor 
V/Va that is resistant to proteolytic inactivation by activated protein C is provided 
exclusively by the non-dissociable GPI-anchored pool. Further, although this factor Va 
pool is susceptible to proteolysis by plasmin, the fragments formed are associated with 
sustained and increased cofactor activity. These observations indicate that tethering of 
factor Va to the membrane surface via a GPI anchor imparts resistance to proteolytic 
inactivation and sustained thrombin generation at sites of vascular injury.  
 For several years it has been known that Prothrombinase assembled on PCPS 
vesicles does not mimic that bound to platelets. While both enzymes cleave prothrombin 
at Arg271 and Arg320 to form thrombin, prothrombin activation proceeds via the 
prethrombin-2 pathway (initial cleavage at Arg271) on the platelet surface, in contrast to the 
meizothrombin pathway (initial cleavage at Arg320) on PCPS vesicles. Using thrombin 
active site inhibitors, we demonstrate that the preference for either pathway is dictated by 
the conformation in which prothrombin is bound by the membrane-bound enzyme. The 
prethrombin-2 pathway of prothrombin activation catalyzed by platelet-bound 
Prothrombinase is a direct consequence of configuring prothrombin in a proteinase-like 
state resulting in the exposure of a pseudo-active site that can be stabilized by active site 
thrombin inhibitors. Conversely, prothrombin is preferentially configured in the zymogen-
like state on PCPS vesicles where the meizothrombin pathway is preferred. 
Additional support for the differential assembly of Prothrombinase on the platelet 
surface is provided by observations made using prethrombin-1, an intermediate formed by 
cleavage of prothrombin at Arg155 by the formed thrombin. Prethrombin-1 is converted into 
fragment-2 and thrombin by platelet-bound Prothrombinase at a substantially higher rate 
than vesicle-bound Prothrombinase. The decreased rate of prethrombin-1 activation in the 
model system is due, in part, to inhibition of the vesicle-bound enzyme by the fragment-2 
generated in the reaction. Taken together, these data not only provide important molecular 
insights into the mechanisms by which Prothrombinase bound to activated platelets at sites 
of vascular injury regulates the procoagulant response to effectively support robust 
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CHAPTER ONE: COMPREHENSIVE LITERATURE REVIEW 
1.1. Hemostasis Overview 
1.1.1 Introduction to Hemostasis 
According to the most recent National Heart, Lung, and Blood Institute report (2015), 
cardiovascular diseases including coronary heart disease, atherosclerosis, cerebrovascular 
disease, and peripheral vascular disease account for more than 30% of all deaths in the 
United States as of 2010. In particular, coronary heart disease remains the most common 
heart disease resulting in slightly less than half a million deaths annually (~400,000 people 
representing ~33% of the total cardiovascular disease deaths per year). Recent statistics 
show that while cardiovascular diseases in the United States have continued to decline in 
the last 20 years, they remain comparatively higher relative to other countries in the world 
especially among the female population (National Heart, Lung, and Blood Institute, 
Chapter 4. Disease Statistics.  Retrieved 8th January 2016; http://www.nhlbi.nih.gov/). 
Taken together, the occurrence of these diseases highlights the importance of sustaining 
cardiovascular research to improve our understanding of the biological and biochemical 
processes regulating the various functions of the vascular system to effect better disease 
prevention and treatment. 
Higher vertebrates including humans have evolved an ultra-secure and effective 
distribution system for the delivery of nutrients, defense molecules, and gases to various 
parts of the body. Our closed vascular system is comprised of a fluid medium (blood), 
fluid-filled spaces (such as the heart, and blood vessels), surrounded by continuous 
connective tissues which permeate all tissues in the body (Ruppert, 1983). The human 
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blood is comprised of a pale yellow liquid known as plasma. The plasma is abundant in 
soluble proteins including clotting factors, defense particles, and a suspension of 
specialized cells such as platelets, white blood cells and red blood cells which circulate in 
the blood vessel network around the entire body (Figure 1).  
 
Figure 1. Components of the human blood and blood vessel.  
Most of the human blood is comprised of fluid, called the plasma, in which several soluble 
proteins and cellular components float and circulate around the body. Red blood cells, 
white blood cells, and platelets are abundant in the plasma and play key roles in both the 
immune and hemostatic responses. Separating the blood from the subendothelial matrix 
are the endothelials cells. A breach of vascular integrity allows plasma-based proteins and 
cells to interact directly with key components in the subendothelial matrix to mount a 
robust hemostatic response.  
Evident from the color of effusing blood, red blood cells form the majority of cells 
in the blood (35-50% of a total volume of ~5 L) and are primarily responsible for the 
delivery of oxygen (via hemoglobin) to various parts of the body. The white blood cells, 
on the other hand, play crucial roles during the immune response to invasion by foreign 
pathogens, and also during the inflammatory response (Williams, 1990). Likewise, human 
platelets have been implicated in both immune and inflammatory responses. However, 
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platelets function mainly as the guardians that maintain normal blood circulation within 
the blood vessels of the vascular system. 
Complex, yet ingenious interrelated systems exist to maintain the fluidity of the 
blood in the vascular system while allowing for the rapid formation of a solid blood clot to 
prevent excessive blood loss or hemorrhage subsequent to blood vessel injury.  These 
interrelated systems are collectively referred to as hemostasis when they are invoked as 
part of the body’s normal defense mechanisms to prevent blood loss.  Alternatively, these 
same interrelated systems are invoked during thrombosis which refers to unwanted, 
pathological, and in some instances life-threatening clot formation.  Thrombosis is indeed 
a pathologic extension of the normal hemostatic response.  The hemostatic response in 
either phenomenon is fundamentally the same, whereas the initiating events are 
considerably different. 
Since platelets are essential for hemostasis, they will play a similar role in 
thrombosis, which can cause significant mortality and morbidity due to myocardial 
infarction and stroke. The role that platelets play in angiogenesis, likewise can be 
beneficial, such as in development of collateral vessels, or detrimental such as in cancer 
progression and metastasis (Nurden, 2011). Likewise, the role that platelets play in wound 
healing (Nurden et al., 2008) is similar to their role in inflammation (Gawaz et al., 2005). 
One mechanism by which they fulfill these various roles is through their ability to support 
the assembly and function of the macromolecular enzyme complex, Prothrombinase, which 
effects the proteolytic conversion of the zymogen prothrombin to the important bioeffector 
and bioregulatory molecule thrombin, the central enzyme of the coagulation cascade 
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(Bouchard et al., 2007). As such, platelets and platelet-derived thrombin play key roles in 
several (patho)physiological processes.  
When the vascular integrity is breached, platelets and coagulation factors, 
circulating in blood in inert forms, interact to effect a “cascade” of events referred to as 
blood coagulation. The first phase of this response, primary hemostasis, requires the 
exposure of subendothelial components to which circulating platelets can bind. Platelet 
exposure to ligands such as von Willebrand factor and collagen triggers their adhesion, 
activation and degranulation, and aggregation to form a platelet plug (Ruggeri, 2009), in 
order to localize the subsequent reactions to the site of injury. Activated platelets release 
constituents from α– and dense granules that promote the hemostatic process and express 
functional receptors which reinforce the activation and aggregation processes. Likewise, 
in what is considered a crucial event for the success of secondary hemostasis, activated 
platelets undergo significant shape change resulting in a 200-fold increase in membrane 
surface area and express anionic phospholipid binding sites and protein receptors that 
provide essential catalytic sites for the assembly and function of the coagulation complexes 
(Walsh, 1974; Robert et al., 1997; Tracy, 2001). The exposure of subendothelial tissue 
factor, which complexes with plasma factor VIIa, initiates secondary hemostasis where the 
coagulation cascade is triggered leading to a series of zymogen to protease conversions and 
further assembly of two enzyme complexes, intrinsic Tenase and Prothrombinase. The 
activated platelet membrane provides binding sites for the assembly of both enzyme 
complexes, which convert factor X to Xa and prothrombin to thrombin, respectively. 
Thrombin further converts fibrinogen into fibrin forming the meshwork which strengthens 
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the unstable platelet plug. The formation of catalytic amounts of thrombin will significantly 
amplify the coagulation response by its ability to activate platelets and several of the other 
factors required for hemostatic competence. 
The ability of platelets to regulate thrombin generation is central to their roles in 
hemostasis and thrombosis. While all platelets may become activated following agonist-
mediated stimulation, it is now accepted that only a subpopulation of platelets appear 
competent to function in supporting Prothrombinase assembly and function. This same 
platelet subpopulation is unique in that it expresses significantly higher membrane 
concentrations of adhesive receptors on its membrane, suggesting that this population 
would be the first one recruited to the site of injury (Fager et al., 2010).  
Prothrombinase is defined as a macromolecular, enzymatic complex consisting of 
a Ca2+-dependent, membrane-bound complex of the cofactor factor Va and the serine 
protease factor Xa (Bouchard et al., 2007). Factor Va can be derived from plasma, 
following the thrombin-catalyzed proteolytic activation of the procofactor, factor V 
(Esmon, 1979; Monkovic & Tracy, 1990a), or subsequent to agonist-induced platelet 
activation resulting in both factor Va release and it membrane expression (Walsh, 1974; 
Harrison & Cramer, 1993; Bouchard et al., 1997b). Thus, in the initial stages of the 
hemostatic response, activated platelets provide the essential cofactor for Prothrombinase 
assembly and function, resulting in thrombin generation. Following thrombin generation, 
additional platelet activation ensues and plasma-derived factor V can be activated to factor 
Va. Consequently, subsequent to thrombin-catalyzed platelet activation, platelet-derived 
and plasma-derived factor Va bind to specific, functional and saturable sites on the 
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activated platelet membrane surface and in so doing form at least part of the receptor for 
factor Xa ensuring that prothrombin is activated to thrombin via platelet-bound 
Prothrombinase (Bouchard et al., 1997b). The absolute requirement of platelet-derived 
factor Va for the initiation and maintenance of an effective hemostatic response 
(Borchgrevink & Owren, 1961; Janeway et al., 1996; Ang et al., 2009; Bouchard et al., 
2015) is discussed in greater detail in Section 1.2.1.7. Remarkably, the procoagulant 
platelet subpopulation discussed above, is also defined by those platelets expressing the 
GPI-anchored factor Va (Wood et al., 2008). Thus, by adhering, activating and aggregating 
at a vascular site of injury, platelets are not only able to form a platelet plug, but are also 
able to provide an essential cofactor in its active form that will be retained at the site of 
injury protected from inactivation.  
The mechanisms by which activated platelets facilitate the appropriate assembly 
and function of Prothrombinase also guarantee that a procoagulant state is sustained. Since 
prothrombin’s proteolytic activation by Prothrombinase requires two cleavages at distant 
sites, two different intermediates can be generated depending on which site is cleaved first. 
Thus, prior to thrombin formation platelet-bound Prothrombinase has the option of 
generating either a prethrombin-2 intermediate which is catalytically inactive, or a 
meizothrombin intermediate, which is catalytically active and functions as an 
anticoagulant. Since platelet-bound Prothrombinase only releases the procoagulant enzyme 
thrombin as its product, robust procoagulant activity is sustained. Consequently, the focus 
of these studies was to define the mechanism by which platelet-bound Prothrombinase 
recognizes and activates prothrombin, as well as defining the unique functional properties 
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of the acquired cofactor, platelet-derived factor Va, which is stored within the platelet’s α-
granules.   
1.1.2 The Coagulant Response – Formation of a Stable Blood Clot 
Normal hemostasis requires that the coagulant response be initiated coincident with the 
formation of a platelet plug at a site of vascular injury. This will ensure the generation of 
thrombin and the deposition of fibrin to reinforce the unstable platelet plug formed during 
the primary phase of the hemostatic response. Insoluble fibrin deposition, and the ultimate 
cessation of a bleeding episode, are the consequence of various highly-regulated 
proteolytic activation reactions that involve both plasma- and platelet-derived proteins of 
the coagulation system. These proteolytic activation reactions are referred to as the 
coagulation cascade and are crucial to this process. The proteins participating in the 
coagulation cascade are designated by Roman numerals that are assigned in the order in 
which they were discovered, e.g. Factor I, now commonly referred to as fibrinogen, and 
factor V, which retained its original designation. The proteolytically activated form of a 
coagulant zymogen or procofactor is indicated by a lower case ‘a’ such as factor Va. The 
physiologically-relevant coagulation cascade mediates a series of zymogen to enzyme 
conversions (activations) which eventually produces physiological concentrations of 
thrombin required to stop a bleeding episode (Figure 2). Concurrent with the primary 
hemostatic response, the extrinsic pathway is initiated when the exposed subendothelial 
matrix presents reactive extravascular tissue factor (TF) molecules to circulating plasma 
factor VIIa (FVIIa). The TF-FVIIa binary association  is referred to as the extrinsic Tenase 
enzyme complex, and initiates the extrinsic pathway of the coagulation response 
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(Nemerson, 1988). The extrinsic pathway is designated as such because the initiator of this 
pathway, tissue factor, does not circulate in blood, and hence is extrinsic to blood. Extrinsic 
Tenase (TF-FVIIa) contributes to the initial generation of thrombin by channeling its 
proteolytic products to other enzymes such as Prothrombinase, and intrinsic Tenase. 
Accordingly, factors IX and X are activated by the extrinsic Tenase complex via limited 
proteolysis to form factors IXa and Xa, respectively (Osterud & Rapaport, 1977) (Figure 
2). Additionally, factor XI can be activated to XIa by thrombin under physiological 
conditions (Gailani & Renne, 2007). Factor XIa activates factor IX  to factor IXa to ensure 
that the intrinsic Tenase complex is sustained during the coagulant response as the extrinsic 
Tenase is rapidly inhibited (Kurachi & Davie, 1977) (Figure 2). 
 The formation of the serine protease factor IXa results in its association with its 
non-enzymatic cofactor, factor VIIIa, on the activated platelet membrane forming intrinsic 
Tenase. This factors VIIIa-IXa-membrane ternary complex generates significant amounts 
of factor Xa from X as compared to extrinsic Tenase (Silverberg et al., 1977; van Dieijen 
et al., 1981). Consistent with this observation, the severe bleeding diatheses accompanying 
hemophilias A,and B are associated with deficiencies in plasma-derived factors VIII and 
IX, respectively (Hemker & Kahn, 1967; Loeliger et al., 1967; Meyer et al., 1967). The 
final enzyme in the coagulation cascade, Prothrombinase, is formed when the serine 
protease factor Xa associates with its non-enzymatic cofactor, factor Va, on the activated 
platelet membrane in the presence of Ca2+. Prothrombinase activates prothrombin to 





Figure 2. The Coagulation Cascade. 
Following an injury, the highly thrombogenic subendothelial extracellular matrix becomes 
exposed to plasma constituents allowing for platelet adhesion and activation and initiation 
of the hemostatic response. Subsequently, the extrinsic Tenase is formed comprised of 
plasma factor VIIa (FVIIa) and its subendothelial cofactor, tissue factor (TF) in the 
presence of Ca2+ (extrinsic pathway). Factors IX (FIX) and X (FX) are proteolytically 
activated to factors IXa (FIXa) and Xa (FXa), respectively by the TF-FVIIa complex. This 
TF-FVIIa complex is immediately ‘shut down’ by tissue factor pathway inhibitor (TFPI). 
Meanwhile, on the activated platelet surface, the FVIIIa-FIXa complex forms intrinsic 
Tenase which generates significant amounts of FXa for the platelet-bound Prothrombinase 
comprised of the FXa-FVa complex in the presence of Ca2+ to ensure thrombin generation 
from prothrombin. Thrombin sustains its own generation by further activating FXI to FXIa 
which then supplies the intrinsic Tenase with FIXa from FIX activation. Thrombin also 
converts FVIII to FVIIIa. Reactions of the Tenases, and Prothrombinase are significantly 
enhanced in the presence of cofactors: TF, FVIIIa, and FVa and membrane surfaces. 
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The thrombin formed, further activates soluble fibrinogen to insoluble fibrin allowing for 
the formation of the mesh-like network that strengthens the platelet plug (Ferry et al., 
1952). Final consolidation of the fibrin network is achieved through the actions of factor 
XIIIa, the transglutaminase, which is formed subsequent to the thrombin-mediated 
cleavage of the zymogen, factor XIII. Factor XIIIa covalently cross-links fibrin molecules 
together to form a stable fibrin clot (Ferry, 1952; Ferry et al., 1952; Doolittle et al., 1971).  
The initial amounts of thrombin generated when the coagulant response is initiated, 
amplifies the hemostatic response allowing for sustained thrombin generation required to 
stop a bleeding episode. Thrombin activates circulating platelets through their protease-
activated receptors 1 and 4 (PARs 1 and 4) allowing for the recruitment of additional 
platelets to the site of injury (Kahn et al., 1998; Kahn et al., 1999). Furthermore, activated 
platelets express the catalytic membrane surfaces (Walsh, 1974) required for the assembly 
of the macromolecular enzyme complexes, intrinsic Tenase and Prothrombinase. 
Thrombin also activates factors V and VIII to factors Va and VIIIa, respectively (Esmon, 
1979; Nesheim & Mann, 1979; Vehar & Davie, 1980). Likewise, the zymogens factors 
VII, and XI are activated to VIIa and XIa by thrombin, respectively (Radcliffe & 
Nemerson, 1975; Gailani & Broze, 1991). All of these reactions are required for the 
coagulant response as shown previously in figure 2. 
1.2. The Generation of Thrombin by Prothrombinase 
Thrombin is often described as the principal enzyme (or protease) in coagulation due 
to its pivotal role in ensuring clot formation (procoagulant functions), cessation of the 
procoagulant response (anticoagulant functions such as activation of protein C), and 
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ultimately clot dissolution. The most important procoagulant functions of thrombin 
includes the proteolytic cleavage of the procofactors, factors V and VIII, fibrinogen, and 
the activation of platelets. Additionally, thrombin has been observed to influence both the 
pro- and anti-inflammatory cell signaling processes as well as promote wound healing. It 
is thought that thrombin has a limited role during the genesis of the coagulation response; 
however, the crucial role for this protease in subsequent hemostatic processes cannot be 
overemphasized as detailed above. Therefore, the generation of significant amounts of 
thrombin under physiological conditions following an injury must await the expression of 
procoagulant surfaces such as the activated platelet membrane.  
Prothrombinase, a macromolecular enzyme complex comprised of a 1:1 
stoichiometric, Ca2+-dependent association of the serine protease, factor Xa, and its non-
enzymatic cofactor, factor Va, assembled on a procoagulant membrane surface (such as 
activated platelets or anionic phospholipids) mediates thrombin generation in vivo (Barton 
et al., 1967; Mann et al., 1990). Through limited proteolysis, platelet-bound 
Prothrombinase catalyzes the activation of the plasma-derived prothrombin zymogen - it’s 
only known physiological substrate.  
Previous studies have shown that the contribution of each non-protease component of 
the Prothrombinase enzyme is saturable and ensures maximum thrombin generation. 
Removal of any one of the components lowers enzymatic activity to a physiologically 
insignificant amount (as shown in Figure 3). In the absence of Ca2+ ions, factor Xa alone 
generates negligible amounts of thrombin (0.004 mol/thrombin/min/mol factor Xa) in an 
extremely slow proteolytic reaction (Nesheim et al., 1979a). The relative rate of thrombin 
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generation by factor Xa is enhanced by two-fold (0.010 mol/thrombin/min/mol factor Xa) 
in the presence of Ca2+ ions.  The addition of an appropriate membrane surface composed 
of anionic phospholipids to this reaction enhances the rate of thrombin generation by 10-
fold (0.094 mol/thrombin/min/mol factor Xa) as shown in Figure 3. A further addition of 
the cofactor, factor Va, to complete optimal Prothrombinase enzymatic activity increases 
the relative rate of thrombin generation by ~300,000-fold (~1200 mol/thrombin/min/mol 
factor Xa) consistent with desired amounts of thrombin capable of an efficient hemostatic 
response compared to factor Xa alone (Nesheim et al., 1979a). 
The substantial contribution of an appropriate membrane surface, physiologically 
provided by the activated platelet, to Prothrombinase function is demonstrated by 
approximately 800-fold decrease in thrombin generation (1.55 mol/thrombin/min/mol 
factor Xa) in reactions catalyzed by factor Xa in the presence of Ca2+ and factor Va. 
Likewise, removal of the cofactor, factor Va from the Prothrombinase enzyme results in a 
~10,000-fold reduction in thrombin generation. Thus, both the non-enzymatic cofactor, 
factor Va, and an appropriate anionic membrane surface are absolutely critical to the 
assembly and function of Prothrombinase expressing optimal catalytic efficiency (Nesheim 
et al., 1979a).  
In summary, the amount of thrombin generated from prothrombin activation by 
all or some of the components of Prothrombinase is variable. Similarly, the pathway of 
prothrombin activation (as discussed in detail in section 1.2.3.1) and the intermediates 
generated during thrombin formation appear distinct and depend on the membrane surface 
and (or) components of Prothrombinase that are present. Such observations suggest a 
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differential membrane-dependent enzyme assembly and function which requires further 
investigation. 
 
Figure 3. Contributions of the Components of Prothrombinase to Thrombin 
Generation. 
The relative rates of thrombin generation are indicated as a function of the constituents of 
the macromolecular prothrombinase enzyme: the serine protease, factor Xa, green color; 
the non-enzymatic cofactor, factor Va (showing its heavy chain, HC, and light chain, LC, 
grey color); assembled on a membrane surface, purple color, in the presence of Ca 2+, 




1.2.1. Coagulation Factor V 
1.2.1.1. Structural Features of Plasma-derived Factor V and Factor Va 
Coagulation factor Va is a key component of Prothrombinase and absolutely essential for 
normal hemostasis. The earliest observation of its importance in normal hemostasis was 
made by Dr. Paul Owren, who identified this protein in a patient with  a variable, but 
significant, bleeding diathesis, which could be corrected by administering prothrombin 
deficient plasma (Owren, 1947). Factor V is also known as proaccelerin or labile factor 
due to its enhancement of factor Xa’s catalytic activity, and its instability during 
purification, respectively. The involvement of factor V/Va in the hemostatic response only 
occurs after initiation of the coagulation cascade suggesting that the participation of this 
molecule in Prothrombinase is highly regulated. 
Plasma-derived factor V is synthesized by hepatocytes. It circulates as a 330 kDa 
single-chain, inactive, procofactor molecule (Esmon, 1979; Nesheim et al., 1979a). The 
earliest studies of the structure and function of coagulation factor V were done with the 
bovine protein and subsequently confirmed using human procofactors. Overall, bovine 
factor V is approximately 70% homologous to human factor V. However, sequence 
alignments of the two proteins indicate that the functional ends of both molecules, the N- 
and C-terminal halves, show as much as 84% and 86% identity, respectively (Guinto et al., 
1992). Several electron microscopy studies have reported that factor V is irregularly shaped 
displaying globular to oblong structures, and containing distinct appendages or domains 
(Lampe et al., 1984; Dahlback, 1985; Mosesson et al., 1990a; Mosesson et al., 1990b). 
Interestingly, blood coagulation proteins show a remarkable conservation of domain 
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structure across species, and homology amongst genes is common. Factor V is composed 
of the A1-A2-B-A3-C1-C2 domain structural arrangements from the N- to the C-terminus 
(Figure 4) (Vehar & Davie, 1980; Gitschier et al., 1984; Toole et al., 1984; Vehar et al., 
1984).  
 
Figure 4. Domain Structures of Human Factor V and Factor Va.  
Factor V is a single chain inactive glycoprotein with three main domain structures: three A 
domains, a single B domain, and two C domains (A1-A2-B-A3-C1-C2). When activated by 
thrombin (IIa, cleavage sites indicated by arrow), the inhibitory B domain is removed. The 
resulting the N-terminal heavy chain (A1-A2) and the C-terminal light chain (A3-C1-C2) 
reassociate non-covalently via a calcium ion to form the functional cofactor, factor Va. 
When factor V is proteolytically activated to factor Va (Figure 4) and described in 
detail in section 1.2.1.3), the N-terminal heavy chain (containing the A1 & A2 domains) 
and C-terminal light chain (containing the A3, C1, & C2 domains) remain non-covalently 
associated via a calcium ion. Crystal structures of full length factor V have been difficult 
to solve making the interpretation of functional studies challenging. Factor V share similar 
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domain organization with other proteins such as factor VIII. Factor V has little homology 
(14% sequence identity) to factor VIII in the central B domain however, approximately 
40% homology is observed in each A or C domain from both proteins (Jenny et al., 1987). 
Nonetheless, X-ray crystals of factor Va fragments including proteolytically inactive 
fragments (factor Vai) (Adams et al., 2004), factor Va domains or homologous proteins 
have proven useful to understanding functional studies and designing experiments to 
elucidate structure-function relationships. The X-ray crystal structure of ceruloplasmin has 
provided some insights into the structure and function of the A domains of factors V and 
VIII (Zaitseva et al., 1996). Additional structural evidence from the Fuentes-Prior and 
Stoddard laboratories implicate a significant role for factor Va (Macedo-Ribeiro et al., 
1999), and factor VIIIa (Pratt et al., 1999) light chains in anionic phospholipid binding, 
respectively. Several amino acids in the C2 region of human factors Va and VIIIa appear 
to make direct contacts with phospholipid membranes in both of their models. Together, 
these studies support a role for hydrophilic and hydrophobic C2-mediated interactions with 
the membrane interface allowing for the binding and assembly of these cofactors as part of 
their respective macromolecular enzyme complexes (Macedo-Ribeiro et al., 1999; Pratt et 
al., 1999; Adams et al., 2004). Similarly, the crystal structure of factor Vai (activated 
protein C-inactivated factor Va) from the Everse laboratory (Adams et al., 2004)  supported 
the involvement of hydrophobic amino acids (Trp26, Trp27, and Leu79) and electrostatic 
interactions (Arg43) in the binding of the C2 domain to membranes.  
Several earlier functional studies suggest a role for the factor Va light chain in 
anionic membrane binding and Prothrombinase assembly (Higgins & Mann, 1983; Tracy 
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& Mann, 1983), which may be supported by the structural evidence reported some studies 
above. For example, studies with phosphatidylserine (PS)-containing membranes have 
implicated a single site around Cys2113 of the C2 domain of factor Va in membrane binding 
(Srivastava et al., 2001). Further alanine substitution analyses of previously identified 
tryptophan and leucine residues on either C domain (C1 and C2) yielded a significant 
decrease in PS-membrane association and a 4-fold reduction in cofactor function in 
Prothrombinase assays implicating an important role for the C2 domain in membrane 
binding (Majumder et al., 2005; Peng et al., 2005). A crucial role for the C1 domain of 
factor Va in Prothrombinase function was confirmed by the observation of a significant 
decrease in the rate of thrombin generation (14,000-fold) when recombinant human factor 
Va Ala variants at Tyr1956 and Leu1957 were assayed for cofactor function (Majumder et al., 
2008). Taken together, the domain organization of factor V provides key regulatory regions 
that dictate the function of the cofactor, factor Va, in Prothrombinase assembly. In 
summary, factor V’s association with the membrane may involve a combination of factors 
including 1) penetration of the cofactor into the hydrophobic core (Krieg et al., 1987; 
Lecompte et al., 1987; Adams et al., 2004); 2) direct binding through electrostatic 
interactions (Pusey et al., 1982; Pusey & Nelsestuen, 1984); and/or 3) hydrophobic 
interactions mediated by key residues within the C domains (Bloom et al., 1979; 
Krishnaswamy & Mann, 1988).  
1.2.1.2. Post-translational Modifications on Factor V  
Since factor V is a very large glycoprotein, it is not surprising that post-translational 
modifications associated with factor V provide additional ways to regulate factor Va 
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function. Carbohydrate moieties or glycans are large, hydrophilic post-translational 
modifications which are regarded as maturation and quality-control determinants in the 
early secretory pathway of most proteins. However, when retained in a mature protein, they 
often perform important regulatory and functional roles post-synthesis. While human 
factor V is inherently a large protein (249 kDa, based on amino acids), glycans contribute 
significantly (13-25%) to its molecular weight (330, kDa including glycans) (Kane & 
Davie, 1986; Kane et al., 1987) as shown in Figure 5A. The glycans on factor V are 
distributed across all the domains of the protein. In total 37 N-linked glycosylation sites 
have been observed on factor V including nine in the heavy chain (A1-A2 domains), 25 
within the B domain, and three in the light chain (A3-C1-C2 domains) (Jenny et al., 1987). 
While some of these glycans on factor V have been confirmed using mass spectrometry 
and lectin-binding techniques, their functional properties remain to be elucidated. Of the 
three potential (Asn1675, Asp1982 & Asn2181) light chain sites, Asn1675, and Asn1982 were 
found to be consistently glycosylated when expressed in a eukaryotic cell system (Kim et 
al., 1999). However, glycosylation at Asn2181 is variable and exists in two forms: factor 
Va1 and factor Va2. The presence or absence of this glycan accounts for the doublet light 
chains formed (74 kDa, factor Va1 or 71 kDa, factor Va2, respectively) following thrombin 
activation of factor V (Kim et al., 1999; Nicolaes et al., 1999). Likewise, this differential 
glycosylation at Asn2181 reportedly decreases the anionic phospholipid membrane affinity 
of factor Va1 by three to 45-fold compared to factor Va2 (Rosing et al., 1993; Koppaka et 
al., 1997; Kim et al., 1999). Accordingly, decreased cofactor function of factor Va1 has 
been reported in various functional assays (Varadi et al., 1996; Hoekema et al., 1997; 
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Nicolaes et al., 1999). It is thought that the observations described above are the 
consequence of the inhibitory effect of the bulky glycan at position 2181. Therefore, by 
limiting access to crucial membrane binding sites on the C2 domain of factor Va, cofactor 
properties are affected. Studies have shown that Asn1982 (located on the light chain) 
contains a high mannose N-linked glycan. Earlier work using a combination of 
immunoaffinity techniques and carbohydrate binding proteins such as lectins predicted the 
presence of another high mannose N-linked glycan at Asn269 on the heavy chain of factor 
Va (Liu et al., 2005). Additional mass spectrometric analyses confirmed the presence of 
these high mannose residues at the two sites above (Lewandrowski et al., 2006). Further 
work evaluating the functional properties of these high mannose N-linked glycans (Asn269 
and Asn1982) particularly the high mannose residue at Asn1982, will be described in detail in 
Chapter Five of this dissertation.  
 While structural interference posed by glycans may explain some functional 
consequences, global removal of human factor V glycans has produced conflicting data 
from various studies. Bruin and colleagues reported that deglycosylation of factor V 
impaired activation by thrombin, and increased clotting time in thrombin generation assays 
(Gumprecht & Colman, 1975; Bruin et al., 1987). Removal of N-linked glycans with 
endoglycosidase has been reported to increase susceptibility to APC-mediated inactivation 
of deglycosylated cofactor, factor Va (Fernandez et al., 1997). Conversely, little change 
with respect to thrombin activation and APC-mediated inactivation of the deglycosylated 




 Interestingly, unlike the N-linked glycans that are found in all regions of the human 
factor V molecule O-linked glycans appear limited in their distribution on the cofactor 
molecule. Treatment with O-glycanases (which removes O-linked glycans) produced 
electrophoresis mobility shifts only within the B domain suggesting an abundance of this 
glycan in this region of factor V (Fernandez et al., 1997; Silveira, 1997). 
 
Figure 5. Schematic of the Post-translational Modifications Identified on Factor V. 
Panel A shows the glycosylation sites and their locations on human factor V. Algorithms 
have identified 37 N-linked glycosylation sites across the single chain molecule (orange + 
black + gray). The heavy chain, the B domain, and the light chain contains nine, 25, and 
three potential N-linked glycans, respectively. Only five of these have been confirmed as 
partially glycosylated (gray) and glycosylated (black). Panel B indicates the seven potential 
tyrosine sulfation sites (purple) and the three confirmed phosphorylation sites (blue) on 
factor V.  
 Phosphorylation is a major post-translational modification which plays important 
roles in the regulation and function of various proteins in vivo. As shown in Figure 5B, 
three main sites have been identified as phosphorylation targets on plasma-derived factor 
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V. Using both purified casein kinase II, and a soluble platelet releasate, following 
thrombin-catalyzed platelet activation, Kalafatis et al. observed the incorporation of 
radioactive phosphates into one site on the light chain and two sites on the heavy chain of 
factor V (Kalafatis et al., 1993). In a subsequent study, Rand and colleagues reported 
limited phosphorylation of the platelet-derived factor Va heavy chain (Rand et al., 1994). 
Additional studies indicated that phosphorylation at Ser692 appears unique to the plasma-
derived factor Va heavy chain and might be mediated by a casein kinase II-like enzyme in 
vivo (Gould et al., 2004). The phosphorylation of Ser692 in plasma-derived factor Va and 
the inability to phosphorylate Ser692 in platelet-derived factor Va have significant 
functional implications and are discussed in detail in sections 1.2.1.6 and 1.2.1.9 
respectively.  
Another post-translational modification observed on human factor V is the 
modification of the hydroxyl of tyrosine residues with sulfates. Using computer algorithms, 
Hortin and colleagues predicted seven tryrosine sulfation sites on recombinant factor V 
grown in the presence of radioactive sulfate (Hortin et al., 1986). Consistent with an 
overlap with O-glycans, the B domain rich tyrosine sulfates bound the O-linked binding 
lectin, jacalin, in their affinity purification system (Hortin, 1990). Two groups of tyrosine 
sulfation sites, Tyr1494, Tyr1510, and Tyr1515 (located in the B domain) and Tyr665, Tyr696, 
and Tyr698 (located in the heavy chain), are close to thrombin cleavage sites at Arg1545 and 
Arg709, respectively. Functional characterization of these modifications by Pittman and 
colleagues demonstrated that sulfation on factor V correlates with efficient thrombin 
activation to factor Va and increased cofactor function (Pittman et al., 1994). Interestingly, 
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studies by Gould and colleagues reported no obvious sulfate modifications of the 
previously identified tyrosine residues on the heavy chain of purified human plasma-
derived factor Va (Gould et al., 2004). 
1.2.1.3. Functional Properties of Factor Va 
Coagulation factor V circulates in plasma as a single-chain, inactive, protein procofactor 
expressing negligible if any cofactor activity (approximately 0.3% that of the active 
cofactor, factor Va) (Nesheim et al., 1979a). This non-enzymatic procofactor must be 
proteolytically activated prior to its association and function as a key component of 
Prothrombinase during hemostasis. Under physiological conditions, factor V is a substrate 
for a variety of human proteases. Cleavage of factor V by these proteases produces several 
fragments which show little to full cofactor activity when compared to factor Va. These 
include elastase (Oates & Salem, 1987; Turkington, 1993; Allen & Tracy, 1995; Samis et 
al., 1997; Camire et al., 1998a), cathepsin G (Turkington, 1993; Allen & Tracy, 1995; 
Camire et al., 1998a), calpain (Rodgers et al., 1987; Bradford et al., 1988), and  plasmin 
(Lee & Mann, 1989). Other proteases such as factor XIa (Whelihan et al., 2010), factor Xa 
(Smith & Hanahan, 1976; Foster et al., 1983; Tracy et al., 1983; Monkovic & Tracy, 1990a, 
b), and thrombin (Esmon, 1979; Nesheim & Mann, 1979; Nesheim et al., 1979b; Kane & 
Majerus, 1981; Suzuki et al., 1982; Foster et al., 1983; Monkovic & Tracy, 1990a, b) which 
are associated with the coagulation response, cleave factor V to produce significant factor 
Va cofactor activity. Principal amongst these proteases is thrombin, which is the main 
physiological activator of coagulation factor V.  
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Factor Va is formed following sequential cleavages at three Arg residues (Arg709, Arg1018 
and Arg1545) of the single chain factor V molecule. As shown in Figure 6, initial cleavage 
at Arg709 produces the amino-terminal derived heavy chain (105 kDa) and a 280 kDa 
fragment (containing the entire B domain and the light chain). Subsequent cleavage at 
Arg1018 of the 280 kDa fragment produces a 71 kDa B domain fragment and a 220 kDa 
intermediate fragment (comprised of a portion of the B domain and the C-terminal half of 
factor V). A final cleavage at Arg1545 of the 220 kDa fragment releases the carboxyl-
terminal derived light chain (71/74 kDa) and a 150 kDa B domain fragment. 
  
Figure 6. Thrombin-mediated Activation of Factor V to Factor Va.  
Thrombin activates plasma-derived single chain factor V to factor Va via three sequential 
cleavages. Cleavage at Arg709 occurs first with the generation of the heavy chain fragment 
(105 kDa). A second cleavage at Arg1018 within the B domain, and a third cleavage at 
Arg1545 releases the light chain fragment. A calcium-dependent reassociation of the heavy 
and light chains forms the functional cofactor factor Va. 
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The heavy chain (105 kDa) and the light chain (74/71 kDa) remain associated non-
covalently in the presence of calcium ions to form the functional cofactor, factor Va 
(Esmon, 1979; Nesheim & Mann, 1979; Guinto & Esmon, 1982; Suzuki et al., 1982; 
Krishnaswamy et al., 1989; Monkovic & Tracy, 1990a).   
Interestingly, factor Xa cleaves factor V at the same sites as thrombin (Arg709, 
Arg1018, & Arg1545) (Figure 6). However, the order of peptide bond cleavages are different 
between the two proteases. Cleavage at Arg1018 within the B domain occurs first generating 
a 150 kDa amino-terminal fragment (comprised of the heavy chain and a portion of the B 
domain) and a 220 kDa carboxyl-terminal fragment (comprised of the light chain and the 
remaining half of the B domain) (Figure 7). The generation of these fragments is associated 
with significant cofactor activity suggesting that cleavage at Arg1018 is crucial for cofactor 
function (Monkovic & Tracy, 1990a). A second cleavage of the 150 kDa fragment at or 
near Arg709 generates the heavy chain (105 kDa). While a third cleavage at Arg1545 occurs 
to release the putative light chain doublet (74/71 kDa) of factor Va, the rate of this cleavage 
is very slow, and does not contribute to additional cofactor activity compared to the initial 
cleavage at Arg1018 (Monkovic & Tracy, 1990a) (Figure 7). Other studies from our 
laboratory showed that cleavage at Arg1545 and the release of the B domain promotes factor 
Xa’s association with factor Va (Camire et al., 1998a).   
Despite the differential pattern of peptide bond cleavages between thrombin and 
factor Xa during factor V activation, both proteases show similar catalytic efficiencies: 3.3 
x106 M-1s-1 and 4.1 x 106 M-1s-1, respectively. The affinity of factor Xa for factor V is 
higher with a Km ~7-fold lower than thrombin (10.4 nM vs 71.1 nM). However, consistent 
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with its higher potency, substrate turnover (kcat) by thrombin appears ~5-fold faster than 
factor Xa (14.0 min-1 vs 2.6 min-1, respectively) (Monkovic & Tracy, 1990a). Interestingly, 
prolonged incubation of factor V with either thrombin or factor Xa is associated with a 
fourth cleavage site near or at Arg643 (Hockin et al., 1997; Erdogan et al., 2007), or Arg1765 
(Tracy et al., 1983; Odegaard & Mann, 1987; Thorelli et al., 1997). Cleavage by the former 
protease is associated with a significant decrease in clotting potential (60%) whereas 
cleavage by factor Xa has no effect on clotting activity (Tracy et al., 1983; Hockin et al., 
1997). 
 
Figure 7. Proteolysis of Factor V by Factor Xa.  
Factor Xa activates factor V following cleavages at Arg residues 709, 1018, and 1545. 
However, the order of bond cleavages are different from those of thrombin. Initial cleavage 
occurs at Arg1018 within the B domain to generate 150 and 220 kDa fragments. Next, the 
150 kDa fragment is cleaved releasing the heavy chain of factor Va (105 kDa), and a 71 
kDa B domain-derived fragment. A subsequent slow cleavage at Arg1545 of the 220 kDa 
fragment releases the light chain of factor Va (71/74 kDa). Together, the heavy (105 kDa) 
and light (71/74 kDa) chains associate in the presence of calcium to form factor Va. 
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From the studies detailed above, it appears that the B domain of factor V plays an 
important role in preserving the procofactor state of this coagulation protein molecule.  
Pioneering work investigating the role of this region of factor V was done by Kane and 
colleagues. In their study, they expressed a partial truncated B domain-less factor V species 
in COS cells and monitored cofactor function in vitro. Factor Vdes811-1491 (FV-DT, 
lacking a significant portion of the B domain) showed substantial cofactor activity, ~ 30-
38% when compared to factor Va produced by thrombin- or snake venom protease-
mediated activation of factor V, respectively (Kane et al., 1990; Keller et al., 1995). A 
more recent study by Toso and Camire (Toso & Camire, 2004), using similar constructs 
revealed that the cofactor functions of FV-DT and factor Va were identical in 
Prothrombinase assays. Thus, full cofactor activity is expressed in the absence of the B 
domain region implicating  a key role of the central B domain in preserving  and 
maintaining the inactive procofactor state of factor V. Together, these studies suggest that 
removal of the B domain eliminates conformational constraints within factor Va allowing 
for productive binding to membranes and interaction with factor Xa during Prothrombinase 
assembly and function (Toso & Camire, 2004). Additional mutational studies of the amino 
acid sequences within the highly conserved basic region in the B domain (via deletions or 
substitutions) suggest that residues 963 through 1008 are essential for maintaining the 
procofactor state of factor V (Zhu et al., 2007). More recently, it has been shown that an 
autoinhibitory motif in the B domain of factor V, contributed by the previously identified 
basic (963-1008) region and a newly identified acidic (1493-1537) region ensures that 
factor V remains inactive until appropriately activated (Mettine & Camire, 2012). 
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Once formed, factor Va contributes to substantial thrombin generation as part of 
Prothrombinase. This function is possible following the loss of the inhibitory B domain, 
and exposure of previously buried key amino acid residues (in factor V) for binding to both 
divalent metal ions, anionic membranes (discussed in section 1.2.1.3), and factor Xa. 
Particularly, the exposure of the carboxyl-terminal region of the factor Va heavy chain and 
access to residues within the A2 domain appears crucial to factor Va function (Kojima et 
al., 1998; Kalafatis & Beck, 2002; Singh et al., 2003; Beck et al., 2004; Barhoover et al., 
2008b; Barhoover et al., 2008a). The earliest work mapping residues of factor Va involved 
in Prothrombinase function were performed by Kojima and colleagues. They observed that 
peptide sequences from Ile311 to Tyr335 noncompetitively inhibited thrombin generation by 
50% (Kojima et al., 1998). Similarly, factor V residues 323 to 331 were found to bind 
factor Xa, and significantly inhibited Prothrombinase in peptide titration studies (Kalafatis 
& Beck, 2002). Singh and others identified four residues in factor V including Glu323, 
Tyr324, Val331, and Glu330 as mediating the inhibition reported earlier (Singh et al., 2003). 
Likewise, an alanine-substituted quadruple mutant of the residues above showed ~400-fold 
lower Prothrombinase activity compared to wild type factor Va (Barhoover et al., 2008b). 
In additional studies, only 25% cofactor activity was observed in clotting assays when 
Asp334 and Tyr335 were substituted with alanine residues (Barhoover et al., 2008a). Several 
other studies have identified amino acids which mediate the binding and association of 
factor Va with factor Xa during Prothrombinase assembly. These include Glu467, Arg501, 
Arg510, Ala511, Asp513, Asp577, Asp578, Arg652 and His1683and with the exception of His1683 
all reside within the heavy chain of factor Va (Steen et al., 2002; Steen et al., 2008).  
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In summary, the majority of the studies detailed above defining the functional 
regions of plasma-derived factor V/Va were done using anionic membranes. Using key 
amino acids identified in factor V above, including the structures of homologous proteins 
such as factor Xa and ceruloplasmin (Brandstetter et al., 1996; Macedo-Ribeiro et al., 
1999), several models of Prothrombinase have been developed. These models have 
contributed to our present understanding of important structure-function relationships of 
the cofactor, and the enzyme in general (Adams et al., 2004; Autin et al., 2006; Lee et al., 
2008; Stoilova-McPhie et al., 2008; Lechtenberg et al., 2013).  Recently, a crystal structure 
of Prothrombinase (pseutarin C) from the venom of the Australian Eastern Brown Snake 
(Pseudonaja textilis) was solved by the Huntington Lab. While this pre-formed snake 
Prothrombinase can function in the presence or absence of an appropriate membrane, the 
structure of factor Va supports previous observations where the C2 domains form the legs 
on the membrane surface and allow for tight interactions of the A domains with factor Xa 
for enzyme formation and Prothrombinase function (Lechtenberg et al., 2013). 
1.2.1.4. Inactivation of Factors V and Va 
While the importance of thrombin generation cannot be overemphasized during the 
procoagulant response, a timely regulation of excessive thrombin generation is equally 
vital to preventing unwanted thrombus growth following an injury. Thrombin down-
regulates its own generation via the thrombin-thrombomodulin complex in a mechanism 
where thrombin’s binding to endothelial derived-thrombomodulin shifts the balance in 
favor of the anticoagulant response. Therefore, the thrombin-thrombomodulin complex has 
high affinity for protein C resulting in its conversion to activated protein C (APC). The 
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major substrates for APC are the cofactors of the intrinsic Tenase (factor VIIIa) and 
Prothrombinase (factor Va). APC can also inactivate factor V. 
APC-catalyzed inactivation of factor Va requires the ordered proteolysis of the 
heavy chain at three key residues: Arg506, Arg306 and Arg679 (Salem et al., 1983; Suzuki et 
al., 1983; Kalafatis et al., 1994). Cleavage at Arg506 produces a 75 kDa fragment with the 
subsequent cleavage of this intermediate at Arg306 producing a 30 kDa fragment. The final 
cleavage at Arg679 produces a 30 amino acid peptide (Figure 8A). Nicolaes and colleagues 
showed that greater than 50% of factor Va’s cofactor activity is lost following initial 
cleavage at Arg506. Consistent with a reduced affinity for factor Xa, the Kd of factor Xa for 
factor Va, following its cleavage at Arg506 decreased by ~97-fold in Prothrombinase assays 
(FVai, 3.9 nM vs FVa, 0.1 nM). A complete loss of factor Va cofactor activity is associated 
with further cleavage at Arg306 (Kd of factor Xa for FVai, 196 nM, vs FVa, 20 nM) 
(Nicolaes et al., 1995). Interestingly, the functional importance of cleavage at Arg679 
appears inconsequential despite contributing to destroying the overall structural integrity 
of factor Va during the proteolytic process. A recombinant factor V lacking this cleavage 
site was inactivated by APC at the same rate as the wild type cofactor (Egan et al., 1997; 
Heeb et al., 1999a).  
The procofactor, factor V, is also inactivated by APC; however, an additional 
cleavage site at Lys994 (Kalafatis et al., 1994) within the B domain is observed (Figure 8B). 
Proteolytic fragments from the APC-catalyzed inactivation of factor V show no cofactor 
activity when further treated with thrombin. Proteolytic inactivation of factor V first occurs 
at Arg306 followed by Arg506 within the heavy chain. A final cleavage is observed at both 
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Arg679 and Lys994 (Kalafatis et al., 1994; Kalafatis et al., 1995). Cleavage at the 306 site 
by APC is associated with complete inactivation of the factor V molecule, similar to that 
observed with the cofactor, factor Va. 
Like most vitamin K-dependent coagulation proteases, membrane binding, and the 
presence or absence of cofactors, are vital to optimizing the functional properties of APC 
and to ultimately achieving catalytic efficiency comparable to other coagulation enzymes 
such as Prothrombinase. Several studies have demonstrated that cleavage at Arg306 on both 
factors Va and V depends on the presence of an anionic phospholipid membrane surface 
(Suzuki et al., 1983; Kalafatis et al., 1994; Heeb et al., 1995; Nicolaes et al., 1995; Hockin 
et al., 1997; Heeb et al., 1999a), which can also be provided by the activated platelet 
(Solymoss et al., 1988). While, cleavages at Arg506 and Arg679 are only slightly enhanced 
by membrane binding, the loss of an appropriate membrane surface significantly decreases 
cleavage at Arg306 by ~1000-fold (Nicolaes et al., 1995; Hockin et al., 1997). 
Other studies have shown that factor Xa protects factor Va from APC-catalyzed 
inactivation at Arg506. Thus, at both sub-saturating and saturating concentrations of factor 
Xa, cofactor activity is decreased by approximately 60% (Egan et al., 1997) and 20% 
(Kalafatis et al., 1994; Rosing et al., 1995; Egan et al., 1997; Hockin et al., 1997; Heeb et 
al., 1999b), respectively. The ability of factor Xa to protect factor Va from inactivation 
was found to be further enhanced (~100-fold) in the presence of prothrombin (Rosing et 
al., 1995).  
Protein S has been proposed as a non-enzymatic cofactor of APC. Impaired 
function or lower levels of protein S has been reported in some individuals with inherited 
 31 
 
thrombophilia (Makris et al., 1997; Esmon, 2000). Interestingly, several studies have 
shown only a marginal increase (two- to ten-fold) in the catalytic activity of APC in the 
presence of protein S (Dahlback, 1986; Solymoss et al., 1988; Tans et al., 1991b). 
 
Figure 8. Schematic of Factor Va and Factor V Proteolytic Inactivation by Activated 
Protein C.  
The activated protein C-mediated proteolysis of factor Va (A) and factor V (B) are 
indicated. The heavy and a light chains of factor V are shown in blue with the B domain in 
grey. The order of bond cleavages are indicated by arrows along with the cleavage sites: 
Arg305, Arg506, Arg679 and Lys994.  
The addition of protein S to APC reactions monitoring the proteolysis of factor Va 
increases cleavage at Arg306 by ~ 20-fold (Rosing et al., 1995). Interestingly, the protection 
by factor Xa at Arg506 within the factor Va heavy chain is eliminated in the presence of 
protein S. It has been suggested that in its role as a cofactor for APC, protein S competes 
for binding to anionic membranes to which Prothrombinase binds thereby weakening the 
protective effect of the bound factor Xa (van Wijnen et al., 1996).  
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The effect of glycans on the APC-catalyzed, membrane-dependent inactivation of 
factor Va was investigated by Fernandez and colleagues. They observed that partial 
removal of the glycans following treatment with neuraminidase and N-glycanase enhanced 
APC-catalyzed inactivation by ~ three-fold (Fernandez et al., 1997). Similar studies from 
our laboratory revealed that glycosidase treatment of factor V increased its susceptibility 
to APC-mediated cleavage at Arg306 by ten-fold, but was without effect on factor Va 
(Silveira, 1997; Silveira et al., 2002).  
Other post-translational modifications including phosphorylation appear to affect 
inactivation of factor Va by APC. Phosphorylation at Ser692 in plasma-derived factor Va 
increased its APC catalyzed cleavage by ~ 3-fold with negligible effect on the cleavages at 
Arg506 and Arg67 (Kalafatis, 1998). Together, these studies support a role for post-
translational modifications in regulating both factor V and factor Va. 
The APC-catalyzed inactivation of factor Va as well as factor VIIIa (Kalafatis et 
al., 1993; Kalafatis et al., 1994) represents an important physiological anticoagulant system 
poised to prevent unwanted thrombosis. Thus, naturally occurring mutations in coagulation 
proteins regulated by this system may predispose individuals to thrombosis. APC 
resistance, identified by Dahlback and colleagues in the early 1990s, is hereditary and 
associated with venous thrombosis (Dahlback et al., 1993). A missense mutation in the 
factor V gene resulting in an Arg to Gln substitution at position 506 (factor V R506Q or 
factor VLeiden) is quite common, and confers resistance to APC-mediated inactivation of the 
cofactor molecule in individuals carrying the mutation (Bertina et al., 1994; Dahlback, 
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1994). Homozygosity or heterozygosity of this mutation is associated with a 30-140 fold 
or 38-fold propensity for venous thrombosis, respectively (Dahlback, 1997). 
Studies of the APC-catalyzed inactivation of factor VaLeiden have indicated that, 
while access to cleavage at Arg506 is eliminated, inactivation will occur via cleavage at 
Arg306; however,  the rate of inactivation is ~10-fold lower compared to normal factor Va 
(Heeb et al., 1995; Kalafatis et al., 1995; Kalafatis & Mann, 1995; Nicolaes et al., 1995; 
Dahlback, 1997; Egan et al., 1997). A reduced risk of  thrombosis is also associated with 
variable factor V mutations at Arg306 including factor V R306T (factor VCambridge) 
(Williamson et al., 1998) and factor V R306G (factor VHong Kong) (Chan et al., 1998). These 
observations are consistent with earlier reports that suggest that cleavage at Arg506 and 
Arg306 are not mutually exclusive, yet are essential for the ultimate inactivation of factor 
Va.  
Plasmin, a key fibrinolytic protease derived from plasminogen activation also 
cleaves factor Va to produce factor Vai. However, compared to APC, plasmin cleaves 
factor Va at multiple lysine residues in both the heavy and the light chains to produce a 
mixture of fragmented polypeptides with no cofactor activity. Five (Lys93, Lys109, Arg348, 
Lys364, and Lys456) heavy chain and three (Lys1656, Lys1765, and Lys1827) light chain 
cleavage sites for plasmin have been identified (Zeibdawi & Pryzdial, 2001). Omar and 
Mann demonstrated that, similar to APC, plasmin-mediated inactivation of factor Va is 
significantly increased in the presence of an anionic phospholipid membrane (Omar & 
Mann, 1987). Additionally, factor Xa appears to protect the cofactor from inactivation by 
plasmin. While both the cofactor and the procofactor are inactivated equally by plasmin, 
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Lee and Mann observed that the initial proteolysis of factor V by plasmin produced 
fragments with short-lived procoagulant activity (Lee & Mann, 1989).  
1.2.1.5. Origins of Plasma-derived and Platelet-derived Factor V/Va  
 Factor V exists in two pools in human blood. Tracy and colleagues demonstrated 
that approximately 75-80% of factor V circulates in the plasma (plasma-derived factor V), 
with the remaining 20-25% residing in platelets (platelet-derived factor V/Va) (Tracy et 
al., 1982). The average concentration of plasma-derived factor V is ~7-10 µg/mL (20-30 
nM). Platelet-derived factor V is stored within α-granules (Vicic et al., 1980) and averages 
approximately 4,600-14,100 molecules of factor V/platelet (Tracy et al., 1982).  
Plasma-derived factor V is synthesized and secreted by hepatocytes (Mattii et al., 
1964; Owen & Bowie, 1977; Mazzorana et al., 1991). Historically, however, the source of 
human platelet-derived factor V was more difficult to establish unequivocally. Even though 
there is a single factor V gene, many studies from our laboratory have demonstrated that 
platelet-derived factor V is phenotypically and functionally different from plasma-derived 
factor V (Monkovic & Tracy, 1990a, b; Camire et al., 1995; Conlon, 1997; Silveira, 1997; 
Camire et al., 1998c; Silveira et al., 2002; Gould et al., 2004; Wood et al., 2008). 
Consequently, we hypothesized that human megakaryocytes, platelet precursor cells, 
synthesized factor V and “re-tailored” it prior to its packaging into platelet α-granules. This 
hypothesis seemed tenable since human megakaryocytes were shown to contain factor V 
(Breederveld et al., 1975; Osterud et al., 1977; Vicic et al., 1980; Tracy et al., 1982) , as 
were other bone marrow-derived cells, e.g. lymphocytes and monocytes (Tracy et al., 
1985).  In addition, studies from other laboratories had demonstrated that megakaryocytes, 
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derived from guinea pigs (Chiu et al., 1985) and mice (Sun et al., 2003), synthesize factor 
V. However, despite collaborations with outstanding megakaryocyte laboratories, we were 
unable to demonstrate factor V synthesis by human megakaryocytes (unpublished 
observations). Consequently, we decided to take a genetic approach.  
Two individuals heterozygous for the factor VLeiden variant were identified who 
received either an allogeneic bone marrow transplant or allogeneic liver transplant from 
individuals expressing wild-type factor V. By assessing the APC-catalyzed proteolytic 
inactivation of factor Va released by thrombin-activated platelets from these recipients, 
Camire, et al. (Camire et al., 1998b) demonstrated that the platelets obtained from the bone 
marrow recipient released both wild-type factor Va and factor VaLeiden, whereas platelets 
obtained from the liver recipient released only wild-type factor Va while retaining the 
factor VaLeiden allele in their megakaryocyte genome. The factor Va released by these two 
individuals mirrored the factor V/Va that was synthesized in and secreted from their 
hepatocytes. Therefore, it appeared that the platelet-derived factor V pool originates from 
megakaryocyte endocytosis of plasma factor V (Camire et al., 1998b).  
Several other studies have shown that the majority of proteins found in platelets are 
acquired from progenitor cells during megakaryocyte maturation and proplatelet formation 
due to the limited synthetic capabilities of mature platelets. Plasma proteins such as 
fibrinogen, IgG, and albumin are endocytosed and packaged into α-granules by 
megakaryocytes (Handagama & Bainton, 1989; Harrison et al., 1989; Handagama et al., 
1990). Using similar approaches, Bouchard and colleagues demonstrated that the platelet 
pool of factor V may be derived entirely from the factor V plasma pool via megakaryocyte 
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endocytosis (Bouchard et al., 2005). They demonstrated that factor V was endocytosed in 
a time-dependent manner by megakaryocytes derived from CD34+ progenitor cells or 
megakaryocyte-like cell lines, but not by platelets. CD41+ ex vivo-derived megakaryocytes 
endocytosed factor V, as did subpopulations of the megakaryocyte-like cells, MEG-01 and 
CMK. In similar studies, Ayombil and colleagues demonstrated that thrombin-activated 
lysates from CMK cells, which had endocytosed factor V, express factor Va cofactor 
activity in clotting assays. Additionally, the electrophoretic phenotype of the endocytosed 
factor V was similar to that observed in normal platelet lysates (Ayombil et al., 2013). 
Bouchard and colleagues further demonstrated that plasma-derived factor V 
endocytosis by megakaryocytes is mediated by low-density lipoprotein receptor related 
protein-1 (LRP-1) through a Ca2+ - and clathrin-dependent process (Bouchard et al., 2008). 
Based on additional studies (Bouchard et al., 2005; Bouchard et al., 2008), they proposed 
a two receptor model to explain the mechanism of factor V endocytosis. Plasma-derived 
factor V binding to a specific receptor facilitates binding to and endocytosis of, a second 
factor V molecule by LRP-1, or a related family member. Subsequent to its endocytosis, 
factor V is trafficked through several compartments including the early and late endosomes 
(Seifert, 2005), and the endoplasmic reticulum before final packaging into α-granules 
(Bouchard et al., 2008) as described in detail in Section 1.2.1.5. Furthermore, we 
hypothesize that through endocytosis, plasma-derived factor V is phenotypically and 
proteolytically modified to form the functionally and physically unique pool of protease-
resistant, platelet-derived factor V/Va. 
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1.2.1.6. Functional and Phenotypic Differences between Platelet- derived and 
Plasma-derived factor V 
In marked contrast to plasma-derived factor V, secretable platelet-derived factor V/Va 
molecules express significant cofactor activity upon their release from α-granules. Platelet 
agonists including collagen, epinephrine, arachidonic acid, and ADP mediate platelet-
derived factor V/Va release from secretory α-granules (Osterud et al., 1977; Kane et al., 
1980; Vicic et al., 1980; Chesney et al., 1981; Tracy et al., 1985; Monkovic & Tracy, 
1990b). When compared to the plasma-derived factor V molecule, platelet-derived factor 
V/Va is composed of a mixture of polypeptide fragments with varying molecular weights 
(46-330 kDa) (Viskup et al., 1987; Monkovic & Tracy, 1990b; Ayombil et al., 2013). 
Between 5-50% of the cofactor activity observed with thrombin-activated plasma-derived 
factor Va is expressed by platelet-derived factor V/Va upon release. Consistent with these 
observations polypeptide fragments similar in molecular weights to factor Va heavy and 
light chains are associated with agonist-mediated platelet activation and secretion (Kane et 
al., 1980; Vicic et al., 1980; Viskup et al., 1987; Monkovic & Tracy, 1990b; Ayombil et 
al., 2013). According to Monkovic and Tracy, further activation of platelet-derived factor 
V/Va molecules by thrombin or factor Xa results in only a two- to three-fold increase in 
cofactor activity (Monkovic & Tracy, 1990a). These studies suggest that platelet-derived 
factor V/Va is pre-packaged and stored in a partially-activated state in α-granules making 
it capable of mounting a rapid procoagulant response during the initial response to vascular 
injury when compared to the plasma-derived factor V that requires proteolytic activation 
prior to expressing cofactor activity.  
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Several studies have reported additional variable physical and functional 
characteristics of the two pools of factor V. According to Monkovic and Tracy, there is no 
obvious electrophoretic mobility differences between the heavy and light chains of factor 
Va derived from either the plasma or platelet pools (Monkovic & Tracy, 1990b). However, 
Gould and colleagues observed, following N-terminal sequencing, that the light chain of 
platelet-derived factor Va is cleaved at Tyr1543 and not Arg1545,  as is seen with thrombin-
or factor Xa-catalyzed factor V activation (Gould et al., 2004). Likewise, Thr402 on the 
heavy chain of platelet-derived factor Va is O-glycosylated with an N-acetylglucosamine 
or N-acetylgalactosamine whereas plasma-derived factor Va is not. Additionally, 
differential phosphorylation at Ser692 of the heavy chain has been reported. While plasma-
derived factor V can be phosphorylated by casein kinase II or a casein kinase II-like 
protease, the platelet-derived molecule is completely resistant to phosphorylation at this 
site (Kalafatis et al., 1994; Kalafatis, 1998).  
Previous studies have reported that plasma- and platelet-derived factor V are 
differentially activated by various proteases of the coagulation system. Platelet-derived 
factor V/Va is a better substrate for factor Xa than thrombin. Monkovic and Tracy 
demonstrated that factor Xa activates platelet-derived factor V/Va ~50-100 times more 
effectively than thrombin (Monkovic & Tracy, 1990b). In contrast, plasma-derived factor 
V is activated equally by factor Xa and thrombin (Monkovic & Tracy, 1990a). Plasmin 
rapidly inactivates plasma-derived factor Va in the presence of anionic phospholipids (Lee 
& Mann, 1989) while platelet-derived factor Va exhibits both increased and sustained 
activity (up to 4 h) in the presence of plasmin and the activated platelet surface. This 
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observation suggests that the platelet membrane or some component of the platelet-
releasate offers a protective effect since inactivation is significantly delayed in contrast to 
inactivation reactions on anionic phospholipid membranes (Conlon, 1997). Additionally, 
studies from our laboratory have shown that platelet-derived factor Va is resistant to 
inactivation by APC compared to plasma-derived factor Va (Camire et al., 1995; Camire 
et al., 1998a).  Following prolonged incubation with APC (120 min), the cofactor activities 
of platelet- vs plasma-derived factor Va were decreased by ~50% and 100% respectively, 
in the presence of activated platelets. The resistance of platelet-derived factor Va to 
inactivation by APC correlated with reduced cleavage at Arg506. Interestingly, normal 
platelet-derived factor Va was as resistant to APC-catalyzed inactivation as was the factor 
Va from individuals with factor VLeiden (Camire et al., 1995; Heeb et al., 1995; Kalafatis et 
al., 1995; Nicolaes et al., 1995; Camire et al., 1998a). These observations are consistent 
with the physiological importance of platelet-secreted factor V/Va molecules as key 
constituents that regulate the procoagulant response following an injury.  
1.2.1.7. Physiological Significance of Platelet-derived vs. Plasma-derived Factor Va 
The importance of  α-granule stored platelet-derived factor Va to the maintenance 
of hemostasis is profound and confirmed by several clinical observations that indicate it is 
the physiologically relevant cofactor pool (Borchgrevink & Owren, 1961; Janeway et al., 
1996; Ang et al., 2009; Bouchard et al., 2015). In an individual completely devoid of 
plasma- and platelet-derived factor V, appropriate hemostasis was maintained by the 
prolonged life span of his platelet-derived factor V/Va pool acquired by endocytosis of 
plasma-derived factor V by megakaryocytes subsequent to his receipt of fresh frozen 
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plasma (Bouchard et al., 2015). While the patient’s plasma-derived factor V was 
undetectable by four days following transfusion, 10 days post-transfusion, he was still able 
to mount robust thrombin generation due to his residual platelet-derived factor Va (~ 7% 
of normal).  
In much earlier studies, Borchgrevink and Owren demonstrated that bleeding 
associated with congenital factor V deficiency in a patient could be corrected temporarily 
by the administration of platelets from a normal donor (Borchgrevink & Owren, 1961).  
Similarly, as reviewed by Ang and colleagues, several studies demonstrate that platelet 
transfusions, rather than plasma transfusions, are more effective at correcting bleeding 
tendencies associated with individuals with non-congenital, acquired factor V inhibitors 
(Ang et al., 2009). Furthermore, Nesheim and colleagues observed that a patient with 
negligible plasma-derived factor V levels (< 1%) due to an acquired factor V inhibitory 
antibody withstood surgical challenge without a significant bleed. They suggested that the 
patient’s normal response to bleeding was not compromised due to the presence of intact 
platelet-derived factor V/Va which was not accessible to the plasma antibody (Nesheim et 
al., 1986). Furthermore, in Quebec platelet disorder in which affected individuals have 
normal levels of plasma-derived factor V, they still present life-threatening bleeding 
conditions due to deficiencies of their α-granule proteins, most notably platelet-derived 
factor Va (Tracy et al., 1984; Janeway et al., 1996). Finally, studies by Weiss and 
colleagues reported impaired platelet-derived Prothrombinase activity in a patient 
expressing a factor V variant, Factor VNew York. They demonstrated that despite having near 
normal, plasma-derived activity (~80%), the patient showed severe bleeding abnormalities 
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due to extremely low platelet-derived factor V/Va concentrations (Weiss et al., 2001). 
These combined studies offer strong support for the notion that platelet-derived factor Va 
is the physiologically-relevant cofactor pool.  
1.2.1.8. Megakaryocyte-Endocytosis of Plasma-derived Factor V: Formation of the 
Functionally and Phenotypically Unique Platelet-derived Factor V/Va pool 
 In confocal microscopy studies completed in our laboratory, megakaryocyte-
endocytosed factor V was shown to initially co-distribute with endocytosed transferrin 
(Harding et al., 1983; Bouchard et al., 2005). Consistent with these data, additional studies 
demonstrated that following its endocytosis, factor V transits through early and late 
endosomes in a time-dependent manner as demonstrated by its colocalization with 
antibodies to Rab 5 and Rab 7, respectively (Figure 9). Using brefeldin A, a compound 
known to disrupt the trans-Golgi network, thus preventing endosomal to Golgi trafficking, 
we have also shown that endocytosed factor V undergoes partial proteolysis, by an 
unknown megakaryocyte protease(s), to form a mixture of factor V/Va molecules 
(unpublished data). Consistent with this observation, platelet-derived factor V/Va 
molecules are released from activated platelets in a partially proteolytically-activated state 
expressing substantial cofactor activity as evidenced by the presence of a bonafide heavy 
chain and a light chain containing two additional N-terminal amino acids formed by 
cleavage at Tyr1543 rather than Arg1545 (Gould et al., 2004). Ayombil et al. further 
demonstrated that subsequent to endocytosis of plasma-derived factor V, the endocytosed 
protein was described by proteolytic fragments similar in molecular weight to the 
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heterodimeric subunits of factor Va and expressed cofactor activity in in vitro clotting 
assays (Ayombil et al., 2013). 
 In additional trafficking studies, endocytosed factor V co-localized with GM130, a 
cis-Golgi element consistent with the unique O-glycosylation at Thr402 observed in platelet-
derived factor V/Va (Figure 9) (Gould et al., 2004). Furthermore, factor V trafficked to the 
endoplasmic reticulum where it colocalized with antibodies to PIGK, a member of the 
cysteine proteases involved in glycosylphosphatidylinositol (GPI)-anchor biosynthesis. In 
support of this observation, Ser692 in the factor V heavy chain is contained within a 
consensus sequence for GPI-anchor addition (Wood et al., 2008). Consistent with those 
combined observations, studies in our laboratory have demonstrated that a pool of platelet-
derived factor Va is GPI-anchored to the activated platelet membrane, which results in its 
resistance to APC-catalyzed inactivation (Chapter Four) (Amthaeur et al., 1993; Camire et 
al., 1995; Camire et al., 1998c). Anchoring of the platelet-derived factor Va heavy chain 
to the activated platelet membrane (Wood et al., 2008), may explain the inability of 
platelet-derived factor Va to be phosphorylated on Ser692, which is marked contrast to what 
is observed with plasma-derived factor Va (Rand et al., 1994). Likewise, selective 
trimming of N-linked oligosaccharides occurs in the endoplasmic reticulum and may 
explain, in part, the different number of high mannose residues on the N-linked glycan at 
Asn1982 on the light chains of platelet-derived factor Va, when compared to the plasma-




Figure 9. Endocytic trafficking of plasma-derived factor V in megakaryocytes to form 
the unique platelet-derived factor V/Va molecules. 
Two factor V molecules bind their receptors at the cell membrane of megakaryocytes and 
are subsequently internalized in a clathrin-dependent manner in the early endosomes and 
late endosomes as shown by their colocalization with antibodies to Rab 5 and Rab 7, 
respectively. In the endosomes factor V is partially proteolyzed by unknown 
megakaryocyte protease(s) before transport in a retrograde faction along compartments of 
the secretory route including the endoplasmic reticulum (as shown by colocalization with 
antibody to phosphatidylinositol, GPI, glycan anchor biosynthesis class K, PIGK) where 
N-linked glycan trimming occurs and a GPI-anchor is added. In the Golgi network (shown 
by colocalization with antibodies to GM130 and von Willebrand factor), O-linked 
glycosylation is added to factor V/Va to form the platelet-derived protease-resistant α-
granule stored molecule (as shown by colocalization with antibodies to P-selectin, 
fibrinogen, von Willibrand factor which are stored in the α-granule). Diagram adapted from 
Bouchard et al., Factor V trafficking, unpublished). 
Consistent with its eventual packaging and transport to the α-granules, endocytosed 
factor V colocalized with fibrinogen (Bouchard et al., 2005), von willebrand factor and P-
selectin, proteins known to be stored in platelet α-granules (Figure 9). These combined 
studies are consistent with the retrograde transport of megakaryocyte-endocytosed, 
plasma-derived factor V as shown in figure 9. Therefore, subsequent to its endocytosis by 
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megakaryocytes, plasma-derived factor V transits through the early and late endosomal 
compartments before trafficking to the endoplasmic reticulum and trans-Golgi network 
where it is posttranslationally retailored to become the unique, protease-resistant α-granule 
pool of platelet-derived factor V/Va. 
1.2.1.9.Characterization of the Non-dissociable Platelet-Derived Factor Va Pool 
 Present evidence suggests that activated platelets contain a non-dissociable pool of 
factor Va. Early studies by Alberio and colleagues showed that a subpopulation of platelets 
(~31% to the total platelet population) express high levels of surface-bound factor V 
following platelet activation by a combination of convulxin and thrombin (Alberio et al., 
2000). Known as COAT-factor V (COAT-FV), they showed that this pool of factor Va 
bound factor Xa and supported significant Prothrombinase activity compared to platelets 
activated independently by either agonist. In additional studies, they proposed, that COAT-
platelets, those expressing COAT-FV, are covalently modified by attaching several α-
granule proteins to the activated platelet membrane in a reaction wherein a 
transglutaminase cross-links the proteins to serotonin (Dale et al., 2002). Interestingly, 
transglutaminases such as factor XIIIa have been reported to interact with factor V. 
However, transamination sites were found only in the inhibitory B domain of the 
procofactor, factor  V, which is absent in factor Va (Francis et al., 1986). Contrasting 
results were reported in recent studies by Jobe and colleagues using murine knockout 
models of the collagen receptor, FcRγ, and transglutaminase, factor XIIIa. They showed 
that the FcRγ receptor but not factor XIIIa was important in the formation of the COAT-
platelets (Jobe et al., 2005). 
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In marked contrast, recent studies from our laboratory demonstrate the existence 
of a functional, yet non-dissociable platelet-derived pool of factor V/Va on thrombin-
activated platelets. Using flow cytometric analyses, Fager and colleagues demonstrated 
that subsequent to thrombin-catalyzed platelet activation, a subpopulation of membrane-
bound, platelet-derived factor Va expressed between 35-50% of the cofactor activity 
associated with the entire membrane-bound factor Va pool. (Fager et al., 2010). Thus, 
following thrombin activation, two factor Va pools are associated with the activated 
platelet membrane, a non-dissociable pool and a dissociable pool. Subsequent studies by 
Wood and colleagues have shown that this non-dissociable pool of platelet-derived factor 
Va is glycosylphosphatidylinositol (GPI)-anchored to the platelet membrane via Ser692 at 
the C-terminus of the factor Va heavy chain, and within a GPI-consensus sequence (Wood 
et al., 2008). The functional characterization of this GPI-anchored pool of platelet-derived 
factor Va is detailed in Chapter Four of this dissertation. 
1.2.2. Structural Features of Prothrombin 
The prothrombin zymogen (also known as Factor II, Figure 10) is one of the most abundant 
(0.1 mg/mL) coagulation proteins found in plasma. Prothrombin is synthesized by the liver 
and released into the circulation as a 579 amino acid single chain polypeptide with a 
molecular weight of ~ 72 kDa (Herbert, 1940; Kisiel & Hanahan, 1973; Lundblad et al., 
1976; McDuffie et al., 1979). As shown in Figure 10, human prothrombin is composed of 
an N-terminal fragment 1 (residues 1-155), followed by fragment 2 (residues 156-271), 
and a serine protease domain at the C-terminal half (residues 272-579). The membrane-
binding γ-carboxyglutamic acid (Gla) domain and kringle 1 domain (residues 1-40 & 65-
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143, respectively) make up fragment 1 while kringle 2 domain (residues 170-248) forms 
part of fragment 2. The serine protease domain is comprised of an A-chain (residues 272-
320), and a catalytic B-chain (residues 321-579) (Heldebrant et al., 1973a; Butkowski et 
al., 1977; Degen et al., 1983). 
 
Figure 10. Structural Domains of Human Prothrombin.  
Prothrombin is composed of 579 amino acids. The amino-terminus contains about 40 γ-
carboxyglutamic acids forming the Gla domain. This is followed by kringle domains 1 and 
2. The Gla domain and kringle 1 form the fragment 1 region of prothrombin (red). The 
fragment 2 regions contains kringle 2 (blue). The carboxyl-terminal half contains the serine 
protease domains which consist of the A- and B-chains of the thrombin (gray). The two 
chains are linked by a disulfide bond between Cys293 and Cys439 as shown above.  
Several mutational studies have identified key regions of prothrombin that interact 
with Prothrombinase at the enzyme-substrate interface and may play a role in the activation 
of the zymogen. Residues within the kringle 1 and 2 domains have been reported to interact 
with the cofactor, factor Va (Kotkow et al., 1995; Deguchi et al., 1997). Similarly, residues 
between the autolysis loop (residues 473-487) (Subramanian et al., 2004) and proexosite 1 
(Chen et al., 2003) all within the serine protease domain of prothrombin contribute to factor 
Va binding in Prothrombinase. Additionally, factor Xa appears to interact with residues 
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557-571 in the protease domain of prothrombin (Yegneswaran et al., 2003). Studies show 
that the kringle 2 domain within the fragment 2 region promotes prothrombin activation by 
Prothrombinase. According to studies by Krishnaswamy and Walker, this fragment 2 
region may mediate conformational changes which expose cleavage sites within the 
protease domain (Krishnaswamy & Walker, 1997). Recent studies by Pozzi and colleagues 
showed that a truncated prothrombin mutant, Prothrombin Δ146-167 (with deletion of 
residues connecting kringle 1 and 2 domains) was defective in thrombin generation due to 
impaired interaction with factor Va (Pozzi et al., 2014). While the complete crystal 
structure of prothrombin remains elusive, a recently solved 3.3 Å resolution structure of a 
Gla-domainless prothrombin has provided key insights into conformational transitions 
which may mediate prothrombin activation by Prothrombinase (Pozzi et al., 2013). Their 
structure shows that residue Arg271 (a cleavage site for Prothrombinase) is located within a 
highly anionic flexible region of fragment 2, whereas Arg320 (another cleavage site for 
Prothrombinase) is buried and inaccessible within the serine protease domain of 
prothrombin. These recent structural details may offer some mechanistic insight into the 
presentation of the prothrombin zymogen to Prothrombinase. 
1.2.2.1 The Activation of Prothrombin to Thrombin  
The prothrombin zymogen is converted into active thrombin following proteolytic 
cleavages at two key residues: Arg271 and Arg320 (Figure 11). Several studies have shown 
that the rates and sequence of peptide bond cleavages at the Arg271 site or the Arg320 site 
are dependent on the reaction conditions: i.e. whether catalysis is being mediated by a 
complete Prothrombinase enzyme or some components of the enzyme in the presence of 
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the prothrombin substrate. While the rate of thrombin generation is very slow (0.0044 mol 
thrombin/min/factor Xa)(Nesheim et al., 1979a), the prethrombin 2 (Pre-2) pathway is 
predominant when prothrombin is activated by only the serine protease, factor Xa, in 
solution. In this pathway (Figure 11, arrows on the left), initial cleavage occurs at Arg271 
producing a non-enzymatic, yet proteinase-like, Pre-2 intermediate, and fragment 1.2. A 
second cleavage of the Pre-2 intermediate at Arg320 generates thrombin. When the progress 
of this reaction is visualized following SDS-PAGE under reducing conditions, the 
appearance and migration of fragment 1.2 is indicative of the formation of the Pre-2 
intermediate (Heldebrant et al., 1973b; Esmon & Jackson, 1974; Rosing et al., 1980).  The 
rate of this reaction is further increased by ~30-fold when anionic phospholipid membrane 
of defined content (75% phosphatidylcholine & 25% phosphatidylserine; PCPS) is added 
to this reaction (Nesheim et al., 1979a).  Similarly, the Pre-2 pathway of prothrombin 
activation still persist in the presence of the membrane-bound factor Xa (Esmon et al., 
1974a; Krishnaswamy et al., 1987).  
 Interestingly, although thrombin generation is enhanced by ~10,000-fold, a shift in 
the order of peptide bond cleavages of prothrombin becomes apparent when factor Va is 
included in the reaction mixtures (Nesheim et al., 1979a). In this case, the meizothrombin 
(mzIIa) pathway predominates when a complete Prothrombinase is assembled (factors Xa 
& Va + Ca2+ ion + PCPS vesicles). Thus, mzIIa, an intermediate with enzymatic properties 
is generated following initial cleavage at Arg320. Subsequent cleavage at Arg271 of the 
mzIIa intermediate produces thrombin (Figure 11, arrows on the right). Under reducing 
conditions, the appearance of fragment 1.2A on a gel is indicative of mzIIa generation and 
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the utilization of the mzIIa pathway (Rosing et al., 1980; Krishnaswamy et al., 1986; 
Rosing et al., 1986; Krishnaswamy et al., 1987). 
 
Figure 11. The Mechanism of Prothrombin Activation to Thrombin.  
Thrombin is generated from prothrombin by two main pathways. The prethrombin 2 (Pre-
2) pathway occurs when there is an initial cleavage at Arg271 to generate a non-enzymatic 
Pre-2 intermediate, and fragment 1.2 (Frag 1.2). Subsequent cleavage at Arg320 within the 
Pre-2 intermediate produces thrombin (arrows on the left). Alternatively, in the 
meizothrombin (mzIIa) pathway, cleavage at Arg320 occurs first generating an enzymatic 
mzIIa intermediate. A second cleavage of the mzIIa intermediate at Arg271 produces 
thrombin (arrows on the right). In both pathways, thrombin, the final enzymatic product 
of prothrombin activation is composed of the A-chain, and the catalytic B-chain linked 
together by a disulfide bond (Cys293-Cys439). 
 The enzymatic properties of mzIIa are well-documented and several studies show 
that it possesses significant anticoagulant properties. Meizothrombin is reportedly more 
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effective at protein C activation to APC compared to thrombin (Doyle & Mann, 1990; 
Hackeng et al., 1996; Cote et al., 1997). Doyle and Mann showed that mzIIa converts 
protein C to APC at more than 100% the efficiency of thrombin in the absence of 
thrombomodulin (Doyle & Mann, 1990). Similarly, using recombinant prothrombin, Cote 
and others showed that in the presence of membrane-bound thrombomodulin, mzIIa is 6-
fold more effective than thrombin in protein C activation (Hackeng et al., 1996; Cote et 
al., 1997). In what may be described as a weak contribution to the procoagulant response, 
mzIIa marginally activates factor V (Tans et al., 1994), platelets, and converts fibrinogen 
to fibrin (Doyle & Mann, 1990) in the absence of anionic phospholipids. As described 
above, the presence of a membrane is crucial, and enhances the catalytic activity of mzIIa 
consistent with the importance of the Gla-domain in mediating membrane binding 
interactions which support various function of coagulation proteins.  
Studies evaluating the mechanism of prothrombin activation by Prothrombinase in purified 
systems are done in the presence of active site inhibitors of thrombin such as dansylarginine 
N-(3-ethyl-1,5-pentanediyl)amine (DAPA). However, during vascular injury in vivo, the 
localization of coagulation proteins at the activated platelet surface protects them from 
inactivating proteins in the plasma and allows for an optimized thrombin generation. 
Therefore, the thrombin formed feedback to cleave the prothrombin substrate at Arg155 to 
generate the Gla-domainless prethrombin-1 (Pre-1) and fragment 1 (which contains the 
Gla-domain and kringle 1) (Figure 12). This truncated prothrombin molecule is widely 
considered a poor substrate for PCPS-bound Prothrombinase due to the absence of the Gla-
domain which is believed to anchor the protein to the membrane surface (Stenn & Blout, 
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1972; Esmon et al., 1974b; Nelsestuen et al., 1974; Bajaj et al., 1975). The conversion of 
Pre-1 to thrombin by Prothrombinase, although slow compared to prothrombin, proceeds 
exclusively through the prethrombin-2 pathway. Initial cleavage at Arg271 produces the 
Pre-2 intermediate and fragment 2 followed by cleavage at Arg320 of the Pre-2 intermediate 
to generate thrombin. Although extremely slow, the Pre-2 intermediate may also be cleaved 
at Arg284 by the thrombin generated in situ to form the Pre-2 des 1-13 (also known as Pre-
2 prime, Pre-2’), and a thirteen amino acid peptide (F 1-13) (Figure 12) (Downing et al., 
1975). Recently, Wood and colleagues monitored prothrombin activation by mimicking 
conditions prevalent in vivo following an injury. Thus, collagen and factor Xa were 
simultaneous added to platelets in the absence of thrombin inhibitors and the reaction 
products monitored over time. They observed that the Pre-1 formed in situ from thrombin 
feedback cleavage was effectively converted to thrombin by platelet-bound 
Prothrombinase in contrast to its accumulation and slow turnover in reactions by PCPS-
bound Prothrombinase (Wood et al., 2011). Their study show a distinction in the utilization 
of Pre-1 by platelet-bound Prothrombinase vs. PCPS-bound Prothrombinase and support a 
differential assembly of the enzyme on either membrane surfaces.  
Further studies investigating the mechanism by which platelet-bound Prothrombinase 
effectively utilizes Pre-1 in thrombin generation is detailed in this dissertation (Chapter 
Three). Several studies have reported that Prothrombinase bound to model membranes do 
not mimic that bound to activated platelets. These differences will be highlighted below to 
raise awareness of the need to conduct research using the more physiologically relevant 
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surfaces such as activated platelets to delineate the molecular mechanisms regulating 
thrombin generation. 
 
Figure 12. The Formation of Prethrombin-1 Intermediate During Prothrombin 
Activation and Further Conversion to Thrombin.  
Prothrombin activation by prothrombinase assembled on the activated platelet surface 
occurs devoid of thrombin inhibitors. The thrombin formed can feedback and cleave 
prothrombin at Arg155 (red) to generate a prethrombin-1 (Pre-1) intermediate. The Pre-1 
intermediate is further activated by prothrombinase via cleavage at Arg271 to generated 
fragment 2 (Frag 2) and the inactive prethrombin-2 (Pre-2) intermediate (Prethrombin-2 
pathway). A second cleavage of the Pre-2 intermediate generates thrombin. Thrombin can 
also cleave the Pre-2 intermediate albeit very slowly at Arg248 (red) to produce a Pre-2 





1.2.3. The Assembly of Prothrombinase on the Activated Platelet Surface versus 
Anionic Phospholipid Vesicles 
Cholesterol, glycolipids, and phospholipids constitute approximately 70% of the plasma 
membrane of platelets. Quiescent platelets like most cells have asymmetric distribution of 
key lipids including phosphatidylethanolamine (PE), phosphatidylcholine (PC), 
phosphatidylserine (PS), phosphatidylinositol (PI), and sphingomyelins. Dormann and 
colleagues observed that when platelets are activated by various agonists, their surface 
concentration  of PS increases from between 2 to 12% via a flip flop mechanism where 
previous inner leaflet-based anionic phospholipids (PS)  move to the outer leaflet providing 
key catalytic surfaces for the assembly of coagulation factors during the procoagulant 
response (Dormann et al., 1998). Similarly, Shi and colleagues reported that the percentage 
of PS exposed following platelet activation was less than 8% (Shi et al., 2008). 
Nonetheless, it is undisputed that activated platelets provide the surface for Prothrombinase 
assembly during hemostasis (Walsh, 1974). While platelets are the main physiological 
surface, the majority of published studies evaluating the structure/function relationships of 
coagulation enzyme complexes in purified systems have been done using phospholipid 
vesicles of defined content containing 75% phosphatidylcholine and 25% 
phosphatidylserine (PCPS vesicles). Early studies by Barton and colleagues demonstrated 
that the surface charge density associated with PS is absolutely essential to factor Xa 
binding. They observed that optimal procoagulant activity for factor Xa, is associated with 
lipid surfaces comprised of both PS and PC (Barton et al., 1970).  
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As described earlier in section 1.2.2.1, thrombin is generated via two major 
pathways from prothrombin: the Pre-2 or meizothrombin pathway. Interestingly, there is 
substantial evidence that the meizothrombin pathway (Figure 11, arrows on the right) is 
utilized exclusively by Prothrombinase bound to PCPS vesicles in purified systems 
(Rosing et al., 1980; Krishnaswamy et al., 1986; Rosing et al., 1986; Krishnaswamy et al., 
1987; Tans et al., 1991a). Other studies by Tans and colleagues monitoring thrombin 
generation in a more complicated system, such as plasma, observed confounding results. 
They observed that when the coagulation system was initiated with  a Tissue factor-factor 
VIIa complex the meizothrombin intermediate was undetectable using immunoblotting 
techniques (Tans et al., 1991a).   Similarly, studies of thrombin generation in whole blood 
following initiation by recombinant tissue factor revealed the accumulation of both Pre-2 
and thrombin after 60 min (Rand et al., 1996). Likewise, using quantitative immunoassays, 
Undas and colleagues detected the accumulation and utilization of the Pre-2 intermediate 
in tissue factor-initiated coagulation in whole blood (Undas et al., 2001). Conversely, using 
active site labeling and streptavidin binding techniques, Bovill and colleagues observed 
meizothrombin generation in ex vivo whole blood clotting studies. Collectively, these 
studies suggest that the Pre-2 pathway (Figure 11, arrows on the left) of thrombin 
generation is paramount in vivo following an injury albeit the meizothrombin pathway may 
be utilized to some extent.   
A recent seminal publication by Wood and colleagues from our laboratory suggest 
that when Prothrombinase is bound to the activated platelet surface, thrombin generation 
proceeds exclusively via the Pre-2 pathway (Wood et al., 2011). Using radiolabeled 
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recombinant prothrombin species with either of the two cleavage sites at Arg271 or Arg320 
mutated to Ala, they showed that when Prothrombinase is bound to collagen- or thrombin-
activated platelets, cleavage at the 271 site is preferred followed by cleavage at the 320 
site. They therefore, proposed that the generation of thrombin via the Pre-2 pathway by 
platelet-bound Prothrombinase avoids the formation of the anticoagulant meizothrombin 
intermediate during injury where the procoagulant response is more desired (Wood et al., 
2011). This mechanism is further supported in recent studies by Haynes and colleagues 
examining prothrombin activation by platelet-bound Prothrombinase under in vitro flow 
conditions similar to venous shear rates.  They observed that the Pre-2 intermediate remain 
associated with the platelet-bound enzyme following its formation consistent with its 
absence in the effluent.  On the other hand, in reactions of PCPS-bound Prothrombinase, 
the effluent contained the meizothrombin intermediate. This study indicated that 
prothrombin activation by platelet-bound Prothrombinase proceeds via a concerted 
mechanism in which cleavage at Arg271 is followed immediately by Arg320 and without 
release of the intermediate from the enzyme (Haynes et al., 2012).  
Several other findings support the differential assembly and functions of PCPS- 
vs platelet-bound Prothrombinase. Prothrombinase components including factor Xa (Kd = 
2.7 x 10-6 M) (Nesheim et al., 1981) and factor Va  (Kd = 2.7 x 10
-9 M) (Krishnaswamy & 
Mann, 1988) independently bind and associate with phospholipid vesicles (e.g. PCPS). 
However, factors Xa and Va cannot bind to quiescent platelets (Bouchard et al., 1997a). 
Both factors would associate with activated platelets yet, binding of the former (factor Xa) 
is absolutely dependent on the binding of the latter (factor Va) to the activated platelet 
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surface (Tracy et al., 1985). Additionally, while prothrombin does not associate with 
activated platelets independently of Prothrombinase, binding interactions of both factors 
Xa, and Va to phospholipid vesicles can be displaced with excess prothrombin(Nesheim et 
al., 1993). On either surface, however, factors Xa and Va associate via 1:1 stoichiometric 
complex in the presence of calcium ions to activate prothrombin to thrombin. This 
interaction is defined by a Kd of ~ 1 x 10
-10 M on both the activated platelet surface and 
phospholipid vesicles, respectively. (Tracy et al., 1985; Krishnaswamy et al., 1988; 
Krishnaswamy, 1990).  
Several studies suggest that the binding of factor Va appears to provide part of the 
receptor for factor Xa on activated platelets (Tracy et al., 1992; Nesheim et al., 1993). 
Additionally, other studies have shown that the degree of platelet activation correlates with 
the exposed binding sites for either protein (Bouchard et al., 1997b) and factor Va binds 
activated platelets with high affinity (Kd = 3 x 10
-10 M) (Tracy et al., 1979). Early studies 
by Miletich and colleagues reported that factor V deficiency correlated with reduced factor 
Xa binding. They showed that adding human factor V antibodies to thrombin-activated 
platelets prevents factor Xa binding, and thrombin generation catalyzed by Prothrombinase 
(Miletich et al., 1978a).  Additionally, they demonstrated that activated platelets express 
high affinity (0.4 x 10-9 M)  binding sites for factor Xa which cannot be competed off by 
the zymogens: factor X, and prothrombin or the protease of the intrinsic tenase, factor IXaβ 
(Miletich et al., 1978b). 
When used as a platelet agonist, approximately 50 times  more thrombin is 
required for the expression of maximal binding sites for factor Xa (50 nM thrombin, ~3000 
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molecules/platelet) compared to factor Va (1 nM thrombin, ~6000 molecules/platelet) on 
platelets, respectively (Tracy et al., 1979). Recent studies by Fager from our group 
demonstrated that distinct subpopulation of activated platelets differentially bind factors 
Xa and Va. They showed that two subpopulations independently bind either factor Va or 
both factors Xa, and Va. A third subpopulation, however, binds neither protein in their 
study (Fager et al., 2010). Together, these studies suggest that not all platelets are the same, 
and that agonist-simulated platelets perhaps express distinct receptors/binding sites which 
support the assembly and function of Prothrombinase, in contrast to the indiscriminate 
binding of the enzyme components on phospholipid vesicles. While the factor Va receptor 
remains elusive, some studies suggest that the membrane-associated protein, effector cell 
protease receptor-1 (EPR-1) interacts with, and binds factor Xa (Altieri & Edgington, 1990; 
Nicholson et al., 1996). Bouchard and colleagues observed that agonist-simulated platelets 
express EPR-1 in a concentration-dependent manner and the activity of factor Xa in 
Prothrombinase reactions incubated with monoclonal antibodies against EPR-1 was 
significantly reduced suggesting the antibodies were inhibiting factor Xa binding to the 
activated platelet surface (Bouchard et al., 1997b). 
Studies with phospholipid vesicles appear to implicate a key role for the Gla domain 
region of factor Xa in membrane binding. Larson and colleagues showed that the activity 
of a factor Xa construct with Asp substitutions at Gla16, Gla29, and Gla32 was impaired in 
Prothrombinase assays on PCPS vesicles. In contrast, significant enzyme activity was 
reported these constructs were monitored in reactions by platelet-bound Prothrombinase 
(Larson et al., 1998). Conversely, characterization of the natural factor X variant (factor 
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XSt Louis, Gly substitution at Gla7) revealed that, thrombin generation catalyzed by 
Prothrombinase was 6-fold higher on phospholipid vesicles compared to thrombin-
activated platelets (Rudolph et al., 1996). These studies suggest that, other regions of factor 
Xa, besides the proposed Gla-dependent membrane association, are required for the 
protease to function in Prothrombinase assembled on the activated platelet surface. 
Binding interactions of factor Va on phospholipid vesicles (section 1.2.1) have 
been well characterized compared to the activated platelet surface. However, on either 
surface, the light chain region including the C1 and C2 domains of factor Va appears 
important in membrane association (Kane et al., 1982; Tracy & Mann, 1983; Tracy et al., 
1992). Tracy and others reported that the light chain region of factor Va additionally 
mediates interaction with factor Xa on the activated platelet surface (Tracy & Mann, 1983; 
Tracy et al., 1992). Other studies have reported a limited role of the heavy chain of factor 
Va in mediating binding interactions with factor Xa (Tracy et al., 1992). The existence of 
additional unknown binding sites for factors Xa, Va, and, perhaps prothrombin on the 
activated platelet surface have been postulated and much more work is required (Tracy et 
al., 1992; Nesheim et al., 1993; Scandura et al., 1996).  
While coagulation complex assembly and binding to the membrane surface 
(PCPS and platelets) protects from circulating and inactivating inhibitors/proteins, the 
activated platelet surface appears to offer additional protection from complete factor Va 
inactivation by APC (Bertina et al., 1994; Camire et al., 1995; Camire et al., 1998a; Oliver 
et al., 1999). The recent identification of a GPI-anchored pool of platelet-derived factor Va 
on the activated platelet surface raises an interesting conundrum of whether there is 
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competition for the remaining binding sites by the dissociable platelet-derived factor V/Va 
(in the releasate) and plasma-derived factor Va. Nonetheless, there is evidence for a 
differential assembly of Prothrombinase on the activated platelet surface compared to 
phospholipid vesicles of defined content. This dissertation investigates the differential 
properties of these surfaces in thrombin generation, as well as the effective utilization of 
prothrombin activation intermediates and the procoagulant contributions of the GPI-
anchored pool of platelet-derived factor Va to Prothrombinase function. 
1.3. Summary of Introduction 
The importance of thrombin generation during the hemostatic response cannot be 
overemphasized. Congenital deficiencies affecting either cellular components or 
coagulation proteins involved in both the initiation and propagation of the coagulant 
response has debilitating consequences for the affected individuals. Thus, insufficient or 
excess thrombin generation produces hemorrhage, and thrombosis, respectively. Both or 
either of these imbalances in thrombin generation can be life threatening, if not managed 
properly. It is therefore imperative that the mechanism and function of the final enzyme 
complex, Prothrombinase, which regulates the generation of thrombin is adequately 
understood. Under physiological conditions, activated platelets provide both the catalytic 
surface and essential cofactor that regulate the function of this enzyme. This dissertation 
investigates further, the platelet-derived components regulating Prothrombinase assembly 
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Platelet-bound prothrombinase effects the generation of hemostatically relevant amounts 
of thrombin from prothrombin via ordered, and concerted cleavages at Arg271 and Arg320, 
referred to as the prethrombin-2 pathway of activation. The molecular mechanism by which 
these distant cleavage sites are presented to the active site of Prothrombinase appears to 
reside in both the conformational flexibility of prothrombin and the quaternary structure of 
the membrane-bound enzyme complex, such that prothrombin can be stabilized in one of 
two states, zymogen-like or proteinase-like, through expression of a pseudo-active site. 
Initial cleavage at Arg271 occurs in a proteinase-like state and at Arg320 in a zymogen-like 
state. Inhibitor binding studies and product formation profiles were used to monitor the 
changes within the catalytic domain of prothrombin subsequent to its binding to platelet-
bound Prothrombinase, or Prothrombinase bound to phospholipid vesicles of defined 
content [(25% phosphatidylserine:75% phosphatidylcholine), PCPS]. Active site blocked, 
platelet-bound Prothrombinase was ~ four times more effective in supporting the 
incorporation of biotinylated D-Phe-Pro-Arg-chloromethylketone (FPRck) into the 
exposed pseudo-active site of prothrombin when compared to the active site-blocked 
PCPS-bound enzyme at equivalent concentrations. Increasing concentrations of the 
reversible, active site inhibitor dansyl-L-arginine N-(3-ethyl-1,5-pentanediyl)amide 
(DAPA) shifted prothrombin equilibrium toward the proteinase-like state, which correlated 
with an increased rate of cleavage at Arg271 confirming that the platelet-bound enzyme 
preferred this conformation. In marked contrast, an inverse relationship was observed with 
the PCPS-bound enzyme. As the equilibrium to the proteinase-like state increased, the 
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initial cleavage at Arg320 became undetectable, and minimal cleavage at Arg271 appeared 
until little thrombin was generated. These combined data suggest that platelet-bound 
Prothrombin effects thrombin generation solely through the prethrombin-2 pathway by 


















Prothrombinase, a 1:1 stoichiometric complex of factors Xa and Va assembles in the 
presence of Ca2+ ions on an appropriate membrane and is the final enzyme complex of the 
coagulation cascade (1,2). Physiologically, prothrombin is the exclusive substrate for 
Prothrombinase and is converted to thrombin (2). The catalytic membrane surface is 
absolutely essential for accelerating the rate of thrombin generation by approximately 
1,000-fold (1). Furthermore, the nature of this membrane surface can dictate the order of 
peptide bond cleavages. Prothrombinase bound to phospholipid vesicles containing 25% 
phosphatidylserine and 75% phosphatidylcholine (PCPS vesicles) results in thrombin 
generation via the anticoagulant enzyme, meizothrombin, following an initial cleavage at 
Arg320 (3,4) (Figure 1, right arrow). Conversely, the zymogen prethrombin-2 intermediate 
predominates when platelet-bound Prothrombinase cleaves prothrombin through an initial 
cleavage at Arg271 (5,6) suggesting the differential assembly of Prothrombinase bound to 
either surface (Figure1, left arrow).  
Prothrombin and its derivatives have been reported (7-10) to undergo a reversible 
equilibrium transition between proteinase-like and zymogen-like states that favor initial 
cleavages at Arg271 and Arg320, respectively. Binding and critical ligand-mediated exosite 
interactions are thought to influence substrate affinity and the stabilization of prothrombin 
in either the zymogen- or proteinase-like state (8,9,11). Using prothrombin constructs, 
Bianchini et al. demonstrated unequivocally that the equilibrium between zymogen- and 
proteinase-like states can be shifted in favor of the latter in the presence of active site 
inhibitors such as dansyl-L-arginine N-(3-ethyl-1,5-pentanediyl)amide (DAPA) and D-
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Phe-Pro-Arg-chloromethylketone (FPRck) (12). DAPA binding to prothrombin stabilizes 
the proteinase-like state and promotes enhanced cleavage at Arg271 rather than Arg320 in 
reactions by PCPS-bound Prothrombinase.  
Steady state kinetic measurements that demonstrate an ~30-fold decrease in the 
catalytic efficiency of cleavage at Arg271 vs Arg320 when Prothrombinase is bound to PCPS 
vesicles offer strong support for the preferred cleavage at Arg320 and the formation of 
meizothrombin in reactions catalyzed by PCPS-bound Prothrombinase (11), whereas 
prethrombin-2 is transiently generated by Prothrombinase bound to the activated platelet 
membrane as demonstrate by Wood, et al. (5).  The mechanisms of prothrombin activation 
by platelet- and PCPS-bound Prothrombinase are further differentiated as the anticoagulant 
meizothrombin intermediate is released from the PCPS-bound enzyme complex, while the 
prethrombin-2 intermediate is not released from platelet-bound Prothrombinase, revealing 
a concerted mechanism that supports the procoagulant response required for hemostasis 
(6). 
Platelet-bound Prothrombinase only releases thrombin, not meizothrombin and we 
hypothesize that this occurs due to the platelet-bound enzyme complex promoting a shift 
in the zymogen- to proteinase-like state of prothrombin or a preference for prothrombin 
already in a proteinase-like state. We demonstrate in the present study that shifting the 
equilibrium of prothrombin towards the proteinase-like state increases both the rate of 
prothrombin activation and confirms the utilization of the prethrombin-2 activation 
pathway during thrombin generation by Prothrombinase assembled on activated platelets. 
Furthermore, the transition to the proteinase-like state makes prothrombin a poorer 
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substrate for the PCPS-bound complex by shifting the proteolytic mechanism to the 
prethrombin-2 pathway (Fig. 1, left arrow) with decreased utilization of the meizothrombin 

















MATERIALS AND METHODS 
Materials 
Dansylarginine N-(3-ethyl-1,5-pentanediyl)amine (DAPA), Phe-Pro-Arg-
chloromethylketone (FPRck), and biotinylated-FPRck (b-FPRck) were purchased from 
Haematologic Technologies (Essex Junction, VT). Hirudin was purchased from 
Calbiochem (Gibbstown, NJ). Re-crystallized bovine albumin was purchased from MP 
Biomedicals (Solon, OH). Arg-Gly-Asp-Ser peptide (RGDS) with greater than 99% purity 
was purchased from ABI Scientific Inc. (Sterling, VA). The chromogenic thrombin-
specific substrate Spectrozyme TH was from Sekisui Diagnostics (San Diego, CA). 
Phospholipid vesicles comprised of 75% phosphatidylcholine (wt/wt) and 25% 
phosphatidylserine (wt/wt) (PCPS) were a generous gift from Dr. Kenneth Mann 
(University of Vermont) and prepared according to the procedure of Higgins and Mann 
(13) with reagents purchased from Avanti Polar Lipids (Alabaster, AL). IODO-GEN tubes 
and proprietary protein-free T20 (TBS) blocking buffer were obtained from Thermo Fisher 
Scientific (Rockford, IL). Precision plus protein molecular weight standards were 
purchased from Bio-Rad (Hercules, CA). X-ray autoradiography film, and Western 
blotting chemiluminescence reagent were purchased from Krackeler Scientific (Albany, 
NY), and PerkinElmer Inc. (Waltham, MA), respectively. Streptavidin-conjugated 
horseradish peroxidase (HRP) was purchased from Sigma (St. Louis, MO).  
Proteins 
Human thrombin, factor Xa, and EGRck-factor Xa (active site blocked with Glu-Gly-Arg- 
chloromethylketone) were obtained from Haematologic Technologies (Essex Junction, 
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VT). Human prothrombin, and factor V were purified as previously described (2,14) from 
freshly frozen plasma obtained from consenting healthy adults, according to the guidelines 
of the University of Vermont’s Institutional Review Board and Committee on Human 
Subjects. Proteins were stored in 50% glycerol containing 5 mM CaCl2 at -20
oC. Before 
use, glycerol was removed by dialysis of sufficient dilution. Factor Va was prepared by 
activating plasma-derived factor V (1.0 µM) with thrombin (20 nM, 10 min, 37oC). The 
activity of thrombin was quenched by the addition of hirudin (30 nM). Protein 
concentrations were determined by UV absorbance at 280 nm with the following extinction 
coefficients (E1% 280nm, M
-1 cm-1) and molecular weights (Da): human prothrombin 13.8, 
72,000 (15); human thrombin 18.3, 36,700 (16); human factor Xa 11.6, 46,000 (17) and 
human factor V, 9.6, 330,000 (18).     
Iodination of prothrombin 
Human prothrombin (0.5 mg) was radiolabeled with iodine-125 (1.0 mCi) according to the 
procedure previously described  for labeling factor V (19). The integrity of the 125I- 
prothrombin was monitored by SDS-PAGE as described by Laemmli (20) followed by 
Coomassie brilliant blue R-250 staining and phosphorimaging. The ability of the 125I- 
prothrombin to be activated by PCPS-bound prothrombinase was confirmed as reported 
previously (5).  
Isolation of platelets from whole human blood 
Blood from healthy, consenting adults was collected by venipuncture into acid citrate 
dextrose (71 mM citric acid, 85 mM trisodium, 2% dextrose, pH 4.5) in a ratio of 6 parts 
of blood to 1 part of acid citrate dextrose. Platelets were subsequently washed and isolated 
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according to the method of Mustard et al. with some minor modifications as previously 
reported (21,22). Following isolation, platelets were resuspended in HEPES-Tyrode (HT) 
buffer (137 mM NaCl, 2.68 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1.0 mM 
MgCl2, 5 mM CaCl2, and 0.2% dextrose, pH 7.4). Platelet concentrations were measured 
using a Coulter Z1 particle counter (Beckman Coulter, Brea, CA) or an ADVIA 120 
Hematology Analyzer (Siemens Healthcare Diagnostics, Austin, TX) both of which 
produced identical cell counts. Washed platelets (3 x 108 /mL) were maximally activated 
(23) with thrombin (50 nM) in HT in the presence of 1 mM RGDS (5 min, 25oC). Thrombin 
was inactivated by the addition of hirudin (75 nM). 
Incorporation of b-FPRcK into prothrombin 
The incorporation of biotinylated FPRcK (b-FPRck) into the active site of prothrombin 
bound by either PCPS- or activated platelet-associated prothrombinase was monitored in 
solution. Prothrombin (1.4 µM) was incubated with PCPS vesicles (20 µM), factor Va (5 
nM) and active site-blocked EGR-factor Xa (0.5 nM) in 50 mM HEPES, 110 mM NaCl, 5 
mM CaCl2 pH 7.4. Equivalent enzyme was assembled on thrombin-activated platelets (1 x 
108 /mL) in a reaction mixture containing factor Va (5 nM), RGDS (1 mM), and EGR-
factor Xa (5 nM) in HT buffer pH 7.4. Each reaction mixture was preincubated (5 min, 
37oC) before the addition of b-FPRck (14 µM) to initiate the reaction. The reaction was 
incubated for an additional 60 min to allow for stoichiometric incorporation of b-FPRck 
into the exposed pseudo-active site of prothrombin associated with prothrombinase. Timed 
aliquots (0 - 60 min) were withdrawn and quenched three-fold into in either quench buffer 
(20 mM HEPES, 150 mM NaCl, 50 mM EDTA, 0.1% PEG 8000, pH 7.4) or sample 
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preparation buffer (62.5 mM Tris, 5 mM ethylenediaminetetraacetic acid, 2% SDS, 10% 
glycerol, 0.01% bromophenol blue, pH 6.8; SPB). Alternatively, after an hour of 
incubation, excess b-FPRck was removed by dialysis into 20 mM HEPES, 150 mM NaCl, 
5 mM CaCl2, pH 7.4 (HBS/Ca
2+). The activity of b-FPR-thrombin derived from PCPS-
associated prothrombinase-catalyzed activation of b-FPR-prothrombin was assessed by 
Spectrozyme TH hydrolysis (24) as described elsewhere in the Materials and Methods 
section. For platelet reactions, the following additional steps were taken to remove 
confounding biotinylated proteins associated with the activated platelets. At predefined 
time points (0 – 60 min), the reaction was sampled (150 µL) and diluted to 250 µL with 
HBS/Ca2+.  The diluted sample was layered over 500 µL Apiezon A oil and n-butylpthalate 
(9:1) and the platelets were pelleted by centrifugation at 10,000 xg for 2 min at room 
temperature. About 150 µL of the supernatant was removed and the reaction quenched as 
described above into SPB containing 1% βME. The incorporation of b-FPRcK into 
prothrombin was detected by immunoblotting with streptavidin-conjugated horseradish 
peroxidase. 
Prothrombin activation pathway in the presence of DAPA 
Prothrombin (1.4 µM) was incubated at 25oC for 15 min with factor Va (20 nM), activated 
platelets (1 x 108 /mL), RGDS (1 mM), trace 125I-prothrombin (2,000 cpm/µL), and DAPA 
(30, 60, 100, or 150 µM) in HT. In parallel experiments, prothrombin (1.4 µM) was 
incubated with PCPS vesicles (20 µM), factor Va (20 nM), and DAPA (60, 100, 200, or 
500 µM) in HBS/Ca2+ with 0.1% PEG 8000, pH 7.4; HBS/Ca2+/PEG). A 50 µL aliquot 
was removed for the 0 sec time point and each reaction was subsequently initiated with 
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factor Xa (5 nM or 0.5 nM for platelet or PCPS reactions, respectively). At timed intervals 
(0 – 60 min), aliquots (50 µL) were withdrawn and quenched in SPB containing 1% βME. 
Samples were subsequently boiled at 90oC for 2 min. The proteins were resolved by SDS-
PAGE (25,000 cpm/lane) and stained with Coomassie brilliant blue R-250, dried (3 h, 
80oC) and visualized by autoradiography. 
Kinetics of prothrombin activation in the presence of DAPA 
Initial velocities of thrombin generation from prothrombin was monitored in two-stage 
assays. Prothrombin (0 - 10 µM) activation was monitored via Prothrombinase (20 nM 
factor Va and 0.5 nM factor Xa) assembled on thrombin-activated platelets (1 x 108/mL) 
in the presence of DAPA (30, 60, 100, 150 µM) and RGDS (1.0 mM) in HT. The reaction 
was preincubated (15 min, 25oC) before the addition of factor Xa to initiate the reaction. 
Aliquots were removed at timed intervals (10, 20, 30 and 40 sec) and diluted three-fold in 
quench buffer. The concentration of thrombin in each aliquote was determined using 
Spectrozyme TH hydrolysis. 
Spectrozyme-TH hydrolysis and estimation of thrombin concentration 
The concentration of thrombin produced at each sampled time point in Prothrombinase 
assays was determined by the rate of hydrolysis of the thrombin-specific substrate, 
Spectrozyme TH (Sekisui) compared to a standard curve containing the appropriate final 
concentration of DAPA. Briefly, 80 µL of Spectrozyme TH was added to 20 µL of sample 
and the rate of hydrolysis of the substrate followed  at 405 nm (10 min, 30oC) using a 
SpectroMax250 microtiter plate reader (Molecular Devices, Sunnyvale, CA).  
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SDS-PAGE, Western blotting and autoradiography 
Samples quenched in SPB were disulfide bond reduced with 1% βME and boiled for 2 min 
at 90oC. An equivalent amount of each sample was loaded onto 10% polyacrylamide Tris-
Glycine gels (Invitrogen, Carlsbad, CA) by protein (µg) or radioactivity (CPM) and the 
proteolytic products resolved by the method of  Laemmli (20). Protein bands were 
transferred onto nitrocellulose membrane as described by Towbin et al. (25), and visualized 
by immunoblotting using streptavidin-conjugated horseradish peroxidase (0.2 µg/mL). 
Alternatively, protein bands were stained with Coomassie brilliant blue R-250, dried at 
80oC for 3 h and then exposed to a phosphorimaging screen overnight. The imaging screen 
was scanned using Molecular Imager FX running Quantity One software v.4.6.3 (Bio-Rad).  
Kinetic data analyses 
Data obtained from kinetic studies were fitted to linear regression plots to obtain initial 
rates and subsequently to nonlinear Michaelis-Menten equation using GraphPad Prism 
v6.0 software (GraphPad) to estimate the kinetic parameters. Alternatively, bands were 
scanned and quantitative densitometry analyses performed using the Bio-Rad Quantity One 









Maturation of prothrombin’s pro-active site upon binding to platelet-bound 
Prothrombinase 
The ability of platelet-bound Prothrombinase to bind prothrombin and expose the active 
site resulting in a proteinase-like state was confirmed by the abundant incorporation of b-
FPRck (Fig. 2). In contrast, minimal b-FPRck was incorporated into the pro-active site of 
prothrombin. Quantitative densitometry analyses showed approximately four-fold more 
incorporation of b-FPRck into prothrombin in the presence of the platelet-bound 
Prothrombinase compared to the PCPS-bound enzyme (Fig. 2). Furthermore, we confirmed 
that the b-FPR-thrombin derived from b-FPR-prothrombin following activation had little 
to no amidolytic activity (< 1%) towards the thrombin-specific chromogenic substrate 
Spectrozyme TH, thus demonstrating the active-site specific incorporation of bFPRck.  
Stabilization of the proteinase-like state of prothrombin by DAPA dictates its 
activation by both platelet- and PCPS-bound Prothrombinase 
Cleavage of 125I-prothrombin by platelet-bound Prothrombinase produced the 
nonenzymatic prethrombin-2 intermediate established as a consequence of ordered and 
concerted cleavages at Arg271 and Arg320 to produce thrombin (5,6). In reactions of platelet-
bound Prothrombinase, the appearance of the fragment 1.2 band is followed by the transient 
appearance of prethrombin-2 similar to reactions of prothrombin activation by factor Xa 
alone in solution or factor Xa bound PCPS (26). As shown in Fig. 3, the prethrombin-2 
pathway of prothrombin activation remained unchanged as the concentration of the 
reversible active site inhibitor, DAPA, was increased from 30 µM (Fig. 3A.i) to 150 µM 
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(Fig. 3A.iv). There were no detectable levels of the enzymatic, meizothrombin 
intermediate. However, the rate of prothrombin consumption and product formation was 
positively correlated with the concentration of DAPA (Figs. 3A and 3B) as determined by 
quantitative densitometry. When the fraction of prothrombin remaining during the time 
course over 60 min was fit to a single exponential phase decay equation, the pseudo-first 
order rate constant for prothrombin activation (Fig 4A) increased by ~ four-fold at 150 µM 
(0.24 min-1) compared to 30 µM DAPA (0.06 min-1) consistent with the increased 
consumption of prothrombin observed in Fig. 3. 
Platelet-bound Prothrombinase preferentially activates prothrombin via the 
prethrombin-2 intermediate pathway (5,6). We therefore reasoned that shifting the 
equilibrium of prothrombin towards a proteinase-like state would accelerate the rate of 
prothrombin activation to thrombin by Prothrombinase assembled on the activated platelet 
membrane. Fig. 4B shows quantitative densitometry of the full time course of fragment 1.2 
generation by platelet-bound Prothrombinase in the presence of increasing concentrations 
of DAPA. The rate of appearance of fragment 1.2 is consistent with increased consumption 
of prothrombin and the generation of thrombin as a function of DAPA concentration (Figs. 
4A and 4C). Densitometric analyses show minimal prethrombin-2 accumulation (Fig. 4D); 
however, when the bands were overexposed via autoradiography, a pattern is evident 
whereby the formation of the transient prethrombin-2 intermediate on the activated 
platelets surface appears and is turned over more rapidly faster with increasing DAPA 
concentrations (Fig. 3B).  
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Likewise, the effect of DAPA on prothrombin activation was monitored on PCPS 
vesicles, albeit at significantly higher DAPA concentrations (60-500 µM), where it can be 
seen that increasing the concentration of DAPA alters the product profiles and the rate of 
prothrombin consumption (Fig. 5). In contrast to Prothrombinase assembled on the 
activated-platelet membrane, prothrombin is activated by an initial cleavage at Arg320 via 
the alternative meizothrombin pathway by PCPS-bound Prothrombinase with little to no 
detection of the prethrombin-2 intermediate (4). As expected, the initial and lingering 
appearance of the meizothrombin intermediate (indicated by Frag 1.2A) was detected by 
SDS-PAGE under reducing conditions consistent with an initial cleavage at Arg320 of 
prothrombin (Fig. 5A-D). In the presence of 200 µM DAPA (Fig. 5C), the meizothrombin 
intermediate unexpectedly persisted at relatively high concentrations over the time course 
of the reaction; however, when 500 µM DAPA (Fig. 5D) was present, virtually no 
prothrombin activation was observed. When the data obtained by quantitative densitometry 
were analyzed by a one-phase decay equation as before, we observed that at approximately 
eight times the initial concentration of DAPA (60 vs 500 µM), the pseudo-first order rate 
constant for prothrombin consumption was reduced by approximately eight-fold (0.25 vs 
0.03 min-1, respectively) on PCPS vesicles (Fig. 6). Our data show an inverse correlation 
between the concentration of DAPA added to PCPS-Prothrombinase reactions and the rate 





Prothrombin is irreversibly converted into thrombin following sequential 
proteolytic cleavages by Prothrombinase at Arg271 and Arg320 (Fig. 1). The biochemical 
mechanism underlying this transition from the zymogen- to the proteinase-like state by the 
Prothrombinase complex is not completely understood. Several models of Prothrombinase 
have been proposed (27-30) yet no definitive structure exists for the complex assembled 
on an appropriate phospholipid membrane. Likewise, a full-length structure of the 
prothrombin molecule has also remained elusive in part due to the presence of the -
carboxyglutamic acid containing Gla-domain; however, recently a structure of a Gla-
domainless prothrombin molecule has been solved (31) providing some insight and 
direction in our interpretations of data from functional studies. Prothrombin exhibits 
considerable length (~80 Å) with reports of significant conformational flexibility that 
allows the zymogen to exist in either an extended or partially collapsed state at a 3 to 2 
ratio, respectively (31).  
We hypothesize that the extended conformation of prothrombin corresponds to the 
proteinase-like state, while the partially collapsed conformation corresponds to its 
zymogen-like state (31,32) and that this plasticity defines the preferred conformation of 
prothrombin for both platelet- and PCPS-bound Prothrombinase. As platelet-bound 
Prothrombinase prefers to activate prothrombin via an initial cleavage at Arg271, we 
postulate that it selectively binds prothrombin in its extended conformation/proteinase-like 
state; however, thrombin generation remains efficient as an equilibrium concentration of 
the proteinase-like state is continually reestablished according to Le Chatelier’s principle. 
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Likewise, we would expect the inverse process to occur when Prothrombinase is assembled 
on PCPS vesicles.  
An alternative hypothesis is that platelet-bound Prothrombinase actively reorients 
prothrombin to a proteinase-like state using a non-proteolytic mechanism prior to its 
activation. Non-proteolytic activations have been reported for both the zymogens 
prothrombin and plasminogen by the bacterial-derived activators staphylocoagulase (33) 
and streptokinase (34), respectively. In drawing some comparison to these findings, it is 
reasonable to speculate that the binding of prothrombin by platelet-bound Prothrombinase 
induces a conformational change which may not expose a functional catalytic site but 
makes accessible the pseudo-active site and allows for the binding and incorporation of b-
FPRck observed in the present study. Conversely, prothrombin interacting with PCPS-
bound Prothrombinase does not transition to a proteinase-like state prior to proteolytic 
activation and therefore maintains an inaccessible pseudo-active site preventing the 
incorporation of b-FPRck. 
The results of the current study do not definitively demonstrate that either of the 
above hypotheses is correct, but rather they suggest that a combination of both mechanisms 
is being utilized by platelet-bound Prothrombinase to promote the activation of 
prothrombin along a transition of proteinase-like states: 1) Platelets selectively bind the 
population of circulating prothrombin that exists in a proteinase-like. The rate of 
prothrombin activation by platelet-bound Prothrombinase can be increased by the addition 
of DAPA, which shifts the equilibrium of prothrombin towards the proteinase-like state. 2) 
Upon binding to platelet-bound Prothrombinase, prothrombin is reoriented such that it is 
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stabilized in a proteinase-like state with an accessible pseudo-active site; thus, b-FPRck 
may be incorporated into this pseudo-active site more so than prothrombin in solution or 
bound to Prothrombinase assembled on PCPS vesicles. 3) Initial cleavage of prothrombin 
at Arg271 to form prethrombin-2 promotes a further transition to a proteinase-like state (35-
37). As prethrombin-2 is already in the proteinase-like substrate orientation preferred by 
Prothrombinase, it remains bound to the enzyme complex prior to and during cleavage at 
Arg320 via a concerted mechanism (6). This series of transitions eloquently describes yet 
another mechanism by which platelets promote a procoagulant response.  
In contrast, Prothrombinase bound to PCPS vesicles lacks the mechanisms 
described above. It has been suggested that prothrombin adopts a zymogen-like character 
during its activation by Prothrombinase assembled on PCPS vesicles due to the established 
binding interaction between the Gla-domain containing fragment-1 of prothrombin and the 
anionic phospholipids of the PCPS membrane restricting the possible orientation the 
substrate may adapt when in complex with Prothrombinase (10,38,39). Interestingly, 
decreasing the phosphatidylserine content of PCPS vesicles from 25% to 2.5% promotes 
initial cleavage of prothrombin at Arg271 and the transient appearance of prethrombin-2 in 
a manner similar to that observed when Prothrombinase is assembled on the activated 
platelet membrane with one notable exception: the rate of the reaction is dramatically 
reduced (11,40). Therefore, it may be possible that while PCPS-bound Prothrombinase 
would prefer prothrombin in a proteinase-like state, the thermodynamic advantage gained 
by membrane binding sufficiently offsets this preferred binding conformation. Again, this 
observation supports the uniqueness of the activated platelet membrane in promoting 
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effective Prothrombinase assembly and thrombin generation (23,24,41,42) without the 
requirement for high phosphatidylserine percent composition of their outer membrane 
leaflet, presumably due to the presence of specific receptors for the components of 
Prothrombinase. 
Finally, we speculate that while platelets must promote a procoagulant response to 
maintain hemostasis in response to vascular injury, other physiologic surfaces exist (e.g. 
microparticles) upon which Prothrombinase may assemble that does not utilize a 
continuum of proteinase-like states in an effort to thwart undesirable thrombin generation 
via the release of the anticoagulant intermediate meizothrombin, an active species that has 
less than 10% the activity of thrombin with regard to platelet activation and fibrin 
formation (43-45). Therefore, while the secondary meizothrombin activation pathway has 
served as a red herring in the coagulation field for over 40 years (4,10,46,47), it is not a 
predominately procoagulant pathway but rather an attempt of the body to avoid unwanted 
thrombosis. 
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Figure 1. Prothrombinase-mediated pathway of prothrombin activation in the 
presence of thrombin inhibitors. 
Prothrombin is composed of N-terminal fragments 1 (Frag 1) and 2 (Frag 2) and a C-
terminal protease domain containing A- and B chains. Thrombin is formed following two 
proteolytic cleavages at Arg271 (R271) and Arg320 (R320). The prethrombin-2 (Pre-2) 
pathway that predominates on the activated platelet surface occurs via an initial cleavage 
at Arg271 resulting in the formation of fragment-1.2 (Frag 1.2), and a non-enzymatic 
prethrombin-2 (Pre-2) intermediate. A second cleavage at Arg320 of the Pre-2 intermediate 
produces α-thrombin (left pathway).  When assembled on a phospholipid membrane, such 
as PCPS vesicles, the meizothrombin pathway predominates with cleavage at Arg320 
occurring first producing a proteinase intermediate, meizothrombin (mzIIa). Further 
cleavage at Arg320 of the mzIIa intermediate produces fragment-1.2 and the active protease 








Figure 2. Biotinylated FPRck is incorporated into PCPS-bound and platelet-bound 
prothrombinase.  
The incorporation of biotinylated FPRck (b-FPRck) into prothrombin was monitored on 
both PCPS vesicles and thrombin-activated platelets. As detailed in the methods section, 
equivalent amounts of Prothrombinase were assembled on either PCPS vesicles (20 µM) 
or thrombin-activated platelets (1 x 108/mL) in reaction mixtures containing active site 
blocked EGR-factor Xa (0.5 or 5 nM for PCPS or activated platelets, respectively), and 
factor Va (20 nM). The reaction was initiated with b-FPRck (14 µM) and prothrombin (1.4 
µM) and then incubated for an hour. Aliquots of the reaction were quenched, resolved by 


























Figure 3. The effect of increasing concentrations of DAPA on prothrombin activation 
by platelet-bound Prothrombinase. 
(A) Prothrombin (1.4 µM) was activated by human Prothrombinase assembled on 
thrombin-activated platelets (1 x 108/mL) in the presence of trace 125I-prothrombin, factor 
Va (20 nM), factor Xa (5 nM) and variable concentrations of DAPA: (i) 30 µM, (ii) 60 
µM, (iii) 100 µM, and (iv) 150 µM. Timed aliquots were taken (0 – 60 min), quenched and 
resolved using 10% polyacrylamide gels via SDS-PAGE. Gels were stained, dried, and 
visualized by autoradiography. Indicated on the left and right sides of the panels are the 
molecular weight standards (x103 Da), and the cleavage products (II, Prothrombin; Frag 
1.2, Fragment 1.2; Pre-2, Prethrombin-2; & B-chain of thrombin), respectively. (B) 
Prolonged autoradiographic exposure of protein bands shows the profile of transient 
prethrombin-2 intermediate during the course of the progress curves at the indicated 













Figure 4. The effect of DAPA on the appearance of prothrombin activation species in 
reactions by platelet-bound Prothrombinase. 
The reaction conditions are the same as those described in Fig. 2. The activation of 
prothrombin by platelet-bound Prothrombinase was assessed over 60 min in the presence 
of 30 µM (●), 60 µM (■), 100 µM (▲), and 150 µM (▼) DAPA. Shown in the panel are 
reaction profiles of (A) the fraction of prothrombin remaining; (B) the fraction of Frag 1.2 
formed; (C) fraction of B-chain of thrombin formed; and (D) the appearance of the transient 
Pre-2 intermediate estimated by quantitative densitometric analyses and normalized to the 





Figure 5. The effect of DAPA on prothrombin activation by PCPS-bound 
Prothrombinase. 
Prothrombinase assays contained prothrombin (1.4 µM) in the presence of 20 nM factor 
Va, 0.5 nM factor Xa at increasing concentrations of DAPA (A ) 60 µM, (B) 100 µM, (C) 
200 µM and (D) 500 µM. Reaction aliquots were removed and quenched at following timed 
intervals: 0, 1, 2, 3, 4, 5, 8, 12, 16, 20, 30, 45, and 60 min. Samples were resolved using 
10% polyacrylamide gels via SDS-PAGE. Protein bands were detected by Coomassie 
brilliant blue staining. The molecular weights (x103 Da) are shown on the left. Cleavage 
products are shown on the right as follows: II, Prothrombin; Frag 1.2A, meizothrombin, 











Figure 6. Substrate depletion curves for prothrombin at variable DAPA 
concentrations in reactions by PCPS-bound Prothrombinase. 
Reaction conditions are the same as those described in Fig. 5. The rate of prothrombin 
activation by platelet-bound Prothrombinase was assessed over 60 min. The prothrombin 
remaining at each time as a fraction of the total at zero seconds is indicated on the y-axis 
following densitometry analyses of bands obtained from autoradiography. Prothrombin 
depletion in the presence of 60 µM (■), 100 µM (□), 200 µM (●), and 500 µM (○) DAPA 
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Prothrombin is composed of fragment-1 (in part consisting of the -carboxy-glutamic acid 
containing Gla-domain), fragment-2, and a serine protease domain. During the hemostatic 
response, thrombin generated following the proteolytic activation of prothrombin by 
Prothrombinase can participate in a feedback reaction whereby fragment-1 is removed 
from prothrombin generating prethrombin-1. Prethrombin-1 has historically been 
considered a “dead end substrate”, as loss of the membrane-binding Gla-domain renders 
its rate of activation negligible by Prothrombinase bound to phospholipid vesicles 
composed of 75% phosphatidylcholine and 25% phosphatidylserine (PCPS). Contradicting 
this long-held dogma, Prothrombinase bound to the activated-platelet membrane can 
effectively activate prethrombin-1 formed in situ to thrombin; however, the pathway of 
prethrombin-1 activation by platelet-bound Prothrombinase is the same as that observed 
when Prothrombinase is assembled on PCPS vesicles: Initial cleavage at Arg271 generates 
fragment 2 and the zymogen intermediate prethrombin-2, while subsequent cleavage at 
Arg320 results in the formation of thrombin. While platelet-bound Prothrombinase 
effectively catalyzes the turnover of both prethrombin-1 and prethrombin-2, PCPS-bound 
Prothrombinase is an ineffective activator of prethrombin-1 and prethrombin-2 due to an 
inability to effectively catalyze cleavage at Arg320. Although the catalytic efficiency of 
Prothrombinase assembled on either surface is similar, super physiologic concentrations of 
prethrombin-1 (>20 µM) can reduce its initial rate of activation three-fold the PCPS-bound 
Prothrombinase. Furthermore, exogenously added prethrombin-2 inhibits prothrombin 
activation by PCPS- but not platelet-bound Prothrombinase. Collectively, these 
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observations suggest that fragment 2 generated in situ inhibits the activation of 
prethrombin-1 by PCPS-bound Prothrombinase, while its inability to inhibit the analogous 
reaction catalyzed by platelet-bound Prothrombinase provides further evidence that 
platelet-bound Prothrombinase possesses unique structural and functional features that 

















The activation of the zymogen prothrombin to the critical serine protease thrombin 
by Prothrombinase, consisting of the protein cofactor factor Va and the serine protease 
factor Xa assembled in a 1:1 stoichiometric complex on an appropriate membrane surface, 
is central to the blood coagulation process, and as such is highly regulated. Prothrombin is 
composed of an N-terminal fragment-1 (comprised of a -carboxy-glutamic acid containing 
Gla-domain; residues 1-155), fragment-2 (Frag 2; residues 156-271), and a C-terminal 
serine protease domain (comprised of disulfide linked A- and B-chains; residues 272-579) 
(Fig. 1) (1). Prothrombin is activated to thrombin following the sequential proteolytic 
cleavage of two peptide bonds, Arg271-Thr272 and Arg320-Ile321 (Fig. 1). Prothrombin 
lacking fragment 1 (prethrombin-1) is activated to thrombin by an initial cleavage at Arg271 
independent of the surface on which Prothrombinase is assembled, resulting in the 
formation of the zymogen intermediate prethrombin-2 (2,3). Conversely, initial cleavage 
of prothrombin at Arg320 would result in the formation of the enzymatically active 
intermediate meizothrombin des fragment-1 (4-6). Prethrombin-1 formation results from 
proteolytic cleavage of prothrombin by thrombin at Arg155 (7-9). As loss of the membrane 
binding Gla-domain dramatically reduces efficiency by which thrombin is generated, this 
reaction has long been considered a mechanism of product feedback inhibition of 
extraneous thrombin generation (9-11). Furthermore, the ineffective activation of 
prethrombin-1 to thrombin is demonstrated by the observation that its activation by 
Prothrombinase in the absence of an appropriate membrane surface results in an incomplete 
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conversion to thrombin and formation of a mixture of approximately equal amounts of 
prethrombin-2 and thrombin (9). 
Our laboratory recently demonstrated that prethrombin-2, resulting from initial 
cleavage at Arg271, is the only major intermediate generated during prothrombin activation 
by Prothrombinase assembled on the physiologically relevant surface of the activated 
platelet membrane (3). We have also demonstrated that prethrombin-1 formed in situ 
during the activation of prothrombin by Prothrombinase assembled on collagen-activated 
platelets (3) or thrombin-activated platelets under flow is more efficiently converted to 
thrombin than PCPS-bound Prothrombinase where both Frag 2 and prethrombin-2, 
resulting from prothrombin cleavage at Arg271, accumulate during their slow activation to 
thrombin (2). The mechanism for these apparent differences in prethrombin-1 activation is 
not known, although a growing body of evidence highlights features of activated platelets 
to promote efficient thrombin generation (12-15). 
In the present study we hypothesize that Frag 2 generated during prothrombin 
activation inhibits the activation of prethrombin-1 by Prothrombinase assembled on PCPS 
vesicles, but not activated platelets. Interestingly, Frag 2 has been reported to inhibit 
prothrombin activation by factor Xa (16), and that it  makes key contacts with factor Va 
(9,17), factor Xa (18), and (pro)exosite II of prethrombin-2 (4,19) during Prothrombinase 
assembly. Therefore, we will examine the effect Frag 2 has on the inhibition of 
prethrombin-1 activation by Prothrombinase assembled on activated platelets and PCPS 
vesicles in order to understand why a previously considered “dead-end” substrate, 
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prethrombin-1, may contribute to relevant thrombin generation in vivo and to describe yet 
















MATERIALS AND METHODS 
Materials  
Phe-Pro-Arg-chloromethylketone (FPRck) and dansylarginine N-(3-ethyl-1,5-
pentanediyl)amine  (DAPA) were purchased from Haematologic Technologies (Essex 
Junction, VT). The peptides Gly-Pro-Arg-Pro (GPRP) and Arg-Gly-Asp-Ser (RGDS) were 
synthesized and characterized by Think Peptides-Proimmune (Sarasota, FL). Hirudin was 
obtained from Calbiochem (Gibbstown, NJ) and bovine serum albumin was from MP 
Biomedicals (Solon, OH). Phospholipid vesicles composed of 75% phosphatidylcholine 
(wt/wt) and 25% phosphatidylserine (wt/wt) (PCPS) were a generous gift from Dr. Kenneth 
Mann (University of Vermont) and prepared according to the procedure of Higgins and 
Mann (20) with reagents purchased from Avanti Polar Lipids (Alabaster, AL). The 
chromogenic, thrombin-specific substrate Spectrozyme TH was purchased from Sekisui 
Diagnostics (San Diego, CA). Horse anti-mouse IgG-HRP was obtained from Vectors 
Laboratories (Burlingame, CA). Burro anti-prethrombin-1 antibody (21) was provided by 
the University of Vermont Antibody Core Facility.   
Coagulation proteins 
Human factor Xa and thrombin were purchased from Haematologic Technologies. Human 
factor V, prothrombin and prothrombin-1 were purified as previously described (22,23) 
from freshly frozen plasma obtained from consenting, healthy adults, according to the 
guidelines of the University of Vermont’s Institutional Review Board and Committee on 
Human Subjects. Purified proteins were stored in 2 mM CaCl2, 50% glycerol and stored at 
-20oC. Excess glycerol was removed by dialyses before experiments. Human factor V (1.0 
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µM) was activated to factor Va by α-thrombin (20 nM, 10 min, 37oC). The activity of 
thrombin was quenched by the addition of hirudin (30 nM). Molar protein concentrations 
were measured by UV absorbance at 280 nm with the following extinction coefficients 
(E1% 280nm) and molecular weights (Da): human prothrombin 13.8, 72,000 (24); human 
prethrombin-1 17.8, 49,900 (22); human α-thrombin 18.3, 36,700 (25); human factor Xa 
11.6, 46,000 (26); and human factor V 9.6, 330,000 (27).     
Isolation of platelets from blood  
Blood from healthy, consenting adults was collected by venipuncture into acid citrate 
dextrose (71 mM citric acid, 85 mM trisodium, 2% dextrose, pH 4.5) in a ratio of 6 parts 
of blood to 1 part of acid citrate dextrose. Platelets were subsequently washed and isolated 
according to the method of Mustard et al. with some minor modifications as previously 
reported (28,29). Following isolation, platelets were resuspended in HEPES-Tyrode (HT) 
buffer (137 mM NaCl, 2.68 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1.0 mM 
MgCl2, 5 mM CaCl2, and 0.2% dextrose, pH 7.4). Platelet concentration was measured 
using a Coulter Z1 particle counter (Beckman Coulter, Brea, CA) or an ADVIA 120 
Hematology Analyzer (Siemens Healthcare Diagnostics, Austin, TX) both of which 
produced identical cell counts. In some experiments, washed platelets (3 x 108/mL) were 
maximally activated (12) with thrombin (50 nM) in the presence of 1 mM RGDS in HT 




Time course of prothrombin activation by platelet-bound Prothrombinase 
In these time course reactions, cofactor activity was provided solely by platelet-derived 
factor Va molecules from α-granule releasates following platelet stimulation. Washed 
platelets (1 x 108 /mL) were stimulated with thrombin protease-activated receptor (PAR) 
agonist peptides; PAR1 (100 µM) and PAR4 (500 µM), or thrombin (2 U/mL) and 
incubated in reaction mixtures containing prothrombin (1.4 µM) and RGDS (1.0 mM) in 
HT. The activity of thrombin was inactivated with hirudin (30 nM). The reactions were 
initiated with 5 or 10 nM factor Xa for thrombin- or PAR-activated platelets following a 
five min preincubation. Aliquots were withdrawn every 10 sec for two min, and at select 
intervals for the next 30 min, and subsequently quenched in sample preparation buffer 
(312.5 mM Tris, 25 mM EDTA, 10% SDS, 50% glycerol, 0.05% bromophenol blue, pH 
6.8; 5X SPB) to make a final of 1X SPB. The proteins were then resolved by SDS-PAGE 
followed by Western blotting.  
Michaelis-Menten kinetic constants of prethrombin-1 activation by human 
Prothrombinase  
Initial velocities of thrombin generation from prethrombin-1 were monitored in 2-stage 
assays. Briefly, prethrombin-1 activation (0.5 - 20 µM) was monitored in a reaction mixture 
containing factor Va (20 nM), DAPA (30 µM), PCPS vesicles (20 µM) in 20 mM HEPES, 
150 mM NaCl, pH 7.4 (HBS) containing 5 mM Ca2+ and 0.1% PEG 8000 buffer pH 7.4 
(HBS/Ca2+/PEG). Following a five min incubation at 25oC, the reaction was initiated by 
the addition of factor Xa (0.5 nM). In platelet experiments, reaction conditions were 
established ensuring equivalent amounts of Prothrombinase (0.5 nM) was assembled on 
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thrombin-activated platelets (1 x 108 /mL) (3) in a reaction mixture containing factor Va 
(20 nM) and RGDS (1 mM) in HT. The reaction was initiated by factor Xa (5 nM). At 
timed intervals, aliquots were removed and diluted three-fold in quench buffer (HBS 
containing 50 mM EDTA and 0.1% PEG-8000). The Michaelis-Menten kinetic constants 
(Km, Vmax, kcat) were estimated from the average of two individual experiments by non-




 ………………………………………………………………Eq. 1 
where vo is the initial rate, So is the initial substrate concentration, and the Km is the substrate 
concentration at half maximum velocity, Vmax. Vmax is the maximum rate of the reaction 
and can also be expressed as Eq. 2. 
𝑉𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡[𝐸]…………………………………………………………….  Eq. 2 
where kcat is the turnover rate of the enzyme and [E] is the concentration of enzyme. 
Progress curves of complete prethrombin-1 activation by human Prothrombinase 
The effect of in situ generated Frag 2 during prethrombin-1 activation on product 
(thrombin) formation was monitored in vitro. Reaction mixtures contained: prethrombin-1 
(1.4 – 40 µM), DAPA (30 or 50 µM), PCPS vesicles (20 µM), and factor Va (20 nM) in 
HBS/Ca2+/PEG. Parallel platelet reaction mixtures contained prethrombin-1 (1.4 µM), 
thrombin-activated platelets (1 x 108/mL) and RGDS (1 mM) in HT. Each reaction was 
preincubated (5 min, 25oC) and initiated with factor Xa: 0.5 nM or 5 nM for PCPS and 
platelet experiments, respectively. Timed (0 - 7 h) aliquots were removed, and diluted in 
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quench buffer or SPB. Reaction products were monitored by chromogenic assays or SDS-
PAGE as described below. 
The effect of fragment-2 on prethrombin-1 activation by human prothrombinase  
Prethrombin-1 (10 µM) was activated to completion (forming Frag 2 and thrombin) by 
equivalent amounts of PCPS-bound or platelet-bound prothrombinase. Increasing 
concentration of Frag 2 (containing thrombin) (0-2 µM) were then titrated into 
prothrombinase assays containing 1.4 µM prethrombin-1 or prothrombin on PCPS or 
activated platelet surfaces as described above. To determine the initial rates of thrombin 
generation, aliquots were removed at timed intervals (0 – 5 min) and the reaction stopped 
by dilution in quench buffer. Experiments to control for the effect of thrombin in the 
reactions were run in parallel.  
Spectrozyme TH hydrolysis for determination of thrombin concentrations 
Thrombin activity in the quenched reaction samples was quantified by monitoring the 
hydrolysis of the chromogenic substrate, Spectrozyme TH. The rate of change in 
absorbance at 405 nm was monitored (10 min, 25oC) following the addition of 80 µL 
Spectrozyme-TH (400 mM) to 20 µL reaction aliquots using a SpectroMax250 microtiter 
plate reader (Molecular Devices, Sunnyvale, CA). The concentration and rates of thrombin 
generation were determined from thrombin standard curves assayed concurrently. 
Electrophoretic analyses of protein samples  
Samples from prothrombin or Prethrombin-1 reactions in SPB containing 1% βME were 
boiled (2 min) and resolved by SDS-PAGE using 4-12% gradient, 10% or 12% 
polyacrylamide gels (Invitrogen) as described by Laemmli (30). Resolved proteins were 
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stained with Coomassie brilliant blue R-250. Alternatively, proteins were transferred onto 
nitrocellulose membranes, probed initially with burro anti-prethrombin-1 (7.5 µg/mL)  and 
developed with HRP-conjugated goat anti-horse IgG (0.2 µg/mL) for detection of the bands 
by addition of Western Lightning chemiluminescence reagent (Perkin-Elmer, Waltham, 
MA) and subsequent X-ray film development.  
Data analyses  
Data obtained from kinetic studies were fit to linear regression plots and the Michaelis-
Menten equation using GraphPad Prism v6.0 software to determine initial rates, and kinetic 
constants (Km and Vmax), respectively. Experimentally observed kinetic constants were fit 
to the integrated Michaelis-Menten derivatization to obtain simulated substrate depletion 
or progress curves using Wolfram Mathematica 10 software (Champaign, IL). 
THEORY 
The Michaelis-Menten equation (Eq. 1) was integrated in order to express instantaneous 






𝐾𝑚 ]…………………………………………………...Eq. 3 Ref (31) 
where W is the Lambert function (product log) as previously described (32), So is the initial 
substrate concentration and t is the time. Experimentally determined Km and Vmax from 
prothrombinase-mediated prethrombin-1 activation were used with Eq. 3 to obtain a 










(1 − 𝑒−𝜂𝑡)…………………………………………………………Eq. 4 Ref (33) 
where [P] is the concentration of product as a function of the initial rate (vo), time (t), and 
a function of initial substrate concentration (So) that represents the deviation from linearity 
in the steady-state enzyme activity resulting from product inhibition or substrate depletion 
(η), whereby a positive correlation between η and So is indicative of an enzyme reaction 

















Activation of prethrombin-1 formed in situ by platelet-bound Prothrombinase 
Previously, our lab demonstrated that in the absence of the thrombin inhibitor DAPA, 
Prothrombinase assembled on collagen-activated platelets effectively converted 
prethrombin-1 formed during prothrombin activation to thrombin (3). With cofactor 
activity provided solely by platelet-derived factor Va and under similar conditions to those 
previously described by Wood et al. (3) platelets were activated by either thrombin or 
protease-activated receptor peptides (PAR1 and PAR4) as shown in Fig. 2. Our data 
demonstrate that prothrombin activation proceeds through the prethrombin-2 intermediate 
pathway consistent with an initial cleavage at Arg271 and independent of the platelet agonist 
used. Furthermore, our results show that the in situ generated prethrombin-1 by thrombin 
cleavage of prothrombin at Arg155 was converted into thrombin after 30 min. 
Activation of exogenous prethrombin-1 by PCPS-bound Prothrombinase 
The cleavage pattern of prethrombin-1 activation and the intermediate species by 
Prothrombinase bound to PCPS vesicles were monitored as shown in Fig. 3. As expected, 
initial cleavage of prethrombin-1 occurs at Arg271 (Fig. 1) generating Frag 2 and the 
prethrombin-2 intermediate via the prethrombin-2 pathway. The appearance of 
prethrombin-2 is closely followed by the B-chain of thrombin consistent with a second 
cleavage of this species at Arg320 by Prothrombinase. No meizothrombin des Frag 1 (initial 
cleavage at Arg320) was detected as inferred by the lack of Frag 2.A on the gel (Fig. 3). 
While thrombin was generated during the time course, a significant amount of the 
prethrombin-2 intermediate persisted after 120 min of incubation with PCPS-bound 
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Prothrombinase implying a slow or inhibited cleavage at Arg320. Our results demonstrate 
that Frag 2 generated in situ may be interfering with prethrombin-2 turnover on PCPS 
vesicles.  
Kinetics constants of prethrombin-1 activation by human Prothrombinase 
While we initially hypothesized that platelet-bound Prothrombinase possessed a higher 
affinity for prethrombin-1 compared to the PCPS-bound enzyme where prethrombin-1 is 
considered a poorer substrate, a Michaelis-Menten kinetic analysis suggested that an 
alternative mechanism was responsible for this phenomenon. The kinetic constants 
obtained from prethrombin-1 activation by Prothrombinase assembled on either surface by 
initial velocity studies are shown in Fig. 4 and Table I. The affinity (Km) of prethrombin-1 
for Prothrombinase bound to platelets from two unrelated donors were similar (Km = 3.4 ± 
0.49, donor 1 vs Km = 3.0 ± 0.23, donor 2). Surprisingly, the Km of prethrombin-1 for 
Prothrombinase assembled on PCPS vesicles (Km = 3.7 ± 0.14, n = 2) was equivalent to 
that observed for the enzyme complex assembled on the activated platelet membrane 
(average Km = 3.2 ± 0.28, n = 2). Likewise, the maximum rate of thrombin generation 
(Vmax) is not affected by the surface on which Prothrombinase is assembled. These data are 
inconsistent with the effective turnover and preferred activation of the prethrombin-1 
substrate by platelet-bound Prothrombinase (3). However, we observed that at a high 
concentration of prethrombin-1 (20 µM), the rate of thrombin generation was 3-fold slower 
on PCPS-bound vs. platelet-bound Prothrombinase suggesting that Frag 2, Prethrombin-2 
or both generated in situ may inhibit Prothrombinase bound to PCPS vesicles (Fig. 4) (34). 
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Exogenous fragment-2 inhibition of thrombin generation from prethrombin-1 by 
PCPS- and platelet-bound prothrombinase 
To verify the effect of Frag 2 on cleavage and activation of prethrombin-1, we first 
activated prethrombin-1 to completion generating Frag 2 and thrombin as the final reaction 
products. As shown in Fig. 5A, the addition of Frag 2/thrombin (2 µM) to prethrombin-1 
(1.4 µM) activation mixtures completely abolished the ability of PCPS-bound 
prothrombinase to convert prethrombin-1 to thrombin (Table II). In contrast, under similar 
conditions platelet-bound prothrombinase was only inhibited by ~20%. The data in Fig. 5B 
show that the apparent inhibition by Frag 2 is unique to prethrombin-1 as an alternate 
substrate for PCPS-bound prothrombinase. Our results show that in either case, the 
inhibition observed is not due to the thrombin added coincident with prethrombin-2 
formation in reactions by both PCPS-bound and platelet-bound prothrombinase (Table II).  
Progress curves of prethrombin-1 activation by human prothrombinase 
Experimentally observed prethrombin-1 activation progress curves were compared to 
theoretical curves (from Eq. 3) corresponding to the best fit kinetic parameters (Km = 3.7 
vs. 3.2 μM and Vmax = 4.5 vs. 5.5 nMs-1; PCPS vs platelets, respectively). We observed that 
within the first 5 min, thrombin generation from prethrombin-1 (1.4 µM) proceeded with 
similar initial rates between the theoretical and the experimental conditions with both 
PCPS-bound (71.3 ± 0.5 vs 74.3 ± 2.1 nM/min; n = 3) and platelet-bound prothrombinase 
(98.4 ± 0.8 vs 112.0 ± 7.0 nM/min; n = 3) respectively (Fig. 6). However, beyond 5 min, 
there was marked deviation in the amount of thrombin generated in the experimental vs. 
theoretical progress curves in reactions for prethrombin-1 activation by PCPS-bound 
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prothrombinase (Fig. 6A). In contrast, the experimentally-observed amounts of thrombin 
formed from prethrombin-1 in reactions by platelet-bound prothrombinase were 
recapitulated by the theoretical progress curves (Fig. 6B).  Following 60 mins of incubation 
with prethrombin-1 (1.4 µM) approximately 0.3 μM vs. to 0.06 μM substrate remained in 
the PCPS vesicle vs platelet activation mixtures, respectively.  
The data obtained from PCPS-bound Prothrombinase activation of prethrombin-1 
at high substrate concentrations are shown in Fig. 7 and Table III. The results show an 
approximate seven-fold increase (105.1 vs. 726.6 nM/s) in the rate of thrombin generation 
when substrate concentration was increased eight-fold from 5 µM to 40 µM (Table III). As 
previously described in Eq. 4, values of η > τ-1, where τ is the time range of data acquisition 
(τ = 420 min, τ-1 = 0.002 min-1), and η = deviation from linearity in enzyme kinetics suggest 
that product inhibition or substrate depletion is responsible for the non-linearity in product 
formation time courses. Theoretically, a secondary plot of η as a function of So 
[Prethrombin-1] where values of η increase with increasing substrate concentration 
indicates an enzyme reaction where product inhibition dominates. Conversely, when values 
of η decrease as increased substrate concentration then substrate depletion dominates the 
enzyme reaction (33). Our data show a deviation from linearity and incomplete activation 
to thrombin across all the prethrombin-1 concentrations (5, 10, 20 and 40 µM) assayed in 
reactions by PCPS-bound Prothrombinase (Fig. 7). While almost 75% of the prethrombin-
1 substrate at 5 and 10 µM was converted to thrombin, only 50% of the possible thrombin 
was formed at higher substrate concentrations (20 and 40 µM prethrombin-1, Fig. 7). 
Therefore, at 5 and 10 µM prethrombin-1, the values of η were indistinguishable (0.029 vs. 
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0.028) when the data was fit to Eq. 4. However, a slight increase in the η-value was 
observed at higher concentrations (20 vs 40 µM, 0.035 vs. 0.034) respectively; Table III). 
The data show that as η increases with substrate concentration, it may be surmised that 
product inhibition is contributing to the non-linearity in prethrombin-1 time courses 
catalyzed by PCPS-bound Prothrombinase most likely due to the in situ generation of Frag 

















In an effort to understand Prothrombinase function and the molecular mechanism of 
thrombin generation, several determinants of prothrombin activation have been identified 
or postulated. The majority of these were determined in studies using model system with 
phospholipid vesicles of defined content (including PCPS) (6,35-39). Membrane binding 
is a critical component for Prothrombinase assembly and function in view of the 1,000-
fold reduction in rates of thrombin generation in the absence of an appropriate membrane; 
however, PCPS vesicles do not fully recapitulate the physiologically relevant surface of 
the activated platelet membrane (12-15,39). Similarly, studies have shown that the pathway 
of prothrombin activation is dictated by whether Prothrombinase is bound to the activated 
platelet membrane (2,3) or PCPS vesicles (5,6). To date the biochemical significance of 
prothrombin’s interaction with the membrane is largely derived from evidence that the Gla-
domain within fragment-1 anchors the substrate onto the membrane surface allowing for 
cleavages at the two distant peptide bonds: Arg271-Thr272 and Arg320-Ile321 on the C-
terminal half of the prothrombin molecule to form the active protease, thrombin, and 
notably this strong membrane interaction is thought to drive initial cleavage at Arg320 via 
the alternative meizothrombin activation pathway (6). Loss of fragment-1 following 
cleavage of prothrombin at Arg155 by thrombin produces prethrombin-1, a Gla-domainless 
intermediate which has a ~10-fold reduced rate in thrombin generation compared to 
prothrombin (9-11). 
With the Gla-domainless prethrombin-1 species as an alternative substrate for 
Prothrombinase, we demonstrate in the present study that despite being considered a poorer 
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substrate for PCPS-bound Prothrombinase, it is a viable source for thrombin generation in 
reactions catalyzed by platelet-bound Prothrombinase. Furthermore, we have deduced 
from our kinetic analyses of prethrombin-1 activation that: 1) initial cleavage of 
prethrombin-1 at Arg271 by human Prothrombinase is unaltered by the membrane surface, 
PCPS vesicles vs. activated platelets; 2) at higher prethrombin-1 concentrations, the rate of 
thrombin generation is significantly reduced in reactions by PCPS-bound compared to 
platelet-bound Prothrombinase; and 3) cleavage at Arg320 of prethrombin-2 formed in situ 
during prethrombin-1 activation on PCPS vesicles is inhibited by the accumulation of Frag 
2, a product of the reaction. These findings are the first to demonstrate that defective 
membrane binding is not the only reason but rather only partly contributes to the reduced 
utilization of prethrombin-1 as an excellent source of thrombin generation in reactions by 
PCPS-bound Prothrombinase thereby adding to the body of evidence that activated 
platelets are unique in regards to maximizing the generation of thrombin and promoting an 
appropriate hemostatic response. 
Several lines of evidence from our laboratory and others suggest that human 
Prothrombinase is differentially assembled on model phospholipid systems (5,6) compared 
to the activated platelet membrane (2,3). Wood et al. first made the observation that 
prethrombin-1 formed in situ during prothrombin activation in the absence of thrombin 
inhibitors is effectively converted into thrombin by Prothrombinase bound to collagen-
activated platelets but not PCPS vesicles (3). Additional data from the present study 
corroborate those results, and we further demonstrated that the agonist (i.e. thrombin, 
PAR1, PAR4 or collagen) used in stimulating platelets does not alter Prothrombinase 
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function during prethrombin-1 activation suggesting that activated platelets maximize their 
procoagulant potential following an injury. Based on the pattern of effective consumption 
of the in situ generated prethrombin-1 we anticipated a higher affinity of prethrombin-1 for 
platelet-bound Prothrombinase compared to the PCPS-bound enzyme. While the affinity 
(apparent Km = ~4 µM) of prethrombin-1 activation on PCPS vesicles was consistent with 
previous studies (34,40), a similar enzyme affinity was obtained on the activated platelet 
membrane. These findings are inconsistent with the rapid turnover of in situ generated 
prethrombin-1 during prothrombin activation on the activated platelet (3) and support the 
conclusion that other features beyond enzyme affinity may account for the differential 
activation of prethrombin-1. 
In contrast to the affinity data, initial rates of thrombin generation from 
prethrombin-1 were 3-fold lower at high prethrombin-1 concentrations catalyzed by 
Prothrombinase assembled on PCPS vesicles compared to when the enzyme complex is 
assembled on the activated platelet membrane. These results demonstrate a preference for 
prethrombin-1 by the platelet-bound enzyme and suggest that some form of product 
inhibition may account for the reduced utilization of this substrate on PCPS vesicles. To 
understand the possible form of inhibition, it is important to reiterate that during 
prethrombin-1 activation in situ the prethrombin-2 and Fragment 2 intermediates are 
formed.  In the present study, we have unequivocally demonstrated that prothrombin 
Fragment 2 can abolish Prothrombinase activity when the enzyme complex is assembled 
on PCPS vesicles but not the activated platelet membrane. 
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Furthermore, results from prethrombin-1 progress curves show a significant 
deviation of the experimental from the predicted when Prothrombinase was assembled on 
PCPS vesicles compared to its assembly on the activated platelet surface. In the context of 
our other finding, we suggest that this deviation is due to the reduced activation of the 
zymogens prethrombin-1 or prethrombin-2 intermediate to thrombin. Indeed, 
densitometric analyses indicated the presence of equivalent amounts of both thrombin and 
prethrombin-2 in prethrombin-1 activation reactions catalyzed by PCPS-bound 
Prothrombinase consistent with previous reports (9,41). The results indicate that the 
fragment-2 formed in situ during the reaction likely inhibits PCPS-bound Prothrombinase 
to a greater extent compared to the platelet-bound enzyme. Furthermore, analyses of the η-
values from increased prethrombin-1 concentration in nonlinear enzyme kinetic time 
courses support a trend whereby η increases with increased substrate concentration 
consistent with product inhibition of PCPS-bound Prothrombinase by fragment-2. In 
conclusion, we speculate that reduced thrombin generation by PCPS-bound 
Prothrombinase activation of prethrombin-1 is the result of impaired cleavage at Arg320 of 
the prethrombin-2 intermediate due to inhibition by fragment-2.  
From our present studies, we speculate that fragment-2 may interfere with efficient 
docking of prethrombin-1 to the PCPS-bound Prothrombinase complex. We hypothesize 
that at a high local concentration, the anionic fragment-2 may bind to PCPS-bound 
Prothrombinase and effectively inhibit the binding of prethrombin-2 to the enzyme 
complex. Platelet-bound Prothrombinase effectively avoids such feedback interactions due 
to its unique structural properties (12-15,39). Alternatively, the recent structure of 
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prethrombin-1 also gives potential structural insight as to the underlying mechanism for 
the observations made in the present study.  It shows that the Arg271 cleavage site is ~ 27 
Å away from the electronegative region of Fragment 2 (Glu254) and ~35 Å away from the 
second cleavage site (Arg320), which is fully exposed to solvent for proteolytic attack (42). 
Therefore, significant conformational changes are required following prethrombin-1 
binding by Prothrombinase to effect cleavages at these two peptide bonds. Likewise, 
prethrombin-1 exhibits conformational plasticity similar to the full length prothrombin by 
transitioning between zymogen-like and proteinase-like states (42). As reported here, 
initial cleavage of prethrombin-1 proceeds via Arg271, which is not preferred by PCPS-
bound Prothrombinase (7,9). Therefore, it is possible that the release of fragment-2 may 
further constrain this undesirable orientation of the prethrombin-2 intermediate on PCPS 
vesicles further inhibiting its turnover and supporting the notion that conformational 
plasticity may dictate the fate of each enzymatic step (42). Collectively, our data allow for 
a model whereby fragment-2 interferes to a greater extent with the binding or recognition 
of the prethrombin-2 intermediate during prethrombin-1 activation by PCPS-bound 
Prothrombinase to a significant extent compared to the platelet-bound Prothrombinase 
implicating distinct binding interfaces between enzymes assembled on either membrane 
surface. Therefore, Prothrombinase associated with the physiologically relevant surface of 
the activated platelet membrane, maximizes prothrombin activation by effectively utilizing 
intermediate species such as prethrombin-1 and prethrombin-2 in thrombin generation at 
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Table I. Kinetic parameters for prethrombin-1 activation on membrane surfaces 
 
PCPS vesicles            Activated platelets   
Trial Km, µM  Vmax, nMs
-1  Donor Km, µM  Vmax, nMs
-1 
1 3.8 4.2  1 3.4 5.4 
2 3.6 4.7  2 3.0 5.6 
Mean ± SD 3.7 ± 0.14 4.5 ± 0.35  Mean ± SD 3.2 ± 0.28 5.5 ± 0.14 
 
The kinetic constants (Km and Vmax) were measured from experimental procedures 
described in Materials and Method by fitting data to the Michaelis-Menten equation using 
GraphPad software v6. On either membrane surface (PCPS vesicles or activated platelets), 
initial velocities were limited to within 10% substrate consumption. The kinetic parameters 



























Table II. Normalized rates of thrombin generation from prethrombin-1 or 
prothrombin activations catalyzed by Prothrombinase bound to PCPS vesicles or 




Relative rate of thrombin generation 
1.4 µM Pre-1 1.4 µM Pre-1 + 2 µM Frag 2 1.4 µM Pre-1 + 2 µM IIa 
PCPS 1.0 ± 0.02 0.00 ± 0.00 1.00 ± 0.16 
Platelet 1.0 ± 0.06 0.77 ± 0.05 1.08 ± 0.01 
    
 1.4 µM II 1.4 µM II + 2 µM Frag 2 1.4 µM II + 2 µM IIa 
PCPS 1.0 ± 0.01 1.11 ± 0.13 1.10 ± 0.09 
Platelet 1.0 ± 0.02 1.20 ± 0.10 0.96 ± 0.19 
 
 
*The rates of thrombin generation were estimated from experimental procedures described in 
Materials and Methods. The Prothrombinase reactions were saturated with factor Va (20 nM). 
factor Xa was the limiting reagent. In these reactions the rates obtained were normalized to 
equivalent concentrations of Prothrombinase/factor Xa (0.5 nM) assembled on each membrane 
surface. The values shown (mean ± SD) are representative of two or more independent 
experimental measurements. Prothrombin, prethrombin-1, fragment 2 and thrombin are 























Table III. Parameters of non-linear enzyme kinetic time courses for prethrombin-1 
activation by PCPS-bound Prothrombinase. 
Prethrombin-1, 
[S]o (µM) 
vo (nM/s)  η (min-1)  
5 105.1 0.029 
10 207.4 0.028 
20 477.9 0.035 
40 726.6 0.034 
The amount of thrombin formed was estimated from experimental procedures described in 
Materials and Methods. The initial rate (vo) and η were estimated by fitting data to Eq. 4 























Figure 1. Schematic of prethrombin-1 formation and activation. 
α-Thrombin is generated from prothrombin by ordered cleavages at Arg271 (initial cleavage 
at R271 - prethrombin-2 pathway) and Arg320 (initial cleavage at R320 - meizothrombin 
pathway) via membrane-bound Prothrombinase. Feedback proteolysis of prothrombin at 
Arg155 (R155) by the formed α-thrombin generates fragment-1 (Frag 1) which contains the 
membrane binding Gla-domain, and a Gla-domainless prethrombin-1 (Pre-1) intermediate 
which contains the serine protease domain (A- and B-chains). Cleavage of prethrombin-1 
at Arg271 (R271) by Prothrombinase generates fragment-2 (Frag 2) and prethrombin-2 (Pre-
2) intermediate via the prethrombin-2 pathway. Subsequent cleavage at Arg320 (R320) of the 




Figure 2. Prothrombin activation and in situ prethrombin-1 turnover by platelet-
Prothrombinase. 
Washed human platelets (3 x 108 /mL) were activated with A) thrombin (2 U/mL), B) PAR1 
(100 µM) or C) PAR4 (500 µM) for 10 min. In reactions with thrombin-activated platelets, 
5 nM factor Xa was used to initiate the reactions. For reactions using PAR-activated 
platelets, 10 nM factor Xa was used. Aliquots of the reaction mixture were removed over 
time, quenched in sample preparation buffer and the proteins resolved via SDS-PAGE. 
Proteins were visualized by Western blotting using mAbs against prethrombin-1. Time 
points are shown on the top of each panel. Molecular weight markers (x103 Da) are shown 
on the left side of each panel. Prothrombin (II), prethrombin-1 (Pre-1), prethrombin-2 (Pre-





Figure 3. Prethrombin-1 activation by Prothrombinase assembled on PCPS vesicles. 
Prethrombin-1 (1.4 µM) was activated by PCPS-bound Prothrombinase (20 µM PCPS, 20 
nM factor Va, 0.5 nM factor Xa) in HBS/Ca2+/PEG containing 30 µM DAPA (120 min, 25 
oC). Aliquots of the reaction mixture were removed at timed intervals, quenched in sample 
preparation buffer and the proteins resolved via SDS-PAGE. Proteins were visualized by 
staining with Coomassie brilliant blue R-250. Molecular weight markers (x103 Da) are 
shown on the left side of each panel. The substrate, prethrombin-1 (Pre-1), reaction 
intermediate, prethrombin-2 (Pre-2) and products, B-chain of thrombin (B) and fragment-
2 (Frag 2) are shown on the right. The Frag 2.A intermediate is not observed indicating that 





Figure 4. Kinetics of prethrombin-1 activation on PCPS vesicles and platelets. 
Initial rates of α-thrombin generation from prothrombin-1 (0.5-20 µM) by human 
Prothrombinase assembled on either A) PCPS vesicles (●) or B) thrombin-activated 
platelets (○) were measured by a two-stage chromogenic substrate assay. Kinetic constants 















Figure 5. Relative rates of thrombin generation from prethrombin-1 or prothrombin 
activation mixtures containing exogenous fragment-2. 
Prethrombin-1 (Pre-1, 10 µM) was activated to completion by membrane-bound 
Prothrombinase producing equivalent amounts of the products fragment-2 (Frag 2) and 
thrombin (IIa). The initial rate of thrombin generation from 1.4 µM (A) Prethrombin-1 
(Pre-1) or (B) prothrombin (II) by either PCPS-bound Prothrombinase (■) or platelet-
bound Prothrombinase (■) were monitored in reaction mixtures containing 2 µM of the in 
situ generated Frag 2 plus IIa or only IIa. The data are presented as a bar graph with the 
relative rates normalized to the appropriate initial rate of thrombin generation in the 
absence of either Frag 2 and/or IIa. The asterisk symbol (*) indicates that no thrombin was 
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Figure 6. Progress curves of prethrombin-1 activation by PCPS- or platelet-bound 
Prothrombinase: empirical vs theoretical  
Reaction conditions were as described in Materials and Methods. Timed aliquots of 1.4µM 
prethrombin-1 activation by 0.5nM Prothrombinase assembled on either (A) PCPS vesicles 
(20µM) or (B) thrombin-activated platelets (1x108/mL) were removed and quenched in 
quench buffer. The amount of thrombin generated was followed continuously in a progress 
curve for PCPS-bound Prothrombinase (▲) vs the predicted curve (∆) based on pre-
determined kinetic constants (fit to Eq. 3 in the Materials and Methods). Similar plots are 
shown for platelet-bound Prothrombinase of experimentally observed (■) vs predicted (□) 
progress curves. The data are represented as mean ± (SD or SEM) for three separate 







Figure 7. Progress curves of prethrombin-1 activation by PCPS-bound 
Prothrombinase. 
Reaction conditions are similar to those described in Fig. 6. The thrombin formed via 
PCPS-bound Prothrombinase was monitored over 420 min (τ) at the following 
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Downregulation of the procoagulant response requires proteolytic inactivation of factor 
Va, the essential cofactor for the Prothrombinase-catalyzed activation of prothrombin to 
thrombin. The anticoagulant serine protease activated protein C (APC) and the fibrinolytic 
enzyme plasmin are its most effective physiological inactivators. Several studies, however, 
demonstrate that a fraction of the platelet-derived factor Va pool is resistant to APC-
catalyzed inactivation when compared to its plasma counterpart. The mechanism 
responsible for this protease resistance is unknown. Subsequent to thrombin-catalyzed 
platelet activation, platelet-bound factor Va is defined by two subpopulations: a dissociable 
pool, and a non-dissociable pool that is tethered to the platelet membrane surface via a 
glycophosphatidylinositol (GPI) anchor on the factor Va heavy chain. Analyses of kinetics 
of prothrombin activation indicate that the GPI-anchored factor Va pool accounts for 
between 25-90% of the total platelet-derived factor Va that supports Prothrombinase 
assembly and function. Furthermore, GPI-anchored factor Va directs Prothrombinase 
assembly and function with kinetic constants comparable to those measured using the 
plasma-derived molecule at concentrations that saturate all remaining factor Va binding 
sites. Remarkably, while the GPI-anchored factor Va was completely resistant to 
inactivation by APC, the dissociably-bound factor Va pool was inactivated similarly to the 
plasma-derived molecule.  Likewise, the dissociably-bound factor Va was susceptible to 
plasmin-catalyzed inactivation, whereas the GPI-anchored pool was completely resistant. 
Thus, GPI-anchored platelet-derived factor Va plays a critical role in promoting and 
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sustaining thrombin generation at sites of vascular injury due to its covalent retention and 




















Activated platelets play several critical roles in normal hemostasis following 
vascular injury. Their adherence and aggregation at the injury site results in 1) the 
formation of a platelet plug (1,2), 2) their activation and release of α- and dense-granule 
constituents, many of which are involved in the procoagulant response (3-5), and 3) their 
provision of the catalytic surface required for the function and assembly of coagulation 
complexes (6,7) that will sustain the procoagulant response. Upon platelet activation, factor 
Va stored within their α-granules is made immediately available to perform its essential 
role in the assembly and function of the final enzyme complex, Prothrombinase.  
Prothrombinase is a calcium-dependent, 1:1 stoichiometric complex of the non-enzymatic 
cofactor, factor Va, and the serine protease, factor Xa, bound to the surface of activated 
platelets adhered to sites of vascular injury that converts the zymogen prothrombin to 
thrombin (3,8). Factor Va plays a critical role in the formation of Prothrombinase since it 
is absolutely required for factor Xa binding to activated platelets (9-11), and therefore 
profoundly influences the amount of thrombin generated. Clinically, this is underscored by 
observations that deficiencies in the procofactor, factor V, are associated with severe 
bleeding abnormalities and possibly even death (12,13), whereas inefficient inactivation of 
factor V and Va by activated protein C (APC), as is seen in factor VLeiden, can lead to venous 
thrombosis (14) (15,16).  
The inactive procofactor factor V is synthesized by, and released from, the liver as 
a single-chain, 330 kDa protein (17-19) that is distributed between two pools.  Of the total 
factor V found in whole blood, 75-80% circulates in plasma (20-30 nM) and 20-25% is 
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found within the α-granules of platelets (~4600-14,000 molecules/platelet) (4,20). The 
conversion of plasma-derived factor V to its active state (21,22), requires limited 
proteolysis by thrombin to yield a 105 kDa N-terminal-derived heavy chain and 75 kDa C-
terminal-derived light chain (21,23) associated by Ca2+ whereas, the platelet-derived pool 
is stored in platelet α-granules in a partial, proteolytically-activated state (factor V/Va) 
(4,20) as a result of the endocytosis of plasma-derived factor V by megakaryocytes (24-
26). Its subsequent proteolytic processing and trafficking to α-granules to produce a 
fraction of the cofactor pool that does need to be activated by thrombin (26-28). 
Considering that at a site of vascular injury the concentration of platelet-derived factor 
V/Va has been estimated to be as much as 600 times that of plasma factor V (7), any 
alterations in this cofactor pool will have a profound impact on hemostasis.  Indeed, several 
studies have reported that the platelet-derived factor V/Va pool possesses physical (29-35) 
and functional (23,27,36,37) characteristics that impart a more procoagulant phenotype 
than that of its plasma counterpart, and allow for sustained thrombin generation at sites of 
vascular injury. 
Plasma- and platelet-derived factor Va exhibit differential susceptibilities to 
proteolysis by various proteases including inactivation by activated protein C (APC) 
(36,38), and plasmin (39,40). Earlier studies indicated that a substantial fraction of the 
platelet-derived factor Va pool is totally resistant to proteolytic inactivation by the 
anticoagulant protease APC (36,38), whereas the plasma-derived factor Va pool is rapidly 
and completely inactivated by APC. Likewise, the fibrinolytic enzyme, plasmin, rapidly 
and completely inactivates plasma-derived factor Va, whereas plasmin-catalyzed cleavage 
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of platelet-derived factor Va increases its cofactor activity approximately 3-6 fold, an 
activity which can be sustained for several hours despite the continued presence of plasmin 
(39). These observations are in marked contrast to the rapid and complete inactivation of 
plasma-derived factor Va catalyzed by plasmin. What physical features make these two 
cofactor pools different substrates for these various proteases have yet to be determined. 
Wood et al. recently identified a non-dissociable, membrane-bound pool of 
platelet-derived factor Va following extensive washing of thrombin-activated platelets 
(10,41), Further studies revealed that the heavy chain of platelet-derived factor Va is 
covalently associated with the activated platelet membrane via a glycosylphosphatidyl 
inositol (GPI) anchor at Ser692 that resides within the heavy chain GPI anchor consensus 
sequence (R678KMHDRLEPEDEES692DADYDYQNRLAAALGIR108). The addition of a 
GPI anchor at this site may explain the inability of platelet-derived factor Va, but not 
plasma-derived factor Va to be phosphorylated at that site (31,41), and which renders the 
plasma-derived factor Va more susceptible to APC-catalyzed inactivation. Other studies 
demonstrated that only a subpopulation of platelets expresses this GPI-anchored cofactor 
pool, which also defines the subpopulation of platelets capable of assembling a functional 
Prothrombinase (10). The goal of the current study is define the functional characteristics 
of the GPI-anchored platelet-derived factor Va pool. Our results demonstrate that GPI-
anchored platelet-derived factor Va can account for 25-90% of released/expressed cofactor 
that supports thrombin generation via Prothrombinase, expresses the same binding affinity 




MATERIALS AND METHODS 
Materials  
Bovine serum albumin was bought from MP Biomedicals (Solon, OH). The peptides Gly-
Pro-Arg-Pro (GPRP), and Arg-Gly-Asp-Ser (RGDS) were synthesized by or purchased 
from the Protein Core Facility, University of Vermont or ABI Scientific Inc. (Sterling, 
VA), respectively. Hirudin was obtained from Calbiochem (Gibbstown, NJ).. 
Dansylarginine N-(3-ethyl-1, 5-pentanediyl) amine (DAPA) was obtained from 
Haematologic Technologies (Essex Junction, VT). Phospholipid vesicles comprised of 
75% phosphatidylcholine (wt/wt) and 25% phosphatidylserine (wt/wt) (PCPS) were a 
generous gift from Dr. Kenneth Mann (University of Vermont) and prepared according to 
the procedure of Higgins and Mann (42) with reagents purchased from Avanti Polar Lipids 
(Alabaster, AL). The chromogenic thrombin-specific substrate Spectrozyme TH was 
purchased from Sekisui Diagnostics (San Diego, CA).  Nitrocellulose membrane (0.45 µm) 
was bought from Bio-Rad (Hercules, CA). The Western Lightning chemiluminescence 
substrate, and iodine-125 were obtained from PerkinElmer (Waltham, MA). IODO-GEN 
tubes were bought from ThermoScientific (Rockford, IL). Antibodies: Horseradish 
peroxidase conjugated to horse anti-mouse IgG was purchased from Vectors Labs 
(Burlingame, CA). Monoclonal antibodies against human factor Va heavy chain (αhFVa 
LC#9)(43) and light chain (αhFVa HC#17)(44) were provided by the University of 





Human factor Xa, α-thrombin, activated protein C (APC), and plasmin were purchased 
from Haematologic Technologies (Essex Junction). Human prothrombin, and factor V 
were purified as previously described (17,45) from freshly frozen plasma obtained from 
consenting healthy adults, according to the guidelines of the University of Vermont’s 
Institutional Review Board and Committee on Human Subjects. . Proteins were stored in 
50% glycerol containing 5 mM CaCl2 at -20
oC. Plasma-derived factor V (1.0 µM) was 
activated to factor Va by α-thrombin (20 nM, 37 oC). The activity of thrombin was 
quenched by the addition of hirudin (30 nM). Protein concentrations were determined by 
UV absorbance at 280 nm with the following extinction coefficients (E1% 280nm) and 
molecular weights (Da):  human APC, 14.5, 56200 (46); human plasmin, 17.0, 83000 (47); 
human prothrombin, 1.38, 72000 (48); human thrombin, 1.83, 36700 (49); human factor 
Xa, 11.6, 46000 (50); and human factor V, 9.6, 330000 (51).  
Isolation of human platelets followed by isolation of the dissociable pool of platelet-
derived factor Va and the factor Va that is GPI-anchored to thrombin-activated 
platelets   
Blood from nonsmoking, healthy, and consenting adults was collected by venipuncture into 
acid citrate dextrose (71 mM citric acid, 85 mM trisodium, 2% dextrose, pH 4.5) in a ratio 
of 6 parts of blood to 1 part of acid citrate dextrose. Platelets were subsequently washed 
and isolated according to the method of Mustard et al. (36) with some minor modifications 
as previously reported (52). Following isolation, platelets were resuspended in HEPES-
Tyrode buffer (137 mM NaCl, 2.68 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1.0 
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mM MgCl2, 5 mM CaCl2, and 0.2% dextrose, pH 7.4; HT buffer). The platelet 
concentration was determined using the ADVIA 120 Hematology Analyzer (Siemens 
Healthcare Diagnostics). Washed platelets were activated at 3 x 108/mL with thrombin (50 
nM) in HT buffer pH 7.4 in the presence of 1 mM RGDS (5 min, 25 oC) and the thrombin 
inhibited by the addition of 75 nM hirudin.  
 Isolation of platelet-derived factor Va that is GPI-anchored to the thrombin-
activated platelet required the following: Platelets were activated and immediately washed 
repeatedly as previously described by Wood et al. (10,53). Isolated platelets (1 x 109/mL) 
in HT buffer containing 5 mM CaCl2, 3.5 mg/mL BSA pH 7.4 (HTA), 3 mM RGDS and 2 
mM GPRP were activated with thrombin (50 nM, 2 min, 25oC). Hirudin (75 nM) was then 
added to inactivate the thrombin. The activated platelet mixture was subjected to 
centrifugation at 660 xg for 3 min. and the supernatant containing the dissociable pool of 
platelet-derived factor Va was removed.  The remaining platelets were resuspended gently 
in 1.0 mL HTA buffer containing RGDS (5 mM) and washed repeatedly to isolate the 
factor Va that is GPI-anchored to the thrombin-activated platelet membrane. Subsequent 
to their final centrifugation, the platelets were resuspended in HTA and the platelet number 
determined. These platelets are referred to as “super-washed” platelets.  
Use of analyses of kinetics of prothrombin activation to define the role of the GPI-
anchored factor Va cofactor pool in Prothrombinase assembly and function.  
Initial velocities of thrombin generation from prothrombin were monitored in 2-stage 
assays. Briefly, prothrombin (0.05 - 15 µM) activation was monitored in a reaction mixture 
containing 1 x 108/mL super-washed platelets, 30 µM DAPA, and 1 mM RGDS in HT 
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buffer. Subsequent to a 5 min incubation at 25oC, the reaction was initiated with factor Xa 
(12 nM). At timed intervals (0, 10, 20, 30 and 40 sec), aliquots were withdrawn and diluted 
3-fold into 20 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 0.1% PEG 8000, pH 7.4 
containing 50 mM EDTA (quench buffer) to stop the reaction. The thrombin concentration 
in each sample was determined using the chromogenic substrate Spectrozyme TH (0.4 mM, 
final). The change in absorbance at 405 nm was monitored (10 min, 30oC) using a 
SpectroMax250 microtiter plate reader (Molecular devices, CA) and compared to a 
standard curve (0 - 100 nM thrombin) prepared daily. The concentrations of thrombin 
determined were fit to linear regression plots to obtain rates followed by non-linear fitting 
to the Michaelis-Menten equation using GraphPad Prism v6.0 software (GraphPad Prism, 
CA) to determine the kinetic constants (Km and Vmax).  
 The binding affinity of factor Xa for GPI-anchored platelet-derived factor Va was 
also determined using a 2-stage assay to measure initial rates of thrombin generation as 
described above. Platelets isolated from three different donors were used as sources of GPI-
anchored platelet-derived factor Va. Prothrombin activation mixtures contained 1.4 µM 
prothrombin, 1 x 108/mL super-washed platelets, 30 µM DAPA, and 1 mM RGDS in HT 
buffer. Subsequent to a 5 min incubation at 25oC, the reaction was initiated with variable 
concentrations of factor Xa (0.25 - 30 nM). At time intervals, aliquots were removed and 
the thrombin present determined as described above. Data from the initial rates of thrombin 
generation as a function of factor Xa was fit to one-site binding equation using GraphPad 




Near identical assay conditions were used to quantify the amount of platelet-derived 
GPI-anchored factor Va bound to thrombin-activated platelets obtained from four different 
donors. Prothrombin activation mixtures contained 1.4 µM prothrombin, 1 x 108/mL super 
washed platelets, 30 µM DAPA, and 1 mM RGDS in HT buffer. Subsequent to a 5 min 
incubation at 25oC, the reaction was initiated with factor Xa (12 nM). At time intervals, 
aliquots were removed and the thrombin present determined as described above. 
Determination of the effect of APC and plasmin on the cofactor activity associated 
with dissociable factor Va pool and the GPI-anchored platelet-derived factor Va pool 
Proteolytic inactivation of the dissociable pool of platelet-derived factor Va and the GPI-
anchored platelet-derived factor Va pool were monitored in the presence of APC or 
plasmin. The supernatant containing dissociable platelet-derived factor Va was prepared 
by centrifugation of thrombin-activated platelets (1 x 109/mL, 1000 xg, 3 min) (36). The 
supernatant is also rich in platelet-derived microparticles that provide the membrane 
surface for Prothrombinase assembly and function. Super-washed platelets retaining GPI-
anchored platelet-derived factor Va were prepared as described. Reactions contained 1 x 
109/mL super-washed platelets or 500 µL of the mixture containing dissociable platelet-
derived factor Va, 1 mM RGDS, and 30 nM hirudin in HT buffer. Following a 5 min 
incubation (37oC), catalytic amounts of APC (0.25 nM) or plasmin (25 nM) were added. 
Timed aliquots (0, 5, 10, 15, 20, 30, 45, 60, 90, 120 min) were removed and quenched in 
sample preparation buffer (62.5 mM Tris, 5 mM EDTA, 2% SDS, 10% glycerol, 0.01% 
bromophenol blue, pH 6.8; SPB). Simultaneously, samples were removed, and assayed for 
residual cofactor activity in a Prothrombinase assay containing 1 x 108/mL protease-treated 
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super-washed platelets, 1 mM RGDS, 30 µM DAPA in the presence of 12 nM factor Xa at 
25oC in HT buffer pH 7.4. 
 The APC- and plasmin-catalyzed inactivation of plasma-derived factor Va used 
PCPS vesicles as the required membrane surface. To assess APC-catalyzed inactivation, 
reaction mixtures contained plasma-derived factor Va (20 nM),  hirudin (30 nM), and PCPS 
vesicles (10 µM) in 20 mM HEPES, 150 mM NaCl, 5 mM CaCl2 containing 0.1% PEG 
8000, pH 7.4. (HBS/Ca2+/PEG). For plasmin-catalyzed inactivation experiments, the 
concentrations of plasma-derived factor Va and PCPS vesicles were increased to 500 nM 
and 30 µM, respectively. Otherwise reaction conditions were identical to those described 
above for APC.  Each reaction mixture was preincubated for 5 min at 37oC followed by 
the addition of 0.25 nM APC or 25 nM plasmin, respectively.  Aliquots of the reaction 
mixtures were removed at timed intervals (0, 5, 10, 15, 20, 30, 45, 60, 90, 120 min) and 
assayed for residual cofactor activity as described. Concurrently, samples were quenched 
in SPB for immunoblotting analyses.  
SDS-PAGE and Western blotting analyses 
All samples diluted in SPB were boiled (45 sec, 90oC) under reducing conditions (5% β-
mercaptoethanol). Protein samples were analyzed based on their  mass (50 ng/lane) using 
10% or 4-12% Tris-Gly gradient gels (Invitrogen), according to the method Laemmli et al. 
(54) of proteins and peptides resolved via SDS-PAGE were transferred to nitrocellulose as 
described by Towbin and colleagues. (55) The factor Va antigen was probed with anti-
human factor V heavy chain monoclonal antibody (αhFV #17), detected with a horse anti-
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mouse coupled to horseradish peroxidase (HRP) by enhanced chemiluminescence and 




Characterization of the contribution of GPI-anchored platelet-derived factor Va to 
Prothrombinase assembly and function on thrombin-activated platelets 
Previous studies from our laboratory demonstrated that when GPI-anchored 
platelet-derived factor Va is the sole source of the cofactor, it supports Prothrombinase 
assembly and efficient prothrombin activation. More importantly, the prothrombin  
cleavage products observed during the reaction indicate that prothrombin was initially 
cleaved at Arg271 followed by cleavage at Arg320 (the prethrombin-2 pathway of activation) 
through a concerted mechanism (56). In this study, the Kd for factor Xa binding to GPI-
anchored platelet-derived factor Va, expressed by super-washed, thrombin-activated 
platelets, was determined by monitoring prothrombin activation at varying factor Xa 
concentrations (Fig. 1).  The data shown are representative of experiments performed with 
platelets isolated from different donors (n = 3). The initial rate of thrombin generation 
increased as a function of the factor Xa concentration and was maximal at 10 - 12 nM 
factor Xa. From these data, an apparent Kd = 1.6 x 10
-9 M was determined to govern factor 
Xa binding to the GPI-anchored cofactor, consistent with  the values for factor Xa assembly 
into platelet-bound Prothrombinase reported in earlier studies (9).  
Studies were done subsequently to determine the kinetic and binding parameters 
governing prothrombin activation when the GPI-anchored platelet-derived cofactor was 
the sole source of factor Va in Prothrombinase assays. Data obtained with two different 
platelet donors (Fig. 2) yielded Km’s for prothrombin activation that were identical (0.50 
vs 0.48 µM) and similar to previous studies (9,57). The different Vmax values (4.01 vs 5.58 
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nMs-1) observed result from the difference of the number of GPI-anchored cofactor 
molecules expressed on the surface of thrombin-activated platelets between donors.  
Subsequently, the amount of GPI-anchored platelet-derived factor Va bound to 
thrombin-activated, super-washed platelets isolated from four different donors was 
determined by monitoring the initial rate of thrombin generation catalyzed by platelet-
bound Prothrombinase under two conditions. By determining the rate of thrombin 
generation supported by GPI-anchored platelet-derived factor Va vs. the total platelet-
derived factor Va associated with the same donor’s unwashed, thrombin-activated 
platelets, the percentage of the GPI-anchored pool could be calculated (Table I). The data 
indicate that between 25% to 90% of the total pool of platelet-derived factor Va, capable 
of supporting Prothrombinase assembly and thrombin production, is GPI-anchored to the 
activated platelet membrane similar to earlier observations from our laboratory (10,41).  
Effects of APC and plasmin on the cofactor activity of GPI-anchored platelet-derived 
factor Va 
Earlier studies have reported a differential protease susceptibility between plasma and 
platelet-derived factor Va (36,39). Experiments were performed to compare APC- and 
plasmin-mediated proteolysis of plasma-derived factor Va to that of the GPI-anchored 
platelet-derived factor Va pool. APC effects factor Va inactivation and loss of cofactor 
activity by targeted proteolysis at Arg306, Arg506 and Arg679 within the factor Va heavy 
chain (58,59). Initial cleavage of the heavy chain at Arg506 results in the generation of 75 
kDa intermediate fragment which can be subsequently cleaved at Arg306 to form a 45/42 
kDa fragments. Final cleavage at Arg679 of the 42 kDa fragment produces a 30 kDa 
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associated with complete inactivation. The APC-catalyzed inactivation of plasma-derived 
factor Va bound to PCPS vesicles and GPI-anchored platelet-derived factor V, expressed 
on the surface of thrombin-activated platelets are shown in Fig. 3. Consistent with several 
studies, approximately 50% of the plasma-derived factor Va was inactivated within 10 min 
of the addition of catalytic amounts of APC (Fig 3A, major graph). By two hours, 
approximately 80% of the cofactor activity of the plasma factor Va was lost, consistent 
with observations made by others (60,61). Loss of cofactor activity of plasma-derived 
factor Va correlated with the generation of low molecular weight proteolytic products from 
immunoblotting analyses (data not shown). In marked contrast, the GPI-anchored platelet-
derived factor Va pool was completely resistant to inactivation by APC (Fig. 3A, graph 
inset). Thus, greater than 95% of the cofactor activity remained after 2 h of incubation of 
GPI-anchored factor Va with APC.  
In support of the cofactor activity measurements (Fig 3A, graph inset), no 
proteolytic fragments were observed after prolonged (60 min) incubation of GPI-anchored 
platelet-derived factor Va with APC (Fig. 3A, immunoblot inset). A faint band representing 
the 75 kDa species was only identified after two hours of incubation with APC, and did not 
result in a significant loss of cofactor activity. In contrast, the APC-catalyzed inactivation 
of the dissociably-bound pool of platelet-derived factor Va was apparent based on the 
proteolytic profile obtained (Fig. 3B). APC initially cleaved this pool of platelet-derived 
factor Va at Arg506 to generate a 75 kDa fragment (Fig. 3B), which was further cleaved at 
Arg306 to generate the 30 kDa fragment that is associated with complete loss of cofactor 
function. Despite both these factor Va pools being derived from the platelet, the dissociable 
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pool of platelet-derived factor Va (Fig. 3B) is more susceptible to APC-catalyzed 
inactivation compared to the GPI-anchored pool (Fig. 3A, inset), which retains close 
proximity to the activated platelet surface.  
Plasmin cleaves the heavy chain of membrane-bound factor Va at multiple sites 
including Lys309, Lys310, Arg313, Arg348 and Arg506 resulting in the generation of several 
low molecular weight fragments and loss of cofactor activity (58,59). As shown in Fig 4A, 
incubation of PCPS-bound plasma-derived factor Va with plasmin resulted in the time-
dependent loss of 85% cofactor activity after 30 min of incubation, consistent with 
observations from other laboratories. (40). In marked contrast, GPI-anchored platelet-
derived factor Va retained 100% of its initial cofactor activity following a 40 min 
incubation with plasmin (Fig. 4B). As the reaction progressed, there was an increase in its 
cofactor activity, which peaked at ~140% after 2 h, consistent with previous observations 
(39).  
The plasmin-mediated cleavage profiles were consistent with the different cofactor 
activities of plasma-derived factor Va and GPI-anchored platelet-derived factor Va. After 
a 5 min incubation with plasmin, proteolysis of the plasma-derived factor Va heavy chain 
(105 kDa) was accompanied by the appearance of fragments of ~75, 50, 45, 30, and 20 
kDa (Fig. 4A, inset) with significant proteolysis and inactivation  observed by 30 min. A 
similar pattern of proteolysis and proteolytic fragments were observed in control 
experiments with or without exogenously added PCPS vesicles in the presence of 
dissociable platelet-derived factor Va (Fig. 5). In contrast, the heavy chain of GPI-anchored 
platelet-derived factor Va was > 95% intact and only the ~50 and 45 kDa fragments were 
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detected after a prolonged (2 h) incubation with plasmin (Fig 4B, inset). These fragments 
are associated with a minimal loss in cofactor activity and may partly explain the negligible 

















Platelets adhered and activated at sites of vascular injury promote hemostasis by 
the release of the contents of α- and dense-granules including von Willebrand factor 
(62,63), fibrinogen (3,62,63), plasminogen activator inhibitor-1 (62), and factor V (5,26), 
Platelet-derived factor V originates following endocytosis of plasma-derived factor V by 
platelet precursor cells, megakaryocytes via a clathrin-dependent, receptor-mediated event 
(24-26,28). Following its endocytosis and prior to its trafficking to α-granules, factor V 
undergoes extensive retailoring intracellularly to yield a physically (29-35) and 
functionally (23,27,36,37) unique cofactor molecule including but not limited to 
differences in protease susceptibility (23,36,39), differences in N- and O-linked 
glycosylation (29,35), and resistance to phosphorylation catalyzed by a platelet-associated 
kinase (31,41). Most recently, Wood et al. identified a subpopulation of platelet-derived 
factor Va associated with thrombin-activated platelets, which is non-dissociably associated 
with the activated platelet membrane (10,41). Thus, when activated platelets are 
extensively washed in the presence or absence of calcium ions, this pool of platelet-derived 
factor Va remains bound. Additional evidence suggests that this pool of factor Va is GPI-
anchored to the activated platelet membrane via the factor Va heavy chain (41). The data 
shown and described in this study have begun to characterize the functional properties of 
GPI-anchored platelet-derived factor Va. This distinct pool of platelet-derived factor Va 
accounts for 40% - 90%, of the total platelet-derived factor Va that participates in 
Prothrombinase assembly and function. When incorporated into Prothrombinase, GPI-
anchored platelet-derived factor Va supports thrombin generation with kinetic parameters 
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that are similar to those observed when the plasma-derived molecule is used as the cofactor 
(17,21,23). As shown previously it supports the cleavage of prothrombin through the 
prethrombin-2 pathway of prothrombin activation (56,57) and not the meizothrombin 
pathway (64-66) indicating that the GPI-anchored platelet-derived factor Va pool will 
sustain only thrombin generation at the activated platelet surface.  
The importance of platelet-derived factor Va to sustaining the procoagulant 
response when required cannot be overstated,  yet processes that down-regulate the activity 
of Prothrombinase are equally important to maintaining the balance between hemostasis 
and thrombosis. In contrast to the plasma-derived molecule, which is rapidly and 
proteolytically inactivated by APC during down-regulation of the procoagulant response 
(38,61,67), the GPI-anchored platelet-derived factor Va is totally resistant to proteolysis 
and inactivation by APC. Similar observations were made by Camire et al. who reported 
that the total platelet-derived factor Va pool (dissociable plus GPI-anchored) retained 
~40% cofactor activity despite prolonged incubation with APC (36). They further 
demonstrated that when plasma-derived factor Va was added to the activated platelet 
membrane, it was completely inactivated by APC and the baseline cofactor activity was 
restored to 40%. Although this GPI-anchored pool was cleaved by the fibrinolytic enzyme, 
plasmin, to some extent, its cofactor activity was sustained and increased over time 
consistent with previous studies using the total platelet-derived cofactor pool as the factor 
Va source (39). It can be hypothesized that plasmin may have proteolytically inactivated 
one or more unknown inhibitory determinants on the activated platelet surface resulting in 
the protease resistance of GPI-anchored platelet-derived factor Va. Alternatively, the 
 151 
 
delayed release of factor V/Va cofactor molecules from the open canalicular system (68) 
may partly contribute to the increased cofactor activity and decreased proteolytic 
inactivation.  
 Previous observations demonstrated that the non-dissociable, GPI-anchored 
platelet-derived factor Va pool defines the subpopulation of platelets capable of assembling 
a functional Prothrombinase, and represents ~50% of the total platelet-derived factor Va 
pool (10). This subpopulation of platelets capable of binding factor Va and factor Xa has a 
significantly (4 to 6-fold) increased expression of several adhesion molecules important 
for normal hemostasis, including glycoprotein Ibα and integrins αIIb and β3, thereby 
placing these platelets in a unique position to contribute to both hemostatic and thrombotic 
events. This subpopulation is hypothesized to play a significant role in regulating both 
normal hemostasis and pathological thrombus formation because the adherent properties 
of platelets and their ability to mount and sustain a procoagulant response are crucial steps 
in both of these processes. Increased adhesive receptor density guarantees the adhesion of 
these procoagulant platelets to von Willebrand factor. Following shear-induced platelet 
activation, GPI-anchored platelet-derived factor Va is expressed on the activated 
membrane surface. Factor Xa, formed via the tissue factor/factor VIIa complex, assembles 
with GPI-anchored platelet-derived factor Va to form Prothrombinase and generate small 
amounts of thrombin, which subsequently activate more platelets. Recruitment and 
incorporation of procoagulant platelet subpopulations into the growing thrombus via their 
increased expression of αIIbβ3 will follow. As these activated platelets also express a pool 
of platelet-derived factor Va that is resistant to proteolytic inactivation, not only will these 
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platelets promote thrombin generation, but they will support a sustained and prolonged 
procoagulant response. It can also be hypothesized that these events will be as likely to 
promote thrombosis as to prevent hemorrhage. 
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Table I. Contribution of the two platelet-derived, membrane-bound pools of factor 
Va to the expression of Prothrombinase activity: dissociably-bound factor Va vs the 
GPI-anchored factor Va 
  
Initial rates of thrombin generation 
(nM/sec) 
  
Source of cofactor activity 1 2 3 4 Mean ± SD 
Total platelet-derived FVa* 6.73 2.50 4.37 6.45 5.01 ±  1.98 
GPI-anchored platelet-derived FVa 2.70 1.11 3.77 1.68 2.32 ± 1.17 
% GPI-anchored platelet-derived FVa 40.12 44.40 86.27 26.05 49.21 ± 25.92 
 
*Total platelet-derived factor Va = the sum of dissociably-bound factor Va and GPI-anchored 






















Figure 1. The binding interactions of factor Xa and super washed platelets as 
measured by prothrombin activation kinetics.  
Thrombin-activated platelets were super washed as described in the Materials and 
Methods. Prothrombinase reactions contained prothrombin (1.4 µM), super washed 
platelets (1 x 108 m/L), and DAPA (30 µM) in HT buffer pH 7.4. Thrombin generation was 
initiated by the addition of factor Xa (0.25 – 30 nM) and the initial rates of thrombin 
generation determined by two-stage assay. The data were fit to a one-site binding equation 








Figure 2. Determination of the kinetic constants of prothrombin activation by 
Prothrombinase bound to super washed platelets.  
Thrombin-activated platelets were super washed as described in the Materials and Methods 
and diluted to 1 x 108/mL. Prothrombinase reactions mixtures contained prothrombin (0.05 
- 15 µM) and DAPA (30 µM) in HT buffer. Thrombin generation was initiated by the 
addition of factor Xa (12 nM), and the initial rates of thrombin generation determined by 
two stage assay. The data from two donors were fit to the Michaelis-Menten equation using 












Figure 3. Comparison of APC-catalyzed inactivation patterns of GPI-anchored, 
dissociable pool of platelet-derived, and plasma-derived factor Va molecules. 
A) APC-inactivation reactions contained thrombin-activated plasma-derived factor Va (20 
nM), 10 µM PCPS vesicles, 30 nM hirudin in HBS/Ca2+/PEG buffer, pH 7.4 or Inset: GPI-
anchored platelet-derived factor Va (500 µL). Each reaction was initiated with APC (0.25 
nM) and aliquots removed at select time points (1, 5, 10, 15, 20, 30, 45, 60, 90 and 120 
min) and then immediately assayed for residual cofactor activity in prothrombinase assays 
at limiting factor Va as described in detailed the Materials and Methods section. 
Alternatively, at the designated time points, samples were withdrawn and quenched in 
sample preparation buffer containing 1% βME for immunoblotting analyses using anti-
human factor Va (αhFV#17) monoclonal antibody against the heavy chain region. In panel 
(B), the dissociable platelet-derived factor Va (500 µL) from activated platelets (1 x 109 
m/L) was treated with APC (0.25 nM) in HT buffer, pH 7.4 and the proteolytic products 











Figure 4. Plasmin-mediated proteolysis of plasma-derived factor Va vs non-
dissociably bound platelet-derived factor Va. 
(A) Thrombin-activated plasma-derived factor Va (500 nM) was treated with plasmin (25 
nM) in a reaction mixture containing 30 µM PCPS vesicles and 30 nM hirudin in the 
presence of HBS/Ca2+/PEG buffer, pH 7.4. Hirudin was added to inhibit the residual 
thrombin present in the reaction mixture. At selected time points, aliquots of the reaction 
were removed and immediately assayed for residual cofactor activity in prothrombinase 
assays at limiting factor Va as described in detailed the Materials and Methods section. 
Inset: alternatively, at the same designated time intervals, samples were withdrawn and 
added to SPB containing 5% βME to quench the reaction. Samples were subsequently 
boiled, resolved by electrophoresis and probed using monoclonal antibodies against human 
factor Va heavy chain (αhFV#17). Similar experiments were performed in panel (B). The 
plasmin concentration was unchanged, however the substrate this time round was super-
washed platelets (1 x 109 m/L), containing the GPI-anchored pool of platelet-derived factor 
Va in HT buffer, pH 7.4. Likewise, the graph shows the residual cofactor activity remaining 











Figure 5. Immunoblotting analyses of plasmin-catalyzed proteolysis of the dissociable 
pool of platelet-derived factor Va. 
Following thrombin (2 U/mL) activation of platelets (1 x 109 /mL), the platelets were gently 
centrifuged (660 xg, 3 min) and the supernatant pooled to form microparticle rich platelet-
releasate containing the dissociable pool of platelet-derived factor Va. Plasmin (25 nM) 
was added to 500 µL of the dissociable platelet-derived factor Va in the presence of hirudin 
(30 nM) and RGDS (1 mM) at 37 oC.  Aliquots were removed at timed intervals and 
quenched in SPB. Products of the reactions were resolved by SDS-PAGE followed by 
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Coagulation factor V exists as two major procoagulant pools in human blood. The platelet-
derived pool is acquired by megakaryocyte uptake and subsequent proteolytic 
modifications of the plasma-derived factor V pool to form a protease-resistant cofactor 
stored within the platelet α-granule. The functional properties of the platelet-derived 
molecule have been attributed to both its close association with the platelet membrane, and 
the post-translational modifications occurring subsequent to endocytic trafficking. One 
such modification is the presence of high mannose N-linked glycans at Asn269 and Asn1982 
on the heavy and light chain regions, respectively. To investigate the importance of these 
glycans, plasma-derived factor V was incubated with endoglycosidase H to selectively 
remove these N-linked glycans. Treatment resulted in the removal of approximately 80% 
of the high mannose glycans on either chain. The proteolytic cleavage profiles obtained by 
incubation with catalytic amounts of APC were indistinguishable between deglycosylated 
factor V and the untreated control. When cofactor activity was assessed, deglycosylated 
factor V expressed 80% of the cofactor activity of the control when assayed in prothrombin 
time clotting assays. In kinetic studies, the catalytic efficiency (8.2 x 107 vs. 5.0 x 107 M-
1s-1) of Prothrombinase was decreased almost two-fold in the presence of deglycosylated 
factor Va compared to the control. There was no observed effect on enzyme affinity (Km ~ 
0.20 µM). Following deglycosylation, factor Va endocytosis was enhanced compared to 
the untreated samples. These combined data suggest that targeted removal of high mannose 





The coagulation protein factor Va is absolutely essential for physiological thrombin 
generation via Prothrombinase assembled on the surface of activated platelets adhered at 
sites of vascular injury. The procofactor factor V (Mr, 330, 000) is found in two distinct 
pools in whole blood. Approximately 75-80% circulates in plasma as inactive single chain 
molecule (1) while the remaining 20-25% is stored in platelet α-granules following its 
endocytosis by megakaryocytes (1,2). While both plasma- and platelet-derived factor Va 
can support thrombin generation via Prothrombinase, the platelet-derived factor V/Va pool 
appears more physiologically relevant (3-5). In addition, platelet-derived factor V 
expresses several physical differences (6-12), which would enhance its ability to promote 
and sustain coagulation at sites of vascular injury. It is hypothesized that these 
modifications occur within the megakaryocyte subsequent to factor V endocytosis. In the 
megakaryocyte, factor V undergoes substantial proteolysis to form a partially, 
proteolytically-activated platelet-derived factor V/Va pool (13,14), including cleavage by 
an unknown protease(s) at Tyr1543 to form the platelet-derived factor Va light chain (12). 
In contrast, the plasma-derived factor Va light chain is formed following cleavage by 
thrombin at Arg1545 (15,16). Using a mass spectrometry-based approach, we also 
determined that Thr402 in platelet-derived factor V contains an N-acetylgalactosamine or 
N-acetylglucosamine not observed in plasma-derived factor V (12). The heavy chain of 
platelet-derived factor Va is also attached to the platelet membrane via a 
glycophosphatidylinosital (GPI) anchor (17,18), which confers total resistance of platelet-
derived factor Va to inactivation by APC and plasmin (as described in Chapter Four).   
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 Mass spectrometry techniques, developed to characterize potential N-linked 
glycosylation sites in tissue factor (19,20) were applied to the study of human factor Va to 
determine the sites, composition, and microheterogeneity of the glycan chains. Of the nine 
potential N-linked glycosylation sites within the heavy chain, glycans were identified at 
five sites (Asn23, Asn27, Asn269, Asn432 and Asn439), three sites were not glycosylated 
(Asn354, Asn526, and Asn639), and one other site (Asn211) still requires identification (Fig. 
1). Two of the five glycosylation sites (Asn269 and Asn432) were identified previously (21). 
All three sites in the light chain (Asn1675, Asn1982, and Asn2181) were glycosylated. Asn2181 
in the light chain had been identified and characterized previously (9,10,21). Four glycans 
were identified as sialic acid-containing complex carbohydrates (Asn432, Asn439, Asn1675, 
and Asn2181) and two still require characterization (Asn23 and Asn27). The remaining two 
sites, Asn269 on the heavy chain and Asn1982 were identified as high-mannose glycans. 
Whereas plasma-derived factor Va contains high mannose glycans with either 6, 7, 8, or 9 
mannose residues at Asn1982, platelet-derived factor Va glycans at the same site have only 
4, 5, or 6 mannose residues, suggesting extensive trimming of this glycan by 
megakaryocytes following endocytosis (2,12). The high mannose glycans of plasma- and 
platelet-derived factor Va on Asn269 are similar.  
Glycan moieties have been shown to modulate multiple facets of factor V/Va 
function (15,22-24), including membrane binding (10), cofactor activity (7,12,25), and 
APC-catalyzed inactivation (15,22-24). These functional effects can be substantial, e.g. 
partial removal of carbohydrate from factor V promotes a ten-fold increase its rate of 
cleavage by APC (6). Thus, the goal of this study was to assess the functional significance 
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of the mannose residues at Asn1982. The high mannose glycans on plasma-derived factor V 
were removed by treatment with endoglycosidase H, which removes Asn-linked mannose 

















MATERIALS AND METHODS 
Materials 
Coomassie Brilliant Blue R-250, and bromophenol blue were purchased from Sigma (St. 
Louis, MO). Calcium chloride and polyethylene glycol (PEG) 8000 were obtained from J. 
T. Baker (Philipsburg, NJ). Precision plus protein molecular weight standards were 
purchased from Bio-Rad (Hercules, CA). X-ray autoradiography film, and Western 
blotting chemiluminescence reagent were obtained from Krackeler Scientific (Albany, 
NY), and PerkinElmer Inc. (Waltham, MA), respectively. Tris base and Pierce proprietary 
protein-Free T20 (TBS) blocking buffer were obtained from Thermo Fisher Scientific 
(Rockford, IL). Thrombin-specific inhibitor, hirudin, was purchased from Calbiochem 
(Gibbstown, NJ). Dansylarginine N-(3-ethyl-1,5-pentanediyl)amine  (DAPA) was bought 
from Haematologic Technologies (Essex Junction, VT). TriniClot PT Simplastin Excel 
thromboplastin reagent was purchased from Tcoag (Wicklow, Ireland). Bovine serum 
albumin was obtained from MP Biomedicals (Solon, OH). Recombinant endoglycosidase 
H from Streptomyces plicatus was purchased from Sigma Chemical Co (St. Louis, MO). 
Recombinant exoglycosidase α1-2,3 mannosidase cloned from Xanthomonas manihotis 
was obtained from New England Biolabs Inc. (Ipswich, MA). Phospholipid vesicles 
comprised of 75% phosphatidylcholine (wt/wt) and 25% phosphatidylserine (wt/wt) 
(PCPS) were a generous gift from Dr. Kenneth Mann (University of Vermont) and 
prepared according to the procedure of Higgins and Mann (27) with reagents purchased 
from Avanti Polar Lipids (Alabaster, AL). The chromogenic α-thrombin substrate 
Spectrozyme TH was purchased from Sekisui Diagnostics (San Diego, CA). Antibodies: 
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Horseradish peroxidase conjugated to horse anti-mouse IgG was purchased from Vectors 
Labs (Burlingame, CA). The lectin from Galanthus nivalis (Snowdrop bulb) conjugated to 
horseradish peroxidase was obtained from US Biologicals (Salam, MA). Monoclonal 
antibodies against human factor Va heavy chain (αHFVa LC#9) and light chain (αHFVa 
HC#17) were provided by the University of Vermont Antibody Core Facility (28,29).  
Proteins 
Human activated protein C (APC), plasmin, factor Xa, and thrombin, were all obtained 
from Haematologic Technologies (Essex Junction). Human factor V and prothrombin were 
purified as previously described (30,31) from freshly frozen plasma obtained from 
consenting healthy adults, according to the guidelines of the University of Vermont’s 
Institutional Review Board and Committee on Human Subjects. Proteins were stored in 
50% glycerol containing 5 mM CaCl2 at -20
oC. Before use, glycerol was removed by 
dialysis of sufficient dilution and protein concentrations of proteins determined by UV 
absorbance at 280nm with the following extinction coefficients (E1% 280nm, M
-1 cm-1) and 
molecular weights (Da): human APC, 14.5, 56200 (32), human plasmin, 17.0, 83000 (33), 
human prothrombin, 13.8, 72000 (34); human thrombin, 18.3, 36700 (35); human factor 
Xa, 11.6, 46000 (36); and human factor V, 9.6, 330000 (37).  
Removal of high mannose glycans on plasma-derived factor V by Endoglycosidase H 
Human plasma-derived factor V (4 µM) was incubated  (2 h, 37oC) with 0.23 µM 
endoglycosidase H under non-protein denaturing conditions in 20 mM HEPES, 150 mM 
NaCl, pH 7.4 (HBS) containing 5 mM CaCl2 and 0.1% PEG 8000 (HBS/Ca
2+/PEG). Factor 
V was incubated under similar conditions in the absence of endoglycosidase H in parallel, 
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control experiments. Following deglycosylation, factor V (1.0 µM) was activated to factor 
Va by α-thrombin (20 nM, 10 min, 37oC). Aliquots of factor Va were either prepared for 
SDS-PAGE by dilution in 5X sample preparation buffer (62.5 mM Tris, 5 mM EDTA, 2% 
SDS, 10% glycerol, 0.01% bromophenol blue, pH 6.8; SPB), or by diluted in 20 mM Tris-
HCl, 150 mM NaCl, pH 7.4 (TBS) or HBS to assess cofactor activity in various in 
functional assays.  
Endocytosis of plasma-derived factor V by megakaryocyte-like cell-lines (CMKs) 
CMK cells were cultured as previously described (2,38). All factor V endocytosis 
experiments were performed under serum-free conditions as previously described (2,38). 
CMK cells (1 x 106/mL) were incubated in the presence of endoglycosidase H-treated 
plasma-derived factor V or untreated plasma-derived factor V (30 nM, 4 h, 37oC). The cells 
were extensively washed by centrifugation (250 xg, 7 min) followed by resuspension of 
the cells in HBS to remove excess and cell surface-bound factor V. The final cell pellets 
were adjusted to 1 x 106/mL and solubilized in protease inhibitor cocktail to prevent 
additional proteolysis of the endocytosed protein (13). A portion of the cell lysate was 
treated with thrombin (2 U/mL, 10 min, 37oC) to convert all of the endocytosed factor V 
and its proteolytic products (15) to factor Va prior to dilution in SPB for SDS-PAGE and 
Western blotting analyses. 
The effect of endoglycosidase H treatment on plasma-derived factor Va cofactor 
activity  
The cofactor activity of demannosylated plasma-derived factor Va was monitored 
in a prothrombin time-based clotting assay using factor V immunodepleted plasma as  
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previously described (31). In this assay, a standard curve is generated by making dilutions 
(1:2 through 1:128) of a normal human plasma pool as the factor V source in TBS, pH 7.4. 
The clot times of native plasma-derived factor Va and endoglycosidase-treated factor Va 
were measured and compared to the standard curve.  
 The cofactor activity of demannosylated factor Va was also assessed via 
Prothrombinase assembled on PCPS vesicles. Endoglycosidase H-treated, or untreated 
factor V were thrombin-activated to factor Va (20 nM) before incubation (5 min, 25oC) 
with PCPS vesicles (20 µM), DAPA (30 µM) and prothrombin (0 - 2 µM) in 
HBS/Ca2+/PEG. The reaction was initiated by the addition of factor Xa (0.5 nM). Timed 
aliquots (0, 10, 20, 30 and 40 sec) were removed and diluted in quench buffer (20 mM 
HEPES, 150 mM NaCl, 50 mM EDTA, 0.1% PEG 8000, pH 7.4). The concentration of 
thrombin in samples was monitored by chromogenic assay (18). The initial rates of 
thrombin generation and kinetic constants (Km, Vmax and kcat) governing Prothrombinase 
were determined using GraphPad Prism v6.0 software. 
APC-catalyzed proteolytic inactivation of endoglycosidase H-treated factor Va 
Factor Va derived from thrombin-activated endoglycosidase H-treated factor V or 
untreated factor V were assayed for their susceptibility to APC-catalyzed proteolytic 
inactivation in vitro.  Factor Va (20 nM), and PCPS vesicles (200 µM) in HBS/Ca2+/PEG 
buffer, pH 7.4 were pre-incubated for 5 min at 37oC. The reaction was initiated by the 
addition of APC (0.2 nM). At timed intervals (0 - 2 h) aliquots of the reaction were removed 
and quenched in SPB containing 1% βME. Samples were subsequently boiled and stored 
for further SDS-PAGE and Western blotting analyses. 
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SDS-PAGE and Western blotting analyses 
Factor V/Va fragments were detected by Western blot analyses using monoclonal 
antibodies against human factor V heavy chain (αhFV HC#17) and light chain (αhFV 
LC#9) (28,29). Alternatively, demannosylation was assessed by probing factor V/Va 
fragments with an HRP-conjugated lectin derived from Galanthus nivalis. To evaluate 

















Removal of high mannose glycans from plasma-derived factor V 
We targeted global removal of N-linked high mannose carbohydrates with 
endoglycosidase H under non-denaturing conditions. No apparent difference in the 
electrophoretic mobility of endoglycosidase H-treated factor V (lane 2) and the untreated 
factor V (lane 1) were detected (Fig. 2A). However, upon thrombin activation of the factor 
V to factor Va, there was an obvious electrophoretic shift in both the heavy and light chains 
of demannosylated factor Va (lane 4) as compared to the untreated control (lane 3) 
indicative of the loss of sugars at Asn269 and Asn1982 (21). Removal of the high mannose 
glycans was confirmed using Galanthus nivalis (Snowdrop bulb) lectin (Fig. 2B). This 
lectin is selective, and has high affinity for mannose residues (39). A substantial loss of 
high mannose glycans was observed following treatment with endoglycosidase H as 
demonstrated by not only an increase in electrophoretic mobility, but also a decrease in the 
lectin signal (Fig. 2B). Further ESI LC MS/MS analyses (40) of the treated factor Va 
samples confirmed that 70-80% of the high mannose glycans were removed at positions 
Asn269 and Asn1982 (data not shown). In control experiments, RNase B, which contains a 
single high mannose residue at Asn34 (41), was fully demannosylated with endoglycosidase 
H under the conditions used in this study (data not shown).  
Effect of endoglycosidase H treatment on factor V and factor Va endocytosis by 
megakaryocyte-like cell-lines 
The effect of removal of high mannose N-linked glycans from factor V on its endocytosis 
and subsequent proteolysis by CMK cells was assessed by Western blotting using heavy 
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chain, αhFVa HC#17 (Fig. 3A), and light chain, αhFVa LC#9 (Fig. 3B) monoclonal 
antibodies. Factor V endocytosis by megakaryocytes is receptor-dependent (42) and 
mediated by its light chain (43,44). To ensure that any differences that were observed were 
due to actual differences in factor V endocytosis or proteolysis, the cell lysates from 
equivalent numbers of cells were subjected to electrophoresis and immunoblotting. 
Comparison of the relative amounts and proteolytic pattern of endocytosed factor V 
demonstrated no substantial differences between untreated and endoglycosidase H-treated 
factor V although shifts in electrophoretic mobility consistent with glycan removal were 
observed (Fig. 3A & B, left panels). Following endocytosis, the cells were lysed and treated 
with thrombin to activate the factor V and its partial activation products (45) to factor Va. 
Interestingly,  comparison of the relative densities of the heavy chain (105 kDa) and light 
chain (74 kDa) following conversion of factor V to factor Va in cell lysates demonstrated 
increased endocytosis of demannosylated factor V (Fig. 3A & B, middle panels). 
Interestingly, in both instances, it was observed that endocytosis of the active cofactor, 
factor Va, was greater than that observed with single chain factor V (Fig. 3A & B, right 
panels).  
Effect of demannosylation on factor Va cofactor activity 
Using a prothrombin time-based clotting assay, endoglycosidase H-treated factor Va 
expressed ~80% the activity of the untreated control. Since subtle differences in cofactor 
activity may be more pronounced in clotting assays as compared to other measures of 
cofactor activity, prothrombin activation via Prothrombinase assembled on PCPS vesicles 
in the presence of untreated and endoglycosidase H-treated factor Va were also compared. 
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The kinetics of prothrombin activation performed in the presence of untreated factor Va 
(Km = 0.22 µM, kcat = 18 s
-1, Fig. 4A) were similar to those determined using 
endoglycosidase H-treated factor Va (Km = 0.20 µM, kcat = 10 s
-1, Fig. 4B). The catalytic 
efficiency of Prothrombinase assembled with demannosylated factor Va (kcat/Km = 5.0 x 
107 M-1s-1) was ~60% that of the untreated control (kcat/Km = 8.2 x 10
7 M-1s-1), consistent 
with the 20% loss in activity observed in clotting assays. While treatment with 
endoglycosidase H had a pronounced effect on the Vmax of the reaction as compared to 
untreated factor Va (5.1 nMs-1 and 8.8 nMs-1, respectively), these studies collectively 
suggest that removal of high mannose N-linked glycan on factor Va may result in altering 
its cofactor activity. 
Effect of endoglycosidase H treatment on APC-mediated inactivation of factor Va 
When sufficient amounts of thrombin are generated following the hemostatic response, 
APC promotes factor Va inactivation by cleavage at three major sites in the heavy chain 
(Arg306, Arg506 and Arg679, Fig. 5) (46,47). Proteolysis of the heavy chain of factor Va is 
accompanied by the appearance of a high molecular weight 75 kD fragment consistent with 
cleavage at Arg506. Subsequent cleavage of the 75 kD fragment at Arg306 produces a 30 kD 
fragment. Cleavage at Arg306 is membrane-dependent and promotes significant loss of 
cofactor function (8). The rates and patterns of APC-mediated proteolysis of untreated 
factor Va (Fig. 6A) and demannosylated factor Va (Fig. 6B) were similar, suggesting that 
selective removal of the high mannose glycans had no effect on the susceptibility of factor 
Va to inactivation by APC. For both cofactors, the 75 kD fragment, consistent with 
cleavage at Arg506, was observed after one minute of incubation, whereas the 30 kD 
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fragment, consistent with cleavage of the 75 kD fragment at Arg306, was detected within 



















Previous studies have demonstrated that glycosylation modulates the cofactor function of 
the plasma-derived protein, factor Va (6,9,10,25,48-50). Various effects on factor Va 
cofactor function and inactivation by APC were observed; however, in those experiments 
the consequences of global removal of glycans, and not specific glycan moieties, were 
monitored. The studies detailed here are the first to characterize the effects of selective 
removal of high mannose N-linked glycans from plasma-derived factor Va by 
endoglycosidase H. Treatment with endoglycosidase H removed the majority of the high-
mannose glycans as demonstrated by a shift in protein electrophoretic mobility and less 
reactivity to a mannose binding lectin, which was confirmed by mass spectrometry (80% 
glycan removal). Endoglycosidase-H treatment, however, appears to moderately decrease 
the cofactor activity of plasma-derived factor Va by approximately 20% in clotting assays. 
Loss of the high mannose glycan slightly increased factor V endocytosis but did not affect 
its proteolysis by the megakaryocyte-like cell line (CMK). Finally, there was no effect of 
endoglycosidase-H treatment on APC-mediated, inactivation of factor Va. In unpublished 
studies by the Bouchard laboratory, selective removal of complex N-linked glycans from 
factor V was also without effect on factor Va cofactor activity, but a similar increase in 
factor V endocytosis by megakaryocytes was observed (unpublished data). 
 N-linked glycans (6,41,49,50) and specifically high mannose glycans (21) play 
prominent roles in the folding, quality control, and intracellular trafficking of proteins. 
Using recombinant factor V and factor VIII molecules, Kaufmann and colleagues 
determined that high mannose glycans in the B-domains of these proteins mediated their 
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intracellular interactions with Lectin Mannose-binding 1, LMAN1 or Endoplasmic 
Reticulum-Golgi Intermediate Compartment 53 kDa, ERGIC-53 (51,52). LMAN1, in 
conjunction with Multiple Coagulation Factor Deficiency protein 2, MCFD2, functions in 
the transport of factor V and factor VIII from the endoplasmic reticulum to the Golgi 
apparatus (53-55). Zheng and others subsequently demonstrated using purified glycans that 
the carbohydrate recognition domain of LMAN1 binds to Man-α-1,2-Man, the terminal 
carbohydrate moiety of high mannose glycans (51,56). Using confocal microscopy, it was 
demonstrated previously that subsequent to its endocytosis by megakaryocytes, factor V is 
taken up into early and late endosomes and undergoes retrograde trafficking through the 
Golgi apparatus and endoplasmic reticulum prior to its storage in α-granules. Its trafficking 
through the Golgi apparatus is consistent with the presence of a nonconventional 
modification, O-linked glycosylation, on the platelet-derived cofactor that is not found in 
its plasma counterpart (12). In addition, as glycoproteins are trafficked through the Golgi 
apparatus, high mannose glycans undergo substantial trimming by Golgi mannosidases 
(51,55,56). Subsequent to factor V endocytosis, high mannose glycans at Asn1982, which 
contain either 6, 7, 8, or 9 mannose residues undergo extensive trimming as the platelet-
derived factor V molecule glycans at the same site have only 4, 5, or 6 mannose residues. 
Finally, its trafficking through the endoplasmic reticulum is consistent with the addition of 
a GPI anchor (57,58). Only a small subset of cellular proteins including SNAREs (soluble 
N-ethylmaleimide-sensitive factor attachment protein), acid hydrolase receptors, and 
processing peptidases undergo retrograde transport (59). Exogenous bacterial (Shiga toxin 
and cholera toxin) and plant (ricin and abrin) toxins exploit this pathway following their 
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cellular uptake as they require proteolytic activation by furin in the trans-Golgi network. 
The active toxins are eventually translocated into the cytosol (59,60). Thus, the retrograde 
trafficking and functional modification of factor V following its endocytosis represents a 
unique cellular process.  
 We have shown that high mannose glycans on factor V have significant effect on 
factor Va cofactor activity in Prothrombinase assembly yet marginal effect on 
susceptibility to APC-catalyzed inactivation. The loss of the glycans appears to promote 
enhanced endocytosis by megakaryocytes. In view of the important roles of mannose 
residues in the intracellular trafficking of secretory proteins, it is possible that these 
carbohydrate moieties may play an essential role during factor V trafficking subsequent to 
endocytosis by megakaryocytes. The results presented here provide a foundation for future 
studies to evaluate the intracellular route of demannosylated factor V upon uptake by 
megakaryocytes to gain a better understanding of the importance of selective trimming of 
mannose residues observed on platelet-derived factor V at Asn1982. 
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Figure 1. Sites of N-linked glycosylation on the factor Va heavy and light chains. 
There are approximately 12 potential N-linked glycosylation sites on factor Va:  nine on 
the heavy chain and three on the light chain. Of these, four complex N-linked glycans (●) 
have been identified on the heavy chain, and two have been identified on the light chain. 
High mannose N-linked glycans (▲) at Asn269 and Asn1982 in the factor Va heavy and light 
chains, respectively, have also been identified. Three sites are not glycosylated (Asn354, 




















Figure 2. Electrophoretic mobility shifts following treatment of factor V and factor 
Va with endoglycosidase H. 
Factor V and thrombin-activated factor Va were treated with endoglycosidase H as 
described in Materials and Methods. Samples were resolved by SDS-PAGE and visualized 
by (A) Coomassie blue staining or (B) Western blotting analyses using mannose binding 
lectin Galanthus nivalis conjugated to HRP as the probe. Lanes 1 & 5 contain untreated 
factor V while lanes 2 & 6 contain endoglycosidase H-treated factor V. Lanes 3 & 7 and 4 
& 8 contain untreated and treated factor Va, respectively. The electrophoretic mobilities of 
the molecular weight standards (kDa) are indicated on the left of each panel. The locations 
of single chain factor V (330 kDa; FV), the factor Va heavy chain (105 kDa; HC) and the 









Figure 3. Endocytosis and proteolytic processing of endoglycosidase H-treated factor 
V and factor Va by a megakaryocyte-like cell line. 
Endoglycosidase H-treated (T) and untreated (C) factor V or factor Va (30 nM) were 
incubated with CMK cells (1 x 106/mL, 2h, 37oC). Endocytosed factor V and factor Va 
present in cell lysates were analyzed by Western blotting using monoclonal antibodies 
against human factor Va (A) heavy chain (αhFV#17) or (B) light chain (αhFV#9). In some 
instances endocytosed factor V and its proteolytic products were converted to factor Va 
with thrombin prior to SDS-PAGE and blotting (middle panels). The electrophoretic 
mobilities of the molecular weight standards (kDa) are indicated on the left of each panel. 
The locations of single chain factor V (330 kDa; FV), the factor Va heavy chain (105 kDa; 





Figure 4. Kinetic analyses of prothrombin activation by PCPS-bound 
Prothrombinase assembled in the presence of demannosylated factor Va. 
Prothrombinase reaction mixtures contained prothrombin (0.05 -2 µM), PCPS vesicles (20 
μM), DAPA (30 µM) in the presence of (A) untreated or (B) endoglycosidase H-treated 
factor Va (20 nM). Thrombin generation was initiated by the addition of factor Xa (0.5 
nM). Initial rates of thrombin generation were determined by two-stage chromogenic 
assays. The data were fit to the Michaelis-Menten equation to estimate the kinetic 




Figure 5. Schematic of activated protein C-catalyzed inactivation of factor Va heavy. 
Factor Va is proteolytically inactivated by activated protein C (APC) via three cleavages 
at Arg306, Arg506, and Arg679. A 75 kDa fragment is formed following cleavage at Arg506. 
Further cleavage of this fragment at Arg306 generates a 30 kDa fragment and results in a 
significant loss of cofactor activity and inactivation. Cleavage at this site (Arg306) is 
membrane-dependent (left hand pathway). In the alternate pathway, cleavage at Arg306 
precedes cleavage at Arg506 resulting in the generation of a 60/62 kDa fragment. This 
doublet is predominant in reactions of APC-mediated inactivation of factor Va derived 
from individuals carrying the natural Arg to Glu mutation at position 506 (Factor VLeiden) 
(right hand pathway). Cleavage at Arg679 produces additional lower molecular weight 
proteolytic fragments (26/28 kDa and 20/22 kDa doublets), which are associated with only 
a slight loss in cofactor activity. Fragments shaded light blue are detected by monoclonal 








Figure 6. APC-mediated proteolysis of thrombin-activated, endoglycosidase H-
treated factor V. 
Factor V was demannosylated following treatment with endoglycosidase H and further 
activated to factor Va as described in Materials & Methods. (A) Untreated or (B) treated 
factor Va (20 nM) were incubated with APC (0.2 nM) in the presence of PCPS vesicles 
(200 µM) at 37oC. Aliquots of the reaction were removed at the times indicated in the 
figure (0 - 120 min) and quenched in SPB. The factor Va proteolytic products were resolved 
by SDS-PAGE and immunoblotted with monoclonal antibodies against human factor Va 
heavy chain (αhFVaHC#17). The electrophoretic mobilities of the molecular weight 
standards (kDa) are indicated on the left of each panel. The locations of heavy chain (105 
kDa; HC), the 75 kDa fragment (representing cleavage at Arg506), the 60/62 kDa fragment 
(representing initial cleavage at Arg306) and the 30 kDa fragment (representing residues 
306-506) are indicated on the right.  
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CHAPTER SIX: PERSPECTIVES AND FUTURE DIRECTIONS 
When the vascular integrity is breached, the most crucial physiological function of the 
procoagulant response is the generation of the blood clotting enzyme, thrombin. 
Subsequent to its generation, thrombin is essential to the anticoagulant and fibrinolytic 
responses, and thus the regulation of thrombin generation is central to maintaining the 
balance between normal hemostasis and pathologic thrombosis. Thrombin is generated 
from prothrombin by the coordinated efforts of the constituents of Prothrombinase, which 
includes an appropriate cellular membrane surface, factor Xa and its cofactor factor Va, 
and calcium ions (1,2). Previous studies of the biochemical functions of the 
Prothrombinase complex under static conditions using purified proteins have demonstrated 
that removal of the membrane surface or factor Va from the enzyme complex results in 
approximately 1,000-fold, and 10,000-fold reduction, in the rate of thrombin generation, 
respectively (3). These reports highlight the critical roles of both the membrane binding 
sites and factor Va to thrombin generation.  
Beyond the physiological environment, the required membrane can also be 
provided by PCPS vesicles, which significantly lessens the complexity of the system.  
While these model membranes have been useful in obtaining our present understanding of 
the assembly and function of Prothrombinase, they do not mimic the physiological surface 
and constituents provided by the activated platelet membrane. Notably, activated platelets 
secrete factor Va molecules from their α-granules, which consist of two populations: a 
dissociable pool and non-dissociable, GPI-anchored pool (4,5). While both pools 
contribute to Prothrombinase function, the activated platelet membrane additionally 
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provides the catalytic surface for the binding and assembly of Prothrombinase at sites of 
vascular injury. Additional, significant functional differences between vesicle- and 
platelet-bound Prothrombinase have been highlighted earlier (Chapter One)  
This dissertation examined how the platelet-derived components, particularly the 
non-dissociable, GPI-anchored pool of platelet-derived factor Va and platelet-bound 
Prothrombinase function to maximize the activation of prothrombin to thrombin. Our 
investigations led to the observations that: 1) the non-dissociable, GPI-anchored pool of 
platelet-derived factor Va is totally resistant to proteolytic inactivation by APC and  only 
partially susceptible to plasmin-catalyzed proteolysis, such that cofactor activity is 
sustained in the presence of both proteases and actually enhanced in the presence of 
plasmin; 2) thrombin generated by Prothrombinase, via the prethrombin-2 pathway, on the 
activated platelet surface is mechanistically different from the meizothrombin pathway 
utilized by vesicle-bound Prothrombinase such that prothrombin, configured in a 
proteinase-like state, is the preferred substrate for the platelet-bound  enzyme and sustains 
the procoagulant response by avoiding the generation of the anticoagulant intermediate, 
meizothrombin produced when the substrate is configured in a zymogen-like state; and, 3) 
the Gla-domainless prethrombin-1 intermediate derived from thrombin feedback cleavage 
of prothrombin at Arg155 is effectively utilized to generate thrombin on the activated 
platelet surface in contrast to the PCPS vesicle surface, on which its turnover is inhibited 
by the accumulation of formed fragment-2. Described below are additional future studies 
and experimental approaches which can be utilized to better understand the observations 
summarized above.  
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Studies detailed in Chapter Two of this dissertation sought to gain additional insight 
into the molecular mechanism by which Prothrombinase bound to the activated platelet 
surface utilizes prethrombin-2, rather than meizothrombin, a pathway of thrombin 
generation, which is observed with vesicle-bound Prothrombinase. Utilization of the 
prethrombin-2 pathway maximizes the coagulation response by preventing the formation 
of the meizothrombin intermediate, an intermediate that expresses significant anticoagulant 
activity. By exploiting the ability of active site inhibitors to stabilize the conformationally-
flexible prothrombin molecule in a proteinase-like state, we were able to show definitively 
that the platelet-bound enzyme prefers a substrate configured in that state, a configuration 
that is not recognized by the vesicle-bound enzyme. The present observations adds to a 
long list of evidence suggesting a differential assembly of Prothrombinase bound to the 
activated platelet surface vs. PCPS vesicles. The activated platelet surface is complex: as 
demonstrated by the expression of glycoprotein receptors, cytoskeletal rearrangements and 
the merger of the granular membrane with that of the platelet membrane, and the exposure 
of the intricate open canalicular system. Additionally, the activated platelets express 
distinct and saturable binding sites for components of Prothrombinase compared to the 
significantly less complex system of PCPS vesicles where binding by Prothrombinase’s 
components is not unique. We further predict that some unidentified distinct membrane 
features (such as receptors for factor Xa or factor factor Va) on the platelet surface regulate 
how the enzyme is assembled and ultimately how the substrate is configured for catalysis. 
Therefore, the absence of these unidentified receptors on non-platelet surfaces including 
PCPS vesicles may affect how the enzyme is assembled and how the substrate is 
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recognized in comparison to the activated platelet surface. One approach to identify some 
of these receptors may involve the use of cross-linking agents (such as Sulfo-SBED) to 
crosslink bound factor Xa, factor Va, and Prothrombinase to the activated platelet-
membrane and then utilize mass spectrometric analyses to profile and identify proteins in 
the cross-linked complex. Crosslinking studies have been previously done in our laboratory 
therefore this technique will help us to identify potential receptors which can be then be 
targeted for selective removal with proteases to evaluate their roles in Prothrombinase 
assembly and function. 
We further hypothesize that Prothrombinase bound to non-platelet surfaces prefers 
its substrate in a zymogen-like state. Previous studies have reported that human 
lymphocytes, monocytes, and endothelial cells (7), red blood cells (6) and other cellular-
derived microparticles support Prothrombinase assembly and thrombin generation via the 
meizothrombin pathway. Therefore, using DAPA inhibitor binding studies employed in 
this dissertation, we can test the above hypothesis on these non-platelet surfaces. If indeed 
Prothrombinase bound to non-platelet surfaces prefers to bind prothrombin in a zymogen-
like configuration, we can then assess the distinct features (via Sulfo-SBED cross-linking 
studies) of these surfaces e.g. monocytes in comparison to platelets and then eliminate 
attributes which are similar on either surfaces (including glycoprotein receptors) while 
documenting distinct cellular features which may affect enzyme assembly. As described 
above, any cellular feature documented on these non-platelet surfaces could potentially be 
removed with proteases as well to verify their role in Prothrombinase function. 
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The studies described in Chapter Three continue to investigate the unique 
functional attributes of Prothrombinase bound to the activated platelet membrane vs. PCPS 
vesicles. Using prethrombin-1 as an alternate substrate for membrane-bound 
Prothrombinase, we were able to conclude that platelet-bound Prothrombinase, binds, or 
stabilizes, prethrombin-1 in a configuration such that the fragment-2 formed by the initial 
cleavage of the substrate at Arg271 does not impede the subsequent cleavage at Arg320. In 
fact, even though both membrane-bound enzymes (platelet vs PCPS vesicle) effect the 
initial cleavage of prethrombin-1 at Arg271 to generate prethrombin-2 and fragment-2, the 
formed fragment-2 only inhibits the PCPS-bound enzyme. This inhibition of PCPS-bound 
Prothrombinase appears to be mediated by some region within fragment-2 of prothrombin. 
One approach to delineating this mechanism of inhibition is to express recombinant 
prethrombin-1 molecules lacking residues within the kringle 2 and linker 3 (residues 170 - 
269) regions within fragment-2 and then monitor thrombin generation via initial rates and 
progress curves in reactions by PCPS-bound Prothrombinase as described in Chapter Three 
of this dissertation. Likewise, the effect of fragment-2 on prethrombin-1 activation by 
Prothrombinase may be better assessed by preparing and purifying fragment-2 from factor 
Xa-catalyzed prethrombin-1 activation reactions (7) and then monitoring the effect of 
fragment-2 in Prothrombinase titration assays. Data from this studies would also confirm 
the type of product inhibition occurring on PCPS vesicles. In contrast, we know that when 
activated, platelets express filopodia and open up their extensive network of canalicular 
system which may provide an ideal microenvironment for the binding of components of 
the Prothrombinase complex. With this unique environment absent on PCPS vesicles, it is 
 203 
 
reasonable to further speculate that during prothrombin activation by the platelet-bound 
Prothrombinase the intermediates formed are localized within the microenvironment of the 
enzyme where their local concentrations are higher allowing for their effective conversion 
into thrombin. Interestingly, prethrombin-1 activation occurs through cleavage at Arg271 
suggesting that the substrate is bound in the proteinase-like state and expresses the pseudo-
active site. We know from the Chapter Two of this dissertation that the substrate bound in 
the proteinase-like configuration is preferred by the platelet-bound Prothrombinase but not 
the vesicle-bound enzyme. Therefore, by investigating the effect of DAPA-induced 
prethrombin-1 stabilization on substrate activation by the platelet-bound enzyme, we can 
appreciate further the mechanism by which all the prothrombin activation species are 
utilized in thrombin generation at the site of vascular injury. Alternatively, on the PCPS 
vesicles we anticipate that, prethrombin-1 activation would be further inhibited by a 
combination of increase presentation of the undesirable proteinase-like substrate to the 
PCPS-bound enzyme and the inhibition being mediated by fragment-2.  
Studies detailed in Chapter Four allowed the functional characterization of a non-
dissociable, GPI-anchored pool of platelet-derived factor Va. This unique factor Va pool 
is tethered to the platelet membrane via a GPI anchor on the heavy chain at Ser692 and 
distinguishes the subpopulation of activated platelets that bind a functional Prothrombinase 
(4,8). This GPI-anchored factor Va pool supports Prothrombinase assembly and function 
identically to the non-tethered dissociably-bound cofactor (9,10). Using clotting assays, 
Wood et al. estimated that ~40% of the platelet-derived factor Va, capable of supporting 
thrombin generation, is GPI-anchored to the platelet membrane. Using analyses of kinetics 
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of prothrombin activation, we were able to demonstrate that the GPI-anchored factor Va 
pool contributed between 25-90% of the total platelet-derived Prothrombinase activity 
expressed by four different platelet donors. While this approach directly assessed cofactor 
function, future studies using immunoassays (5) will be more appropriate to quantify the 
both the expression and variability of GPI-anchored, platelet-derived factor Va among a 
large group of donors. By generating antibodies against the GPI-anchored factor Va pool 
via targeting the GPI anchor, we can directly assess the contribution of this pool of platelet-
derived factor Va to thrombin generation in Prothrombinase assays.  
Earlier studies from our laboratory reported the presence of a subpopulation of 
platelet-derived factor Va which retained ~50% of its residual cofactor activity or showed 
a sustained and increased cofactor activity when treated with catalytic amounts of APC 
(11) or plasmin (12), respectively. We have demonstrated that the GPI-anchored, platelet-
derived factor Va represents this unique pool of protease-resistant factor Va.  
Consequently, further study of the susceptibility of this factor Va pool to cleavage and  
perhaps, inactivation or activation by other proteases known to cleave factor Va, e.g. 
cathepsin G, elastase (13) and platelet calpains (14) is warranted. Future studies showing 
resistance of this pool to a known battery of other proteases will provide strong support for 
a concept of resistance mediated by the GPI-anchor modification on factor Va. Platelet-
derived factor Va is critical to the coagulant response via Prothrombinase function; 
therefore, additional mechanistic insights into the protease resistance phenotype observed 
here and in the proposed future studies could be a useful therapeutic target. As described 
in Chapter One of this dissertation, platelet-derived factor Va is enough to sustain 
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hemostatic competence as shown in individuals with antibodies against their plasma factor 
V (15) and in congenital factor V deficiency (16). Therefore, for individuals predisposed 
with thrombophilia including arterial thrombosis, the development and administration of 
antibodies to the GPI-anchored platelet-derived factor Va may be key to reducing their 
risks to platelet triggered cardiovascular diseases. 
Work described in Chapter Five describes initial attempts to characterize functional 
properties provided by the high mannose glycans (Asn269 and Asn1982) present on both the 
heavy and light chains of factor Va. Our initial approach targeted global removal of the 
high mannose glycans at Asn269 (heavy chain) and Asn1982 (light chain) on plasma-derived 
plasma factor V using mannose-specific endoglycosidase H. While a marginal difference 
in cofactor activity was observed in functional assays, an enhanced uptake of both 
deglycosylated plasma-derived factor V and factor Va by the CMK megakaryocyte-like 
cell line was observed when compared to the untreated control. Studies have implicated 
mannose residues in the intracellular trafficking of both secretory and endocytosed proteins 
(17-20). Therefore, future experiments should monitor the fate of deglycosylated plasma-
derived factor V following its endocytosis by megakaryocytes. Our laboratory has detailed 
how endocytosed, plasma-derived factor V is trafficked within the megakaryocyte and 
therefore has the expertise to perform such experiments. It would be interesting to know if 
the increased uptake of deglycosylated factor Va reported here corresponds to its normal 
trafficking, yet increased packaging into α-granules, or if the increased uptake is simply 
due to an enhanced cycling in endosomal compartments with no clear path of trafficking 
to other organelles such as the endoplasmic reticulum and trans-golgi network.  
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Procedures for the isolation of platelet-derived factor V from  donor platelets has 
been previously published by our laboratory (21); therefore future studies should evaluate 
the effect of treatment with endoglycosidase H on the cofactor activity of platelet-derived 
factor Va vs. plasma-derived factor Va. 
In conclusion, studies detailed in this dissertation clearly and significantly 
underscore the functional importance of platelet-derived factor Va particularly the GPI-
anchored pool, as well as the activated platelet membrane in the assembly and function of 
Prothrombinase, and hence the procoagulant response. However more information is 
required if the activated platelet and its constituents are to be considered as potential 
therapeutic targets to inhibit thrombin formation catalyzed by platelet-bound 
Prothrombinase, as detailed previously. 
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